



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A61K 31/40, 31/41, 31/415, 31/445, 31/495, 31/505, C07D 209/04, 209/12, 209/18, 231/56, 235/04, 235/06, 235/08, 249/16, 401/12, 403/12, 409/12</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/00128 (43) International Publication Date: 7 January 1999 (07.01.99)</p>
<p>(21) International Application Number: PCT/US98/13416 (22) International Filing Date: 26 June 1998 (26.06.98) (30) Priority Data: 60/050,888 26 June 1997 (26.06.97) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BEIGHT, Douglas, Wade [US/US]; Apartment G, 9368 Benchmark Drive, Indianapo- lis, IN 46240 (US). CRAFT, Trelia, Joyce [US/US]; 10404 East 46th Street, Indianapolis, IN 46236 (US). FRAN- CISKOVICH, Jeffry, Bernard [US/US]; 5036 Quail Ridge Lane, Indianapolis, IN 46254 (US). GOODSON, Theodore, Junior [US/US]; 4045 Devon Drive, Indianapolis, IN 46226 (US). HALL, Steven, Edward [US/US]; 102 Nuttal Place, Chapel Hill, NC 27514 (US). HERRON, David, Kent [US/US]; 5945 Andover Road, Indianapolis, IN 46220 (US). KLIMKOWSKI, Valentine, Joseph [US/US]; 4504 Camelot Lane, Carmel, IN 46033 (US). KYLE, Jeffrey, Alan</p>		<p>[US/US]; 10434 Collingswood Lane, Fishers, IN 46038 (US). MASTERS, John, Joseph [US/US]; 8338 Crystal Pointe Lane, Indianapolis, IN 46236 (US). MENDEL, David [US/US]; 11348 Woods Bay Lane, Indianapolis, IN 46236 (US). MILOT, Guy [CA/US]; 2 Farrington Street, Foxbor- ough, MA 02035 (US). SAWYER, Jason, Scott [US/US]; 5718 North Winthrop Avenue, Indianapolis, IN 46220 (US). SHUMAN, Robert, Theodore [US/US]; 830 Ashton Park Drive, Greenwood, IN 46143 (US). SMITH, Gerald, Floyd [US/US]; 825 Queenswood Court, Indianapolis, IN 46217 (US). TEBBE, Anne, Louise [US/US]; 6202 North Sher- man Drive, Indianapolis, IN 46220 (US). TINSLEY, Jen- nifer, Marie [US/US]; 4542 State Road 39 North, Mar- tinsville, IN 46151 (US). WEIR, Leonard, Crayton [US/US]; 6520 Englehardt Drive, Raleigh, NC 27613 (US). WIKEL, James, Howard [US/US]; 4068 Sunshine Way, Greenwood, IN 46142 (US). WILEY, Michael, Robert [US/US]; 7725 Langwood Drive, Indianapolis, IN 46268 (US). YEE, Ying, Kwong [US/US]; 5127 Briarstone Trace, Carmel, IN 46033 (US). (74) Agents: JACKSON, Thomas, E. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.</p>
<p>(54) Title: ANTITHROMBOTIC AGENTS (57) Abstract This application relates to a compound of formula (I) (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/40, 31/41, 31/415, 31/445, 31/495, 31/505, C07D 209/04, 209/12, 209/18, 231/56, 235/04, 235/06, 235/08, 249/16, 401/12, 403/12, 409/12	A1	(11) International Publication Number: WO 99/00128 (43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13416 (22) International Filing Date: 26 June 1998 (26.06.98) (30) Priority Data: 60/050,888 26 June 1997 (26.06.97) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BEIGHT, Douglas, Wade [US/US]; Apartment G, 9368 Benchmark Drive, Indianapolis, IN 46240 (US). CRAFT, Trelia, Joyce [US/US]; 10404 East 46th Street, Indianapolis, IN 46236 (US). FRANCISKOVICH, Jeffry, Bernard [US/US]; 5036 Quall Ridge Lane, Indianapolis, IN 46254 (US). GOODSON, Theodore, Junior [US/US]; 4045 Devon Drive, Indianapolis, IN 46226 (US). HALL, Steven, Edward [US/US]; 102 Nuttal Place, Chapel Hill, NC 27514 (US). HERRON, David, Kent [US/US]; 5945 Andover Road, Indianapolis, IN 46220 (US). KLIMKOWSKI, Valentine, Joseph [US/US]; 4504 Camelot Lane, Carmel, IN 46033 (US). KYLE, Jeffrey, Alan [US/US]; 10434 Collingswood Lane, Fishers, IN 46038 (US). MASTERS, John, Joseph [US/US]; 8338 Crystal Pointe Lane, Indianapolis, IN 46236 (US). MENDEL, David [US/US]; 11348 Woods Bay Lane, Indianapolis, IN 46236 (US). MILOT, Guy [CA/US]; 2 Farrington Street, Foxborough, MA 02035 (US). SAWYER, Jason, Scott [US/US]; 5718 North Winthrop Avenue, Indianapolis, IN 46220 (US). SHUMAN, Robert, Theodore [US/US]; 830 Ashton Park Drive, Greenwood, IN 46143 (US). SMITH, Gerald, Floyd [US/US]; 825 Queenswood Court, Indianapolis, IN 46217 (US). TEBBE, Anne, Louise [US/US]; 6202 North Sherman Drive, Indianapolis, IN 46220 (US). TINSLEY, Jennifer, Marie [US/US]; 4542 State Road 39 North, Martinsville, IN 46151 (US). WEIR, Leonard, Crayton [US/US]; 6520 Englehardt Drive, Raleigh, NC 27613 (US). WIKEL, James, Howard [US/US]; 4068 Sunshine Way, Greenwood, IN 46142 (US). WILEY, Michael, Robert [US/US]; 7725 Langwood Drive, Indianapolis, IN 46268 (US). YEE, Ying, Kwong [US/US]; 5127 Briarstone Trace, Carmel, IN 46033 (US). (74) Agents: JACKSON, Thomas, E. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).		Published With international search report.
(54) Title: ANTITHROMBOTIC AGENTS (57) Abstract This application relates to a compound of formula (I) (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

ANTITHROMBOTIC AGENTS

This application claims the benefit of U.S. Provisional
5 Application No. 60/050,888, filed June 26, 1997.

This invention relates to antithrombotic bicyclic
heterocycles which demonstrate activity as inhibitors of
factor Xa and, accordingly, which are useful anticoagulants
in mammals. In particular it relates to bicyclic
10 heterocycles having high anticoagulant activity, and
antithrombotic activity. Thus, this invention relates to
new inhibitors of factor Xa, pharmaceutical compositions
containing the compounds as active ingredients, and the use
of the compounds as anticoagulants for prophylaxis and
15 treatment of thromboembolic disorders such as venous
thrombosis, pulmonary embolism, arterial thrombosis, in
particular myocardial ischemia, myocardial infarction and
cerebral thrombosis, general hypercoagulable states and
local hypercoagulable states, such as following angioplasty
20 and coronary bypass operations, and generalized tissue
injury as it relates to the inflammatory process. In
addition, the antithrombotic agents are useful as
anticoagulants in *in vitro* applications.

The process of blood coagulation, thrombosis, is
25 triggered by a complex proteolytic cascade leading to the
formation of thrombin. Thrombin proteolytically removes
activation peptides from the A α -chains and the B β -chains of
fibrinogen, which is soluble in blood plasma, initiating
insoluble fibrin formation. The formation of thrombin from
30 prothrombin is catalyzed by factor Xa.

- 2 -

Anticoagulation currently is achieved by the administration of heparins and coumarins. Parenteral pharmacological control of coagulation and thrombosis is based on inhibition of thrombin through the use of heparins.

5 Heparins act indirectly on thrombin by accelerating the inhibitory effect of endogenous antithrombin III (the main physiological inhibitor of thrombin). Because antithrombin III levels vary in plasma and because clot-bound thrombin seems resistant to this indirect mechanism, heparins can be

10 an ineffective treatment. Because coagulation assays are believed to be associated with efficacy and with safety, heparin levels must be monitored with coagulation assays (particularly the activated partial thromboplastin time (APTT) assay). Coumarins impede the generation of thrombin

15 by blocking the posttranslational gamma-carboxylation in the synthesis of prothrombin and other proteins of this type. Because of their mechanism of action, the effect of coumarins can only develop slowly, 6-24 hours after administration. Further, they are not selective

20 anticoagulants. Coumarins also require monitoring with coagulation assays (particularly the prothrombin time (PT) assay).

Recently, interest has grown in small synthetic molecules which demonstrate potent direct inhibition of

25 thrombin and factor Xa. See, Jeremy J. Edmunds and Stephen T. Rapundalo (Annette M. Doherty, Section Editor), Annual Reports in Medicinal Chemistry, (1996), 31, 51-60.

Although the heparins and coumarins are effective anticoagulants, no commercial drug has yet emerged from the


30 small synthetic molecules; and despite the continuing promise for this class of compounds, there still exists a need for anticoagulants which act selectively on factor Xa or thrombin, and which, independent of antithrombin III, exert inhibitory action shortly after administration,

- 3 -

preferably by an oral route, and do not interfere with lysis of blood clots, as required to maintain hemostasis.

The present invention is directed to the discovery that the compounds of the present invention, as defined below,
 5 are potent inhibitors of factor Xa which may have high bioavailability following oral administration.

According to the invention there is provided a method of inhibiting factor Xa comprising using an effective amount of a factor Xa inhibiting compound of formula I
 10



wherein

A³, A⁴, A⁵ and A⁶, together with the two carbons to
 15 which they are attached, complete a substituted benzene in which A³ is CR³, A⁴ is CR⁴, A⁵ is CR⁵, and A⁶ is CR⁶;
 wherein

R³ is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω-carboxy substituent), benzoyloxy (which
 20 may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;

one of R⁴ and R⁵ is hydrogen, methyl, halo, trifluoromethyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO-, R^fO₂C-, R^fO₂C-CH₂-, R^fO₂C-CH₂-O-,
 25 3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-amino;

the other of R⁴ and R⁵ is hydrogen, halo or methyl; and
 R⁶ is hydrogen, fluoro, hydroxy, [(1-2C)alkyl]-carbonyloxy (which may bear an ω-carboxy substituent),
 30 benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;

- 4 -

in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is hydrogen, acetyl, trifluoroacetyl, phenylalanyl, 2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or R^hSO_h- (wherein h is 1 or 2); and R^h is (1-4C)alkyl, trifluoromethyl, phenyl, 3,5-dimethylisoxazol-4-yl or dimethylamino; or

two adjacent residues selected from R^3 , R^4 , R^5 and R^6 together form a benz ring; and the other two are each hydrogen; or

10 A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted heteroaromatic ring in which

(a) one of A^3 , A^4 , A^5 and A^6 is N, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively;

15 (b) two adjacent residues of A^3 , A^4 , A^5 and A^6 together form S, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively;

(c) two non-adjacent residues of A^3 , A^4 , A^5 and A^6 are each N, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 ,

20 respectively; or


(d) A^3 and A^4 together form a fused benz ring, and A^5 and A^6 together form -NH-;

wherein

each of R^3 , R^4 , R^5 and R^6 is hydrogen, or one or two of R^3 , R^4 , R^5 and R^6 is independently chloro, bromo or methyl and the others are hydrogen;

L^1 is -NH-CO- or -CO-NH- such that - L^1 - Q^1 is -NH-CO- Q^1 or -CO-NH- Q^1 ;

Q^1 is




30

- 5 -

wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-,
-C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen,
fluoro, chloro, bromo or methyl;


R² is -L^{2A}-Q^{2A}, -L^{2B}-Q^{2B}, -L^{2C}-Q^{2C} or -L^{2D}-Q^{2D} wherein
5 L^{2A} is a direct bond; and
Q^{2A} is



in which D is carbonyl or -CHR^k- in which R^k is hydrogen,
10 hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy,
[(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or
two (1-2C)alkyl substituents on the nitrogen; and one of R^m
and Rⁿ is hydrogen and the other is amino, bromo,
(1-4C)alkyl or (1-4C)alkoxy, or R^m and Rⁿ together form a
15 benz ring;

L^{2B} is -NH-CO-, -O-CO-, -CH₂-O- or -O-CH₂- such that
-L^{2B}-Q^{2B} is -NH-CO-Q^{2B}, -O-CO-Q^{2B}, -CH₂-O-Q^{2B} or -O-CH₂-Q^{2B};
and

Q^{2B} is



20

in which R^o is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy,
benzyloxy or (1-4C)alkylthio; and R^p is 1-hydroxyethyl,
1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl,
25 4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or -J-R^q
in which J is a single bond, methylene, carbonyl, oxo,
-S(O)_q- (wherein q is 0, 1 or 2), or -NR^r- (wherein R^r is
hydrogen or methyl); and R^q is (1-6C)alkyl, phenyl,
3-pyridyl or 4-pyridyl;

- 6 -

L^{2C} is -NR^V-CO-X-, -NR^V-CS-Y-, -CH₂-CO-NR^W-CH₂-,
-O-CO-, -O-CH₂-, -S-CH₂- or -CH₂-NR^X-CH₂- such that -L^{2C}-Q^{2C}
is -NR^V-CO-X-Q^{2C}, -NR^V-CS-Y-Q^{2C}, -CH₂-CO-NR^W-CH₂-Q^{2C},
-O-CO-Q^{2C}, -O-CH₂-Q^{2C}, -S-CH₂-Q^{2C} or -CH₂-NR^X-CH₂-Q^{2C} in
5 which X is -(CH₂)_x- (wherein x is 0, 1 or 2), -NR^W-,
-NR^W-CH₂-, -O-, -O-CH₂- or -S-CH₂-; Y is -NR^W-CH₂- or
-O-CH₂-; each of R^V and R^W is independently hydrogen, benzyl
or (1-6C)alkyl which is not branched at the α-position; and
R^X is hydrogen, benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl;
10 and

Q^{2C} is 1-(4-pyridyl)piperidin-4-yl, 1-(4-pyridyl)-
piperidin-3-yl or 1-(4-pyridyl)pyrrolidin-3-yl in which the
pyridyl may bear a substituent at its 2-position selected
from cyano, aminomethyl, carboxy, hydroxymethyl and
15 (1-2C)alkyl;

L^{2D} is -NH-CO- such that -L^{2D}-Q^{2D} is -NH-CO-Q^{2D}; and
Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-
9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a
chloro, methyl or methoxy substituent), benzofuran-2-yl
20 (which may bear a chloro, methyl or methoxy substituent),
4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl or
3,4-didehydropiperidin-4-yl (either one bearing a
substituent at the 1-position selected from methylsulfonyl,
phenylsulfonyl, (1-5C)alkyl, (4-7C)cycloalkyl, tetrahydro-
25 pyran-4-yl, 4-thiacyclohexyl and -CH₂-R^Z in which R^Z is
isopropyl, cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl,
or pyridyl in which the phenyl may bear one or two
substituents independently selected from halo, cyano,
hydroxy, methoxy, acetoxy, benzyloxy, amino, acetylamino,
30 nitro and 3,4-methylenedioxy, and the thienyl or furyl may
bear a methyl or nitro substituent);

or a prodrug of the compound of formula I;

or a pharmaceutically acceptable salt of the compound
of formula I or prodrug thereof.

- 7 -

A particular factor Xa inhibiting compound of formula I is one wherein

A³, A⁴, A⁵ and A⁶, together with the two carbons to which they are attached, complete a substituted benzene in
5 which A³ is CR³, A⁴ is CR⁴, A⁵ is CR⁵, and A⁶ is CR⁶;
wherein

R³ is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω-carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl
10 substituents), methyl or methoxy;

one of R⁴ and R⁵ is hydrogen, methyl, halo, trifluoromethyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO-, R^fO₂C-, R^fO₂C-CH₂-, R^fO₂C-CH₂-O-,
3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-
15 amino;

the other of R⁴ and R⁵ is hydrogen, halo or methyl; and
R⁶ is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω-carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl
20 substituents), methyl or methoxy;

in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is hydrogen, acetyl, trifluoroacetyl, phenylalanyl,
2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or R^hSO₂-; and R^h is (1-4C)alkyl, trifluoromethyl, phenyl,
25 3,5-dimethylisoxazol-4-yl or dimethylamino; or

two adjacent residues selected from R³, R⁴, R⁵ and R⁶ together form a benz ring; and the other two are each hydrogen; or

A³, A⁴, A⁵ and A⁶, together with the two carbons to
30 which they are attached, complete a substituted heteroaromatic ring in which
(a) one of A³, A⁴, A⁵ and A⁶ is N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;

- 8 -

(b) two adjacent residues of A³, A⁴, A⁵ and A⁶ together form S, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;

(c) two non-adjacent residues of A³, A⁴, A⁵ and A⁶ are each N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively; or


(d) A³ and A⁴ together form a fused benz ring, and A⁵ and A⁶ together form -NH-;

wherein

each of R³, R⁴, R⁵ and R⁶ is hydrogen, or one or two of R³, R⁴, R⁵ and R⁶ is independently chloro, bromo or methyl and the others are hydrogen;

L¹ is -NH-CO- or -CO-NH- such that -L¹-Q¹ is -NH-CO-Q¹ or -CO-NH-Q¹;

Q¹ is




wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-,

-C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen, fluoro, chloro, bromo or methyl;

R² is -L^{2A}-Q^{2A}, -L^{2B}-Q^{2B}, -L^{2C}-Q^{2C} or -L^{2D}-Q^{2D} wherein

L^{2A} is a direct bond; and

Q^{2A} is




in which D is carbonyl or -CHR^k- in which R^k is hydrogen, hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy, [(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or

- 9 -

two (1-2C)alkyl substituents on the nitrogen; and one of R^m and R^n is hydrogen and the other is amino, bromo, (1-4C)alkyl or (1-4C)alkoxy, or R^m and R^n together form a benz ring;

- 5 L^{2B} is $-NH-CO-$, $-O-CO-$, $-CH_2-O-$ or $-O-CH_2-$ such that $-L^{2B}-Q^{2B}$ is $-NH-CO-Q^{2B}$, $-O-CO-Q^{2B}$, $-CH_2-O-Q^{2B}$ or $-O-CH_2-Q^{2B}$; and

Q^{2B} is



10

in which R^O is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy, benzyloxy or (1-4C)alkylthio; and R^P is 1-hydroxyethyl, 1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl, 4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or $-J-R^Q$ in which J is a single bond, methylene, carbonyl, oxo, $-S(O)_q-$ (wherein q is 0, 1 or 2), or $-NR^F-$ (wherein R^F is hydrogen or methyl); and R^Q is (1-6C)alkyl, phenyl, 3-pyridyl or 4-pyridyl;

- 15 L^{2C} is $-NR^V-CO-X-$, $-NR^V-CS-Y-$, $-CH_2-CO-NR^W-CH_2-$, $-O-CO-$, $-O-CH_2-$, $-S-CH_2-$ or $-CH_2-NR^X-CH_2-$ such that $-L^{2C}-Q^{2C}$ is $-NR^V-CO-X-Q^{2C}$, $-NR^V-CS-Y-Q^{2C}$, $-CH_2-CO-NR^W-CH_2-Q^{2C}$, $-O-CO-Q^{2C}$, $-O-CH_2-Q^{2C}$, $-S-CH_2-Q^{2C}$ or $-CH_2-NR^X-CH_2-Q^{2C}$ in which X is $-(CH_2)_x-$ (wherein x is 0, 1 or 2), $-NR^W-CH_2-$, $-O-CH_2-$ or $-S-CH_2-$; Y is $-NR^W-CH_2-$ or $-O-CH_2-$; each of R^V and R^W is independently hydrogen, benzyl or (1-6C)alkyl which is not branched at the α -position; and R^X is hydrogen, benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl; and

- 20 Q^{2C} is 1-(4-pyridyl)piperidin-4-yl in which the pyridyl may bear a substituent at its 2-position selected from
25 cyano, aminomethyl, carboxy, hydroxymethyl and (1-2C)alkyl;

30 L^{2D} is $-NH-CO-$ such that $-L^{2D}-Q^{2D}$ is $-NH-CO-Q^{2D}$; and

- 10 -

Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a chloro, methyl or methoxy substituent), benzofuran-2-yl (which may bear a chloro, methyl or methoxy substituent),
5 4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl bearing a substituent at the 1-position selected from methylsulfonyl, phenylsulfonyl and -CH₂-R^Z in which R^Z is isopropyl, cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl, or pyridyl in which the phenyl may bear one or two substituents
10 independently selected from halo, cyano, hydroxy, methoxy, acetoxy, benzyloxy, amino, acetyl amino, nitro and 3,4-methylenedioxy, and the thienyl or furyl may bear a methyl or nitro substituent;
or a prodrug of the compound of formula I;
15 or a pharmaceutically acceptable salt of the compound of formula I or prodrug thereof.

In addition, there is provided the use of a factor Xa inhibiting compound of formula I (or prodrug or salt) as described herein as an active ingredient in the manufacture
20 of a medicament for use in producing an anticoagulant or antithrombotic effect.

The present invention also provides a method of inhibiting coagulation in a mammal comprising administering to a mammal in need of treatment, a coagulation inhibiting
25 dose of a factor Xa inhibiting compound of formula I having any of the definitions herein.

The present invention further provides a method of inhibiting factor Xa comprising administering to a mammal in need of treatment, a factor Xa inhibiting dose of a
30 factor Xa inhibiting compound of formula I having any of the definitions herein.

Further, the present invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment, an effective dose of a

- 11 -

factor Xa inhibiting compound of formula I having any of the definitions herein.

In addition, there is provided the use of a factor Xa inhibiting compound of formula I having any of the
5 definitions herein for the manufacture of a medicament for treatment of a thromboembolic disorder.

As an additional feature of the invention there is provided a pharmaceutical formulation comprising in
association with a pharmaceutically acceptable carrier,
10 diluent or excipient, a prodrug of a factor Xa inhibiting compound of formula I (or of a pharmaceutically acceptable salt thereof) as provided in any of the descriptions herein.

In general, the factor Xa inhibiting compounds of formula I are believed to be novel and, thus, to constitute
15 an additional aspect of the invention. Thus, according to the invention there is provided a novel compound of formula I (or a pharmaceutically acceptable salt thereof) according to any of the definitions herein of a compound of formula I, provided that the compound is not one which is
20 not novel.

A pharmaceutically acceptable salt of an antithrombotic agent of the instant invention includes one which is an acid-addition salt made from a basic compound of formula I and an acid which provides a pharmaceutically acceptable
25 anion, as well as a salt which is made from an acidic compound of formula I and a base which provides a pharmaceutically acceptable cation. Thus, a salt of a novel compound of formula I as provided herein made with an acid or base which affords a pharmaceutically acceptable
30 counterion provides a particular aspect of the invention. Examples of such acids and bases are provided hereinbelow.

As an additional aspect of the invention there is provided a pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier,

- 12 -

diluent or excipient, a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any of the descriptions herein.

In this specification, the following definitions are used, unless otherwise described: Halo is fluoro, chloro, bromo or iodo. Alkyl, alkoxy, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain ("normal") radical, a branched chain isomer such as "isopropyl" being specifically denoted. When two adjacent residues form a (fused) benz ring, they form a cis,cis-but-1,3-dien-1,4-diyl divalent radical.


It will be appreciated that certain compounds of formula I (or salts or prodrugs, etc.) may exist in, and be isolated in, isomeric forms, including tautomeric forms, cis- or trans-isomers, as well as optically active, racemic, or diastereomeric forms. It is to be understood that the present invention encompasses a compound of formula I in any of the tautomeric forms or as an a mixture thereof; or as a mixture of diastereomers, as well as in the form of an individual diastereomer, and that the present invention encompasses a compound of formula I as a mixture of enantiomers, as well as in the form of an individual enantiomer, any of which mixtures or form possesses inhibitory properties against factor Xa, it being well known in the art how to prepare or isolate particular forms and how to determine inhibitory properties against factor Xa by standard tests including those described below.

In addition, a compound of formula I (or salt or prodrug, etc.) may exhibit polymorphism or may form a solvate with water or an organic solvent. The present invention also encompasses any such polymorphic form, any solvate or any mixture thereof.

- 13 -

Particular values are listed below for radicals, substituents, and ranges, for illustration only, and they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

- 5 For an alkyl group or the alkyl portion of an alkyl containing group such as, for example alkoxy, a particular value for (1-2C)alkyl is methyl or ethyl, and more particularly is methyl; for (1-4C)alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl, and more
10 particularly is methyl, isopropyl, butyl or t-butyl; for (1-6C)alkyl is methyl, ethyl, propyl, butyl, pentyl or hexyl, and more particularly is methyl, butyl, or hexyl. A particular value for halo is bromo or chloro, and more particularly is chloro.
- 15 A particular compound of formula I is one of formula Ia



wherein A⁴, L¹, Q¹ and R² have any of the values defined herein.

- 20 A particular value for Q¹ is 6-indolyl or 6-indazolyl.
A particular value for R² is, for example, (4-t-butylbenzoyl)amino, (4-methoxybenzoyl)amino, or [1-(4-pyridyl)-piperidin-4-yl]methoxycarbonylamino.

- One particular compound of formula I as described
25 herein is one in which L¹-Q¹ is -NH-CO-Q¹.

Another particular compound of formula I as described herein is one in which L¹-Q¹ is -CO-NH-Q¹.

- A prodrug of a compound of formula I may be one formed in a conventional manner with a functional group of the
30 compound, such as with an amino, hydroxy or carboxy group.


A compound of formula I may be prepared by processes which include processes known in the chemical art for the

- 14 -

production of any known compounds of formula I or of structurally analogous compounds or by a novel process described herein. A process for the preparation of a novel compound of formula I (or a pharmaceutically acceptable salt thereof), novel processes for the preparation of a compound of formula I and novel intermediates for the manufacture of a compound of formula I as defined above provide further features of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as defined above, unless otherwise specified. It will be recognized that it may be preferred or necessary to prepare a compound of formula I in which a functional group is protected using a conventional protecting group, then to remove the protecting group to provide the compound of formula I.

Thus, there is provided a process for preparing a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any of the above descriptions which is selected from any of those described in the examples, including the following.

(A) For a compound of formula I in which the linkage of R^2 to the ring terminates in $-NH-CO-$, $-NR^V-CO-$ or $-NR^V-CS-$, acylating an amine of formula II,



II

25


or a corresponding amine in which the nitrogen bears the group R^V , using a corresponding acid which terminates with the group $HO-CO-$ or $HO-CS-$, or an activated derivative thereof. Typical activated derivatives include the acid halides, activated esters, including 4-nitrophenyl esters and those derived from coupling reagents, as well as (when

30

- 15 -

the product is a urea or thiourea) isocyanates and isothiocyanates. It may be preferred to deprotonate the amine using a strong base in anhydrous conditions for the acylation reaction.

- 5 (B) For a compound of formula I in which $-L^1-Q^1$ is $-NH-CO-Q^1$, acylating an amine of formula III




III

- 10 using an acid of formula $HO-CO-Q^1$, or an activated derivative thereof.

(C) For a compound of formula I in which $-L^1-Q^1$ is $-CO-NH-Q^1$ and R^2 is of the form $-NH-CO-Q^2$, acylating an amine of formula H_2N-Q^1 using a [1,3]oxazine of formula IV,


15



IV

wherein Q^2 represents, for example, Q^{2B} , Q^{2C} or Q^{2D} .


- 20 (D) For a compound of formula I in which R^2 is $-L^{2A}-Q^{2A}$ and D is carbonyl, diacylating a compound of formula II using an anhydride of formula V.



V

- 16 -

(E) For a compound of formula I in which R^2 is $-O-CO-Q^{2B}$, acylating an alcohol of formula VI



VI

using an acid of formula $HO-CO-Q^{2B}$, or an activated derivative thereof.

(F) For a compound of formula I in which $-E-G-NH-$ is $-CH_2-CH_2-NH-$, reducing the double bond of a corresponding compound of formula I in which $-E-G-NH-$ is $-CH=CH-NH-$.

(G) For a compound of formula I in which R^4 or R^5 is amino, reducing the nitro group of a corresponding compound of formula I in which R^4 or R^5 is nitro.

(H) For a compound of formula I in which R^4 or R^5 is methylsulfonylamino, substituting the amino group of a corresponding compound of formula I in which R^4 or R^5 is amino using an activated derivative of methanesulfonic acid.

(I) For a compound of formula I in which R^4 or R^5 is bis(methylsulfonyl)amino, substituting the methylsulfonylamino group of a corresponding compound of formula I in which R^4 or R^5 is methylsulfonylamino.

Whereafter, for any of the above procedures, when a functional group is protected using a protecting group, removing the protecting group.

Whereafter, for any of the above procedures, when a pharmaceutically acceptable salt of a compound of formula I is required, it is obtained by reacting the basic form of a basic compound of formula I with an acid affording a physiologically acceptable counterion or the acidic form of an acidic compound of formula I with a base affording a physiologically acceptable counterion or by any other conventional procedure.

- 17 -

A novel intermediate or starting material compound such as, for example, a novel compound of formula II, III, IV or VI, etc., provides a further aspect of the invention.

As mentioned above, a compound corresponding to a
5 compound of formula I but in which a functional group is protected may serve as an intermediate for a compound of formula I. Accordingly, such a protected intermediate for a novel compound of formula I provides a further aspect of the invention. Thus, as one particular aspect of the invention,
10 there is provided a compound corresponding to a novel compound of formula I as defined above in which R⁴ is hydroxy, but in which the corresponding substituent is -OPP in place of hydroxy, wherein PP is a phenol protecting group other than (1-4C)alkyl or benzyl. Phenol protecting groups
15 are well known in the art, for example as described in T.W. Greene and P.G.M. Wuts, "Protecting Groups in Organic Synthesis" (1991). Further, PP may denote a functionalized resin, for example as disclosed in H.V. Meyers, et al., Molecular Diversity, (1995), 1, 13-20.

20 As mentioned above, the invention includes a pharmaceutically acceptable salt of the factor Xa inhibiting compound defined by the above formula I. A basic compound of this invention possesses one or more functional groups sufficiently basic to react with any of a number of
25 inorganic and organic acids affording a physiologically acceptable counterion to form a pharmaceutically acceptable salt. Acids commonly employed to form pharmaceutically acceptable acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid,
30 sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluene sulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically acceptable

- 18 -

salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Preferred pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid, hydrobromic acid and sulfuric acid.

For a compound of formula I which bears an acidic moiety, such as a carboxy group, a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as triethylamine, morpholine, piperidine and triethanolamine.

If not commercially available, a necessary starting material for the preparation of a compound of formula I may be prepared by a procedure which is selected from standard techniques of organic chemistry, including aromatic and heteroaromatic substitution and transformation, from techniques which are analogous to the syntheses of known, structurally similar compounds, and techniques which are analogous to the above described procedures or procedures

- 19 -

described in the Examples. It will be clear to one skilled in the art that a variety of sequences is available for the preparation of the starting materials. Starting materials which are novel provide another aspect of the invention.

5 Selective methods of substitution, protection and deprotection are well known in the art for preparation of a compound such as one of formula II, III, IV or VI discussed above.

10 Generally, a basic compound of the invention is isolated best in the form of an acid addition salt. A salt of a compound of formula I formed with an acid such as one of those mentioned above is useful as a pharmaceutically acceptable salt for administration of the antithrombotic agent and for preparation of a formulation of the agent.

15 Other acid addition salts may be prepared and used in the isolation and purification of the compounds.

As noted above, the optically active isomers and diastereomers of the compounds of formula I are also considered part of this invention. Such optically active

20 isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. This resolution can be carried out by derivatization with a chiral reagent followed by chromatography or by repeated crystallization. Removal

25 of the chiral auxiliary by standard methods affords substantially optically pure isomers of the compounds of the present invention or their precursors. Further details regarding resolutions can be obtained in Jacques, et al., Enantiomers, Racemates, and Resolutions, John Wiley & Sons,

30 1981.

The compounds of the invention are believed to selectively inhibit factor Xa over other proteinases and nonenzyme proteins involved in blood coagulation without appreciable interference with the body's natural clot lysing

- 20 -

ability (the compounds have a low inhibitory effect on fibrinolysis). Further, such selectivity is believed to permit use with thrombolytic agents without substantial interference with thrombolysis and fibrinolysis.

5 The invention in one of its aspects provides a method of inhibiting factor Xa in mammals comprising administering to a mammal in need of treatment an effective (factor Xa inhibiting) dose of a compound of formula I.

10 In another of its aspects, the invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment an effective (thromboembolic disorder therapeutic and/or prophylactic amount) dose of a compound of formula I.

15 The invention in another of its aspects provides a method of inhibiting coagulation in a mammal comprising administering to a mammal in need of treatment an effective (coagulation inhibiting) dose of a compound of formula I.

20 The factor Xa inhibition, coagulation inhibition and thromboembolic disorder treatment contemplated by the present method includes both medical therapeutic and/or prophylactic treatment as appropriate.

25 In a further embodiment the invention relates to treatment, in a human or animal, of a condition where inhibition of factor Xa is required. The compounds of the invention are expected to be useful in mammals, including man, in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. Disorders in which the compounds have a potential utility are in treatment or prophylaxis of thrombosis and hypercoagulability in blood
30 and tissues. Disorders in which the compounds have a potential utility, in treatment and/or prophylaxis, include venous thrombosis and pulmonary embolism, arterial thrombosis, such as in myocardial ischemia, myocardial infarction, unstable angina, thrombosis-based stroke and

- 21 -

peripheral arterial thrombosis. Further, the compounds have expected utility in the treatment or prophylaxis of atherosclerotic disorders (diseases) such as coronary arterial disease, cerebral arterial disease and peripheral
5 arterial disease. Further, the compounds are expected to be useful together with thrombolytics in myocardial infarction. Further, the compounds have expected utility in prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass
10 operations. Further, the compounds have expected utility in prevention of rethrombosis after microsurgery. Further, the compounds are expected to be useful in anticoagulant treatment in connection with artificial organs and cardiac valves. Further, the compounds have expected utility in
15 anticoagulant treatment in hemodialysis and disseminated intravascular coagulation. A further expected utility is in rinsing of catheters and mechanical devices used in patients *in vivo*, and as an anticoagulant for preservation of blood, plasma and other blood products *in vitro*. Still further,
20 the compounds have expected utility in other diseases where blood coagulation could be a fundamental contributing process or a source of secondary pathology, such as cancer, including metastasis, inflammatory diseases, including arthritis, and diabetes. The anti-coagulant compound is
25 administered orally or parenterally, e.g. by intravenous infusion (iv), intramuscular injection (im) or subcutaneously (sc).

The specific dose of a compound administered according to this invention to obtain therapeutic and/or prophylactic
30 effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the rate of administration, the route of administration, and the condition being treated.

- 22 -

A typical daily dose for each of the above utilities is between about 0.01 mg/kg and about 1000 mg/kg. The dose regimen may vary e.g. for prophylactic use a single daily dose may be administered or multiple doses such as 3 or 5 times daily may be appropriate. In critical care situations a compound of the invention is administered by iv infusion at a rate between about 0.01 mg/kg/h and about 20 mg/kg/h and preferably between about 0.1 mg/kg/h and about 5 mg/kg/h.

10 The method of this invention also is practiced in conjunction with a clot lysing agent e.g. tissue plasminogen activator (t-PA), modified t-PA, streptokinase or urokinase. In cases when clot formation has occurred and an artery or vein is blocked, either partially or totally, a clot lysing agent is usually employed. A compound of the invention can be administered prior to or along with the lysing agent or subsequent to its use, and preferably further is administered along with aspirin to prevent the reoccurrence of clot formation.

20 The method of this invention is also practiced in conjunction with a platelet glycoprotein receptor (IIb/IIIa) antagonist, that inhibits platelet aggregation. A compound of the invention can be administered prior to or along with the IIb/IIIa antagonist or subsequent to its use to prevent the occurrence or reoccurrence of clot formation.

25 The method of this invention is also practiced in conjunction with aspirin. A compound of the invention can be administered prior to or along with aspirin or subsequent to its use to prevent the occurrence or reoccurrence of clot formation. As stated above, preferably a compound of the present invention is administered in conjunction with a clot lysing agent and aspirin.

This invention also provides a pharmaceutical composition for use in the above described therapeutic

- 23 -

method. A pharmaceutical composition of the invention comprises an effective factor Xa inhibiting amount of a compound of formula I in association with a pharmaceutically acceptable carrier, excipient or diluent.

5 The active ingredient in such formulations comprises from 0.1 percent to 99.9 percent by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious
10 to the recipient thereof.

For oral administration the antithrombotic compound is formulated in gelatin capsules or tablets which may contain excipients such as binders, lubricants, disintegration agents and the like. For parenteral administration the
15 antithrombotic is formulated in a pharmaceutically acceptable diluent e.g. physiological saline (0.9 percent), 5 percent dextrose, Ringer's solution and the like.

The compound of the present invention can be formulated in unit dosage formulations comprising a dose between about
20 0.1 mg and about 1000 mg. Preferably the compound is in the form of a pharmaceutically acceptable salt such as for example the sulfate salt, acetate salt or a phosphate salt. An example of a unit dosage formulation comprises 5 mg of a compound of the present invention as a pharmaceutically
25 acceptable salt in a 10 mL sterile glass ampoule. Another example of a unit dosage formulation comprises about 10 mg of a compound of the present invention as a pharmaceutically acceptable salt in 20 mL of isotonic saline contained in a sterile ampoule.

30 The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. The compounds of the present invention are preferably formulated prior to administration.

- 24 -

The present pharmaceutical compositions are prepared by known procedures using well known and readily available ingredients. The compositions of this invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. In making the compositions of the present invention, the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like.

The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient," of course, means a compound according to formula I or a pharmaceutically acceptable salt or solvate thereof.

25

Formulation 1: Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	<u>10</u>
Total	460 mg

- 25 -

Formulation 2: A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	<u>5</u>
Total	665 mg

The components are blended and compressed to form tablets
5 each weighing 665 mg.

Formulation 3: An aerosol solution is prepared containing the following components:

	<u>Weight</u>
Active ingredient	0.25
Ethanol	29.75
Propellant 22 (Chlorodifluoromethane)	<u>70.00</u>
Total	100.00

10

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30 °C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the
15 remainder of the propellant. The valve units are then fitted to the container.

- 26 -

Formulation 4: Tablets, each containing 60 mg of active ingredient, are made as follows:

Active ingredient	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	<u>1 mg</u>
Total	150 mg

- 5 The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced
- 10 are dried at 50 °C and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each
- 15 weighing 150 mg.

Formulation 5: Capsules, each containing 80 mg of active ingredient, are made as follows:

Active ingredient	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	<u>2 mg</u>
Total	200 mg

- 27 -

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation 6: Suppositories, each containing 225 mg of active ingredient, are made as follows:

Active ingredient	225 mg
Saturated fatty acid glycerides	<u>2,000 mg</u>
Total	2,225 mg

10

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7: Suspensions, each containing 50 mg of active ingredient per 5 mL dose, are made as follows:

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mL
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to total	5 mL

20

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and

- 28 -

added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8: An intravenous formulation may be prepared as follows:


Active ingredient	100 mg
Isotonic saline	1,000 mL

The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 mL per minute.

The ability of a compound of the present invention to be an effective and orally active factor Xa inhibitor may be evaluated in one or more of the following assays or in other standard assays known to those in the art.

The inhibition by a compound of the inhibition of a serine protease of the human blood coagulation system or of the fibrinolytic system, as well as of trypsin, is determined in vitro for the particular enzyme by measuring its inhibitor binding affinity in an assay in which the enzyme hydrolyzes a particular chromogenic substrate, for example as described in Smith, G.F.; Gifford-Moore, D.; Craft, T.J.; Chirgadze, N.; Ruterbories, K.J.; Lindstrom, T.D.; Satterwhite, J.H. *Efegatran: A New Cardiovascular Anticoagulant. New Anticoagulants for the Cardiovascular Patient*; Pifarre, R., Ed.; Hanley & Belfus, Inc.: Philadelphia, 1997; pp. 265-300. The inhibitor binding affinity is measured as apparent association constant K_{app} which is the hypothetical equilibrium constant for the reaction between enzyme and the test inhibitor compound (I).

- 29 -



$$K_{\text{ass}} = \frac{[\text{Enzyme-I}]}{[(\text{Enzyme}) \times (\text{I})]}$$

Conveniently, enzyme inhibition kinetics are performed in 96-well polystyrene plates and reaction rates are determined from the rate of hydrolysis of appropriate p-nitroanilide substrates at 405 nm using a Thermomax plate reader from Molecular Devices (San Francisco, CA). The same protocol is followed for all enzymes studied: 50 μL buffer (0.03 M Tris, 0.15 M NaCl pH 7) in each well, followed by 25 μL of inhibitor solution (in 100% methanol, or in 50% v:v aqueous methanol) and 25 μL enzyme solution; within two minutes, 150 μL aqueous solution of chromogenic substrate (0.25 mg/mL) is added to start the enzymatic reaction. The rates of chromogenic substrate hydrolysis reactions provide a linear relationship with the enzymes studied such that free enzyme can be quantitated in reaction mixtures. Data is analyzed directly as rates by the Softmax program to produce [free enzyme] calculations for tight-binding K_{ass} determinations. For apparent K_{ass} determinations, 1.34 nM human factor Xa is used to hydrolyze 0.18 mM BzIle-Glu-Gly-Arg-pNA; 5.9 nM human thrombin or 1.4 nM bovine trypsin is used to hydrolyze 0.2 mM BzPhe-Val-Arg-pNA; 3.4 nM human plasmin is used with 0.5 mM HD-Val-Leu-Lys-pNA; 1.2 nM human nt-PA is used with 0.81 mM HD-Ile-Pro-Arg-pNA; and 0.37 nM urokinase is used with 0.30 mM pyro-gfsGlu-Gly-Arg-pNA.

K_{ass} is calculated for a range of concentrations of test compounds and the mean value reported in units of liter per mole. In general, a factor Xa inhibiting compound of formula I of the instant invention exhibits a K_{ass} of 0.1 to 0.5 $\times 10^6$ L/mole or much greater.

The factor Xa inhibitor preferably should spare fibrinolysis induced by urokinase, tissue plasminogen

- 30 -

activator (t-PA) and streptokinase. This would be important to the therapeutic use of such an agent as an adjunct to streptokinase, tp-PA or urokinase thrombolytic therapy and to the use of such an agent as an endogenous fibrinolysis-sparing (with respect to t-PA and urokinase) antithrombotic agent. In addition to the lack of interference with the amidase activity of the fibrinolytic proteases, such fibrinolytic system sparing can be studied by the use of human plasma clots and their lysis by the respective fibrinolytic plasminogen activators.

Materials

Dog plasma is obtained from conscious mixed-breed hounds (either sex Butler Farms, Clyde, New York, U.S.A.) by venipuncture into 3.8 percent citrate. Fibrinogen is prepared from fresh dog plasma and human fibrinogen is prepared from in-date ACD human blood at the fraction I-2 according to previous procedures and specification. Smith, Biochem. J., 185, 1-11 (1980; and Smith, et al., Biochemistry, 11, 2958-2967, (1972). Human fibrinogen (98 percent pure/plasmin free) is from American Diagnostica, Greenwich, Connecticut. Radiolabeling of fibrinogen I-2 preparations is performed as previously reported. Smith, et al., Biochemistry, 11, 2958-2967, (1972). Urokinase is purchased from Leo Pharmaceuticals, Denmark, as 2200 Ploug units/vial. Streptokinase is purchased from Hoechst-Roussel Pharmaceuticals, Somerville, New Jersey.

Methods - Effects on Lysis of Human Plasma Clots by t-PA

Human plasma clots are formed in micro test tubes by adding 50 μ L thrombin (73 NIH unit/mL) to 100 μ L human plasma which contains 0.0229 μ Ci 125-iodine labeled fibrinogen. Clot lysis is studied by overlaying the clots with 50 μ L of urokinase or streptokinase (50, 100, or 1000 unit/mL) and

- 31 -

incubating for 20 hours at room temperature. After incubation the tubes are centrifuged in a Beckman Microfuge. 25 μ L of supernate is added into 1.0 mL volume of 0.03 M tris/0.15 M NaCl buffer for gamma counting. Counting controls 100 percent lysis are obtained by omitting thrombin (and substituting buffer). The factor Xa inhibitors are evaluated for possible interference with fibrinolysis by including the compounds in the overlay solutions at 1, 5, and 10 μ g/mL concentrations. Rough approximations of IC₅₀ values are estimated by linear extrapolations from data points to a value which would represent 50 percent of lysis for that particular concentration of fibrinolytic agent.

Anticoagulant Activity

Materials

Dog plasma and rat plasma are obtained from conscious mixed-breed hounds (either sex, Butler Farms, Clyde, New York, U.S.A.) or from anesthetized male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, Indiana, U.S.A.) by venipuncture into 3.8 percent citrate. Fibrinogen is prepared from in-date ACD human blood as the fraction I-2 according to previous procedures and specifications. Smith, Biochem. J., **185**, 1-11 (1980); and Smith, et al., Biochemistry, **11**, 2958-2967 (1972). Human fibrinogen is also purchased as 98 percent pure/plasmin free from American Diagnostica, Greenwich, Connecticut. Coagulation reagents Actin, Thromboplastin, Innovin and Human plasma are from Baxter Healthcare Corp., Dade Division, Miami, Florida. Bovine thrombin from Parke-Davis (Detroit, Michigan) is used for coagulation assays in plasma.

Methods

Anticoagulation Determinations

Coagulation assay procedures are as previously described. Smith, et al., Thrombosis Research, **50**, 163-174 (1988). A CoAScreener coagulation instrument (American LABor, Inc.) is

- 32 -

used for all coagulation assay measurements. The prothrombin time (PT) is measured by adding 0.05 mL saline and 0.05 mL Thromboplastin-C reagent or recombinant human tissue factor reagent (Innovin) to 0.05 mL test plasma. The activated partial thromboplastin time (APTT) is measured by incubation of 0.05 mL test plasma with 0.05 mL Actin reagent for 120 seconds followed by 0.05 mL CaCl_2 (0.02 M). The thrombin time (TT) is measured by adding 0.05 mL saline and 0.05 mL thrombin (10 NIH units/mL) to 0.05 mL test plasma. The compounds of formula I are added to human or animal plasma over a wide range of concentrations to determine prolongation effects on the APTT, PT, and TT assays. Linear extrapolations are performed to estimate the concentrations required to double the clotting time for each assay.

Animals

Male Sprague Dawley rats (350-425 gm, Harlan Sprague Dawley Inc., Indianapolis, IN) are anesthetized with xylazine (20 mg/kg, s.c.) and ketamine (120 mg/kg, s.c.) and maintained on a heated water blanket (37 °C). The jugular vein(s) is cannulated to allow for infusions.

Arterio-Venous shunt model

The left jugular vein and right carotid artery are cannulated with 20 cm lengths of polyethylene PE 60 tubing. A 6 cm center section of larger tubing (PE 190) with a cotton thread (5 cm) in the lumen, is friction fitted between the longer sections to complete the arterio-venous shunt circuit. Blood is circulated through the shunt for 15 min before the thread is carefully removed and weighed. The weight of a wet thread is subtracted from the total weight of the thread and thrombus (see J.R. Smith, Br J Pharmacol, 77:29, 1982).

- 33 -

FeCl₃ model of arterial injury

The carotid arteries are isolated via a midline ventral cervical incision. A thermocouple is placed under each artery and vessel temperature is recorded continuously on a strip chart recorder. A cuff of tubing (0.058 ID x 0.077 OD x 4 mm, Baxter Med. Grade Silicone), cut longitudinally, is placed around each carotid directly above the thermocouple. FeCl₃ hexahydrate is dissolved in water and the concentration (20 percent) is expressed in terms of the actual weight of FeCl₃ only. To injure the artery and induce thrombosis, 2.85 µL is pipetted into the cuff to bathe the artery above the thermocouple probe. Arterial occlusion is indicated by a rapid drop in temperature. The time to occlusion is reported in minutes and represents the elapsed time between application of FeCl₃ and the rapid drop in vessel temperature (see K.D. Kurz, Thromb. Res., 60:269, 1990).

Coagulation parameters

Plasma thrombin time (TT) and activated partial thromboplastin time (APTT) are measured with a fibrometer. Blood is sampled from a jugular catheter and collected in syringe containing sodium citrate (3.8 percent, 1 part to 9 parts blood). To measure TT, rat plasma (0.1 mL) is mixed with saline (0.1 mL) and bovine thrombin (0.1 mL, 30 U/mL in TRIS buffer; Parke Davis) at 37 °C. For APTT, plasma (0.1 mL) and APTT solution (0.1 mL, Organon Teknika) are incubated for 5 minutes (37 °C) and CaCl₂ (0.1 mL, 0.025 M) is added to start coagulation. Assays are done in duplicate and averaged.

Index of Bioavailability

Bioavailability studies may be conducted as follows. Compounds are administered as aqueous solutions to male Fisher rats, intravenously (iv) at 5 mg/kg via tail vein injection and orally (po) to fasted animals at 20 mg/kg by

- 34 -

gavage. Serial blood samples are obtained at 5, 30, 120, and 240 minutes postdose following intravenous administration and at 1, 2, 4, and 6 hours after oral dosing. Plasma is analyzed for drug concentration using an HPLC procedure involving C8 Bond Elute (Varion) cartridges for sample preparation and a methanol/30 mM ammonium acetate buffer (pH 4) gradient optimized for each compound. % Oral bioavailability is calculated by the following equation:

$$\% \text{ Oral bioavailability} = \frac{\text{AUC po}}{\text{AUC iv}} \times \frac{\text{Dose iv}}{\text{Dose po}} \times 100$$

where AUC is area under the curve calculated from the plasma level of compound over the time course of the experiment following oral (AUC po) and intravenous (AUC iv) dosing.

Compounds

Compound solutions are prepared fresh daily in normal saline and are injected as a bolus or are infused starting 15 minutes before and continuing throughout the experimental perturbation which is 15 minutes in the arteriovenous shunt model and 60 minutes in the FeCl₃ model of arterial injury and in the spontaneous thrombolysis model. Bolus injection volume is 1 mL/kg for i.v., and 5 mL/kg for p.o., and infusion volume is 3 mL/hr.

Statistics

Results are expressed as means +/- SEM. One-way analysis of variance is used to detect statistically significant differences and then Dunnett's test is applied to determine which means are different. Significance level for rejection of the null hypothesis of equal means is P<0.05.

Animals

Male dogs (Beagles; 18 months - 2 years; 12-13 kg, Marshall Farms, North Rose, New York 14516) are fasted overnight and

- 35 -

fed Purina certified Prescription Diet (Purina Mills, St. Louis, Missouri) 240 minutes after dosing. Water is available *ad libitum*. The room temperature is maintained between 66-74 °F; 45-50 percent relative humidity; and
5 lighted from 0600-1800 hours.

Pharmacokinetic model.

Test compound is formulated immediately prior to dosing by dissolving in sterile 0.9 percent saline to a 5 mg/mL
10 preparation. Dogs are given a single 2 mg/kg dose of test compound by oral gavage. Blood samples (4.5 mL) are taken from the cephalic vein at 0.25, 0.5, 0.75, 1, 2, 3, 4 and 6 hours after dosing. Samples are collected in citrated Vacutainer tubes and kept on ice prior to reduction to
15 plasma by centrifugation. Plasma samples are analyzed by HPLC MS. Plasma concentration of test compound is recorded and used to calculate the pharmacokinetic parameters: elimination rate constant, K_e ; total clearance, Cl_t ; volume of distribution, V_D ; time of maximum plasma test compound
20 concentration, T_{max} ; maximum concentration of test compound of T_{max} , C_{max} ; plasma half-life, $t_{0.5}$; and area under the curve, A.U.C.; fraction of test compound absorbed, F .

Canine Model of Coronary Artery Thrombosis

25 Surgical preparation and instrumentation of the dogs are as described in Jackson, et al., Circulation, 82, 930-940 (1990). Mixed-breed hounds (aged 6-7 months, either sex, Butler Farms, Clyde, New York, U.S.A.) are anesthetized with sodium pentobarbital (30 mg/kg intravenously, i.v.),
30 intubated, and ventilated with room air. Tidal volume and respiratory rates are adjusted to maintain blood PO_2 , PCO_2 , and pH within normal limits. Subdermal needle electrodes are inserted for the recording of a lead II ECG.

35 The left jugular vein and common carotid artery are isolated through a left mediolateral neck incision. Arterial blood

- 36 -

pressure (ABP) is measured continuously with a precalibrated Millar transducer (model MPC-500, Millar Instruments, Houston, TX, U.S.A.) inserted into the carotid artery. The jugular vein is cannulated for blood sampling during the experiment. In addition, the femoral veins of both hindlegs are cannulated for administration of test compound.

A left thoracotomy is performed at the fifth intercostal space, and the heart is suspended in a pericardial cradle. A 1- to 2-cm segment of the left circumflex coronary artery (LCX) is isolated proximal to the first major diagonal ventricular branch. A 26-gauge needle-tipped wire anodal electrode (Teflon-coated, 30-gauge silverplated copper wire) 3-4 mm long is inserted into the LCX and placed in contact with the intimal surface of the artery (confirmed at the end of the experiment). The stimulating circuit is completed by placing the cathode in a subcutaneous (s.c.) site. An adjustable plastic occluder is placed around the LCX, over the region of the electrode. A precalibrated electromagnetic flow probe (Carolina Medical Electronics, King, NC, U.S.A.) is placed around the LCX proximal to the anode for measurement of coronary blood flow (CBF). The occluder is adjusted to produce a 40-50 percent inhibition of the hyperemic blood flow response observed after 10-s mechanical occlusion of the LCX. All hemodynamic and ECG measurements are recorded and analyzed with a data acquisition system (model M3000, Modular Instruments, Malvern, PA. U.S.A.).

Thrombus Formation and Compound Administration Regimens
Electrolytic injury of the intima of the LCX is produced by applying 100- μ A direct current (DC) to the anode. The current is maintained for 60 min and then discontinued whether the vessel has occluded or not. Thrombus formation proceeds spontaneously until the LCX is totally occluded (determined as zero CBF and an increase in the S-T segment).

- 37 -

Compound administration is started after the occluding thrombus is allowed to age for 1 hour. A 2-hour infusion of the compounds of the present invention at doses of 0.5 and 1 mg/kg/hour is begun simultaneously with an infusion of thrombolytic agent (e.g. tissue plasminogen activator, streptokinase, APSAC). Reperfusion is followed for 3 hour after administration of test compound. Reocclusion of coronary arteries after successful thrombolysis is defined as zero CBF which persisted for at least 30 minutes.

10

Hematology and template bleeding time determinations

Whole blood cell counts, hemoglobin, and hematocrit values are determined on a 40- μ L sample of citrated (3.8 percent) blood (1 part citrate:9 parts blood) with a hematology analyzer (Cell-Dyn 900, Sequoia-Turner. Mount View, CA, U.S.A.). Gingival template bleeding times are determined with a Simplate II bleeding time device (Organon Teknika Durham, N.C., U.S.A.). The device is used to make 2 horizontal incisions in the gingiva of either the upper or lower left jaw of the dog. Each incision is 3 mm wide x 2 mm deep. The incisions are made, and a stopwatch is used to determine how long bleeding occurs. A cotton swab is used to soak up the blood as it oozes from the incision. Template bleeding time is the time from incision to stoppage of bleeding. Bleeding times are taken just before administration of test compound (0 min), 60 min into infusion, at conclusion of administration of the test compound (120 min), and at the end of the experiment.

30

All data are analyzed by one-way analysis of variance (ANOVA) followed by Student-Neuman-Kuels post hoc *t* test to determine the level of significance. Repeated-measures ANOVA are used to determine significant differences between time points during the experiments. Values are determined to be statistically different at least at the level of $p < 0.05$. All values are mean \pm SEM. All studies are

35

- 38 -

conducted in accordance with the guiding principles of the American Physiological Society. Further details regarding the procedures are described in Jackson, et al., J. Cardiovasc. Pharmacol., (1993), 21, 587-599.

5

The following Examples are provided to further describe the invention and are not to be construed as limitations thereof.

10 The abbreviations, symbols and terms used in the examples have the following meanings.

Ac = acetyl

AIBN = azobisisobutyronitrile

Anal. = elemental analysis

aq = aqueous

15

Bn or Bzl = benzyl

Boc = t-butyloxycarbonyl

Bu = butyl

n-BuLi = butyllithium

Calc = calculated

20

conc = concentrated

DCC = dicyclohexylcarbodiimide

DMAP = 4-dimethylaminopyridine

DMF = dimethylformamide

DMSO = dimethylsulfoxide

25

EDC = 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride

eq = (molar) equivalent

Et = ethyl

EtOAc = ethyl acetate

30

Et₃N = triethylamine

Et₂O = diethyl ether

EtOH = ethanol

FAB = Fast Atom Bombardment (Mass Spectroscopy)

FD-MS = field desorption mass spectrum

35

FIA-MS = flow injection analysis mass spectrum

Hex = hexanes

- 39 -

HOAt = 1-hydroxy-7-azabenzotriazole
HOBT = 1-hydroxybenzotriazole
HPLC = High Performance Liquid Chromatography
HRMS = high resolution mass spectrum
5 i-PrOH = isopropanol
IR = Infrared Spectrum
IS-MS = ion spray mass spectrum
Me = methyl
MeI = methyl iodide
10 MeOH = methanol
NBS = N-bromosuccinimide
NMR = Nuclear Magnetic Resonance
Ph = phenyl
i-Pr = isopropyl
15 RPHPLC = Reversed Phase High Performance Liquid
Chromatography
satd = saturated
SiO₂ = silica gel
TBS = tert-butyldimethylsilyl
20 TFA = trifluoroacetic acid
THF = tetrahydrofuran
TIPS = triisopropylsilyl
TLC = thin layer chromatography
tosyl = p-toluenesulfonyl
25 triflic acid = trifluoromethanesulfonic acid

Unless otherwise stated, pH adjustments and work up are with aqueous acid or base solutions. ¹H-NMR indicates a satisfactory NMR spectrum was obtained for the compound
30 described. IR indicates a satisfactory infra red spectrum was obtained for the compound described.

For consistency and clarity, a number of compounds are named as substituted diamine derivatives.

The following conditions were used for reverse phase
35 HPLC analysis and purification in some of the compounds described in the examples below.

- 40 -

Solvents: A = 0.05% conc. HCl in water, B = acetonitrile

Column: Vydac C18 - 5 x 25 cm


- 5 Method A: 10 mL/min; 80/20 (A/B) through 50/50 (A/B), linear gradient over 120 min.

Method B: 10 mL/min; 90/10 (A/B) through 40/60 (A/B), linear gradient over 180 min.

- 41 -

Example 1

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)benzamide.



5

A) 1-Boc-6-nitroindazole

To a stirring solution of 6-nitroindazole (5 g, 31 mmol) in dichloromethane (100 mL) and DMF (10 mL), was added di-t-butyl dicarbonate (13 g, 61 mmol) followed by DMAP (3.7 g, 31 mmol). After stirring 16 h, the solvent was removed by rotary evaporation and the residue was dissolved in ethyl acetate (300 mL) and washed with 1 M citric acid, brine, satd aq NaHCO₃ and again with brine. The organic phase was then dried with MgSO₄, filtered and concentrated in vacuo. The solid was suspended in ether with vigorous stirring and filtered, then washed again with ether and dried in vacuo to give 7.1 g (88%) of white solid.

¹H-NMRFD-MS, m/e 263 (M⁺)20 Analysis for C₁₂H₁₃N₃O₄:

Calc: C, 54.75; H, 4.98; N, 15.96;

Found: C, 54.72; H, 4.96; N, 16.01.

B) 1-Boc-6-aminoindazole

25 To a stirring solution of 1-Boc-6-nitroindazole (2.5 g, 9.5 mmol) in ethyl acetate (75 mL) under nitrogen was added 10% Pd/C (500 mg). The mixture was placed under vacuum and

- 42 -

the atmosphere was replaced with hydrogen (1 atm). After stirring for 12 h, the hydrogen balloon was removed and diatomaceous earth was added. The mixture was then filtered over a pad of diatomaceous earth and the solvent was removed
5 by rotary evaporation to give 2.17 g (98%) of light pink solid.

¹H-NMR

FD-MS, m/e 233 (M⁺)

Analysis for C₁₂H₁₅N₃O₂:

10 Calc: C, 61.79; H, 6.48; N, 18.01;
 Found: C, 61.49; H, 6.39; N, 17.94.

C) N-(1-Boc-6-indazolyl)-2-nitrobenzamide

To a stirring solution of 1-Boc-6-aminoindazole (1.5 g,
15 6.4 mmol) in dichloromethane (25 mL) was added pyridine
(1.55 mL, 19.2 mmol) followed by 2-nitrobenzoyl chloride
(1 mL, 7.1 mmol). After stirring for 12 h, the solvent was
removed by rotary evaporation and the residue was
partitioned between ethyl acetate (250 mL) and water
20 (250 mL). The aqueous phase was separated and the organic
phase was washed with 1 M citric acid, brine, satd aq
NaHCO₃, and brine. The organic phase was then dried with
MgSO₄, filtered and concentrated in vacuo to give 2.64 g of
off-white solid.

25 ¹H-NMR

FD-MS, m/e 382 (M⁺)

Analysis for C₁₉H₁₈N₄O₅·0.3H₂O:

 Calc: C, 58.85; H, 4.83; N, 14.44;
 Found: C, 58.82; H, 4.77; N, 14.29.

30

- 51 -


¹H NMRFD-MS, m/e 413.4 (M⁺)Anal. for C₂₆H₂₇N₃O₂·0.3H₂O:

Calc: C, 74.55; H, 6.64; N, 10.03;
5 Found: C, 74.75; H, 6.80; N, 9.38.

Example 6

Preparation of N-(6-Indolinyl)-2-[(4-methoxybenzoyl)amino]-
benzamide.

10



A) N-(1-Boc-6-indolinyl)-2-[(4-methoxybenzoyl)amino]-
benzamide

By methods substantially equivalent to those described
15 in Example 1-C, N-(1-Boc-6-indolinyl)-2-[(4-methoxybenzoyl)-
amino]benzamide (250 mg, 39%) was prepared from p-anisoyl
chloride and 2-amino-N-(1-Boc-6-indolinyl)benzamide.

¹H NMR

20 B) N-(6-Indolinyl)-2-[(4-methoxybenzoyl)amino]benzamide

By methods substantially equivalent to those described
in Example 1-F, N-(6-indolinyl)-2-[(4-methoxybenzoyl)-
amino]benzamide (160 mg, 100%) was prepared from N-(1-Boc-
6-indolinyl)-2-[(4-methoxybenzoyl)amino]benzamide.

25 ¹H NMR


FD-MS, m/e 387 (M⁺)Anal. for C₂₃H₂₁N₃O₃·0.5H₂O:

- 52 -

Calc: C, 69.69; H, 5.59; N, 10.59;
Found: C, 69.79; H, 5.28; N, 10.37.

Example 7

- 5 **Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(3-methyl-6-indazolyl)benzamide.**



- A) 1-Boc-3-methyl-6-nitroindazole
- 10 By methods substantially equivalent to those described in Example 1-A, 1-Boc-3-methyl-6-nitroindazole (3 g, 64%) was prepared from 3-methyl-6-nitro-indazole (Chem. Abstr., (1966), 65, p 2245).
- ¹H NMR
- 15 FD-MS, m/e (M⁺)
- Anal. for C₁₃H₁₅N₃O₄:
- Calc: C, 56.31; H, 5.45; N, 15.15;
Found: C, 55.86; H, 5.62; N, 14.80.
- 20 B) 6-Amino-1-Boc-3-methylindazole
- By methods substantially equivalent to those described in Example 2-B, 6-amino-1-Boc-3-methylindazole (2.26 g, 85%) was prepared from 1-Boc-3-methyl-6-nitroindazole.
- ¹H NMR
- 25 FD-MS, m/e (M⁺)
- Anal. for C₁₃H₁₇N₃O₂:

- 53 -

Calc: C, 63.14; H, 6.93; N, 16.99;
Found: C, 62.84; H, 6.93; N, 17.05.

C) N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide

- 5 By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide (2.07 g, 100%) was prepared from 2-nitrobenzoyl chloride and 6-amino-1-Boc-3-methylindazole.

10 D) 2-Amino-N-(1-Boc-3-methyl-6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 2-B, 2-amino-N-(1-Boc-3-methyl-6-indazolyl)-benzamide (1.62 g, 89%) was prepared from N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide.

15 ¹H NMR

FD-MS, m/e 366.2 (M⁺)

Anal. for C₂₀H₂₂N₄O₃:

Calc: C, 65.55; H, 6.05; N, 15.29;
Found: C, 65.54; H, 6.04; N, 15.11.

20

E) N-(1-Boc-3-methyl-6-indazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-methyl-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (1.21 g, 96%) was prepared from 4-t-butylbenzoyl chloride and 2-amino-N-(1-Boc-3-methyl-6-indazolyl)benzamide.

¹H NMR

FD-MS, m/e 526 (M⁺)

30 Anal. for C₃₁H₃₄N₄O₄:

- 46 -

D) 2-Amino-N-(1-Boc-6-indolyl)benzamide

By methods substantially equivalent to those described in Example 2-B, 2-amino-N-(1-Boc-6-indolyl)benzamide (870 mg, 95%) was prepared from 1-[N-(1-Boc-6-indolyl)]-2-nitro-
5 benzamide.

¹H-NMRFD-MS, m/e 351 (M⁺)E) N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-
10 benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide (140 mg, 41%) was prepared from 4-t-butylbenzoyl chloride and 2-amino-N-(1-Boc-6-indolyl)benzamide.

15 ¹H-NMRFD-MS, m/e 511 (M⁺)Analysis for C₃₁H₃₃N₃O₄:

Calc: C, 72.78; H, 6.50; N, 8.21;

Found: C, 72.57; H, 6.39; N, 8.11.

20

F) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)benzamide

N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-benzamide (75 mg, 0.147 mmol) was placed in a 10 dram (37 mL) glass scintillation vial and the vial was placed
25 under nitrogen on a hot plate. As the solid melted, gas evolution was observed. After the solid had completely melted (about 5 min), the vial was removed from the hot plate and allowed to cool. The residue was then dissolved in DMF (2 mL), diluted with ethyl acetate (150 mL) and
30 washed twice with water, once with satd aq NaHCO₃ and once with brine. The organic phase was dried with MgSO₄,

- 47 -

filtered and concentrated in vacuo. The crude solid was recrystallized from Et₂O to give 30 mg (50%) of white solid.

¹H-NMR

FD-MS, m/e 411.2 (M⁺)


5 Analysis for C₂₆H₂₅N₃O₂·H₂O:

Calc: C, 72.71; H, 6.34; N, 9.78;

Found: C, 72.73; H, 6.17; N, 9.39.

Example 3

10 Preparation of N-(6-Indazolyl)-2-[(4-methoxybenzoyl)-amino]benzamide.



A) N-(1-Boc-6-indazolyl)-2-[(4-methoxybenzoyl)amino]-benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indazolyl)-2-[(4-methoxybenzoyl)-amino]benzamide (280 mg, 39%) was prepared from p-anisoyl chloride and 2-amino-N-(1-Boc-6-indazolyl)benzamide.

20 ¹H-NMR

FD-MS, m/e 486.1 (M⁺)

Analysis for C₂₇H₂₆N₄O₅:

Calc: C, 66.66; H, 5.39; N, 11.52;

Found: C, 66.39; H, 5.54; N, 11.45.

25

B) N-(6-Indazolyl)-2-[(4-methoxybenzoyl)amino]benzamide

By methods substantially equivalent to those described in Example 1-F, N-(6-indazolyl)-2-[(4-methoxybenzoyl)amino]-

- 48 -

benzamide (160 mg, 100%) was prepared from N-(1-Boc-6-indazolyl)-2-[(4-methoxybenzoyl)amino]benzamide.

¹H-NMR

FD-MS, m/e 386 (M⁺)


5 Analysis for C₂₂H₁₈N₄O₃:

Calc: C, 68.38; H, 4.70; N, 14.50;

Found: C, 68.79; H, 5.16; N, 14.00.

Example 4

10 Preparation of N-(6-Indolyl)-2-[(4-methoxybenzoyl)-amino]benzamide.



A) N-(1-Boc-6-indolyl)-2-[(4-methoxybenzoyl)amino]-
15 benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indolyl)-2-[(4-methoxybenzoyl)-amino]benzamide (436 mg, 83%) was prepared from p-anisoyl chloride and 2-amino-N-(1-Boc-6-indolyl)benzamide.

20 ¹H-NMR

FD-MS, m/e 485.1 (M⁺)

Analysis for C₂₈H₂₇N₃O₅:

Calc: C, 69.26; H, 5.60; N, 8.65;

Found: C, 68.96; H, 5.73; N, 8.53.

25

B) N-(6-Indolyl)-2-[(4-methoxybenzoyl)amino]benzamide

By methods substantially equivalent to those described in Example 2-F, N-(6-indolyl)-2-[(4-methoxybenzoyl)amino]-

- 49 -

benzamide (76 mg, 94%) was prepared from N-(1-Boc-6-indolyl)-2-[(4-methoxybenzoyl)amino]benzamide.

¹H-NMR

FD-MS, m/e (M⁺)


5 Analysis for C₂₃H₁₉N₃O₃·0.5H₂O:

Calc: C, 70.04; H, 5.11; N, 10.65;

Found: C, 70.13; H, 4.99; N, 10.37.

Example 5

10 Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indoliny1)-benzamide.



A) 1-Boc-6-aminoindoline

15 By methods substantially equivalent to those described in Example 1-B, 1-Boc-6-aminoindoline (2.2 g, 98%) was prepared from 1-Boc-6-aminoindole.

¹H NMR

20 B) N-(1-Boc-6-indoliny1)-2-nitrobenzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indoliny1)-2-nitrobenzamide (2.5 g, 100%) was prepared from 1-Boc-6-aminoindoline.

¹H NMR

25 FD-MS, m/e 383 (M⁺)

Anal. for C₂₀H₂₁N₃O₅:

- 50 -

Calc: C, 62.66; H, 5.52; N, 10.96;
Found: C, 62.58; H, 5.46; N, 10.66.

C) 2-Amino-N-(1-Boc-6-indoliny1)benzamide

- 5 By methods substantially equivalent to those described in Example 1-B, 2-amino-N-(1-Boc-6-indoliny1)benzamide (0.92 g, 100%) was prepared from N-(1-Boc-6-indoliny1)-2-nitrobenzamide.

¹H NMR

- 10 FD-MS, m/e 353 (M⁺)

Anal. for C₂₀H₂₃N₃O₃·H₂O:

Calc: C, 64.68; H, 6.78; N, 11.31;
Found: C, 64.48; H, 6.64; N, 11.19.

- 15 D) N-(1-Boc-6-indoliny1)-2-[(4-t-butylbenzoyl)amino]-benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indoliny1)-2-[(4-t-butylbenzoyl)-amino]benzamide (245 mg, 69%) was prepared from 4-t-butyl-

- 20 benzoyl chloride and N-(1-Boc-6-indoliny1)-2-aminobenzamide.

¹H NMR

FD-MS, m/e 513.2 (M⁺)

Anal. for C₃₁H₃₅N₃O₄:

- 25 Calc: C, 72.49; H, 6.87; N, 8.18;
Found: C, 72.70; H, 6.97; N, 8.16.

E) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indoliny1)benzamide

By methods substantially equivalent to those described in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indoliny1)-

- 30 benzamide (87 mg, 54%) was prepared from N-(1-Boc-6-indoliny1)-2-[(4-t-butylbenzoyl)amino]benzamide.

- 51 -


¹H NMRFD-MS, m/e 413.4 (M⁺)Anal. for C₂₆H₂₇N₃O₂·0.3H₂O:

Calc: C, 74.55; H, 6.64; N, 10.03;
 5 Found: C, 74.75; H, 6.80; N, 9.38.

Example 6

Preparation of N-(6-Indolinyl)-2-[(4-methoxybenzoyl)amino]-
 benzamide.

10



A) N-(1-Boc-6-indolinyl)-2-[(4-methoxybenzoyl)amino]-
 benzamide

By methods substantially equivalent to those described
 15 in Example 1-C, N-(1-Boc-6-indolinyl)-2-[(4-methoxybenzoyl)-
 amino]benzamide (250 mg, 39%) was prepared from p-anisoyl
 chloride and 2-amino-N-(1-Boc-6-indolinyl)benzamide.

¹H NMR

20 B) N-(6-Indolinyl)-2-[(4-methoxybenzoyl)amino]benzamide

By methods substantially equivalent to those described
 in Example 1-F, N-(6-indolinyl)-2-[(4-methoxybenzoyl)-
 amino]benzamide (160 mg, 100%) was prepared from N-(1-Boc-
 6-indolinyl)-2-[(4-methoxybenzoyl)amino]benzamide.

25 ¹H NMR


FD-MS, m/e 387 (M⁺)Anal. for C₂₃H₂₁N₃O₃·0.5H₂O:

- 52 -

Calc: C, 69.69; H, 5.59; N, 10.59;
Found: C, 69.79; H, 5.28; N, 10.37.

Example 7

- 5 **Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(3-methyl-6-indazolyl)benzamide.**



A) 1-Boc-3-methyl-6-nitroindazole

- 10 By methods substantially equivalent to those described in Example 1-A, 1-Boc-3-methyl-6-nitroindazole (3 g, 64%) was prepared from 3-methyl-6-nitro-indazole (Chem. Abstr., (1966), 65, p 2245).

¹H NMR

- 15 FD-MS, m/e (M⁺)

Anal. for C₁₃H₁₅N₃O₄:

Calc: C, 56.31; H, 5.45; N, 15.15;
Found: C, 55.86; H, 5.62; N, 14.80.

20 B) 6-Amino-1-Boc-3-methylindazole

By methods substantially equivalent to those described in Example 2-B, 6-amino-1-Boc-3-methylindazole (2.26 g, 85%) was prepared from 1-Boc-3-methyl-6-nitroindazole.

¹H NMR

- 25 FD-MS, m/e (M⁺)

Anal. for C₁₃H₁₇N₃O₂:

- 53 -

Calc: C, 63.14; H, 6.93; N, 16.99;
Found: C, 62.84; H, 6.93; N, 17.05.

C) N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide

5 By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide (2.07 g, 100%) was prepared from 2-nitrobenzoyl chloride and 6-amino-1-Boc-3-methylindazole.

10 D) 2-Amino-N-(1-Boc-3-methyl-6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 2-B, 2-amino-N-(1-Boc-3-methyl-6-indazolyl)-benzamide (1.62 g, 89%) was prepared from N-(1-Boc-3-methyl-6-indazolyl)-2-nitrobenzamide.

15 ¹H NMR

FD-MS, m/e 366.2 (M⁺)

Anal. for C₂₀H₂₂N₄O₃:

Calc: C, 65.55; H, 6.05; N, 15.29;
Found: C, 65.54; H, 6.04; N, 15.11.

20

E) N-(1-Boc-3-methyl-6-indazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-methyl-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (1.21 g, 96%) was prepared from 4-t-butylbenzoyl chloride and 2-amino-N-(1-Boc-3-methyl-6-indazolyl)benzamide.

25 ¹H NMR

FD-MS, m/e 526 (M⁺)

30 Anal. for C₃₁H₃₄N₄O₄:

- 54 -

Calc: C, 70.70; H, 6.51; N, 10.64;

Found: C, 70.05; H, 6.51; N, 10.73.

5 F) 2-[(4-t-butylbenzoyl)amino]-N-(3-methyl-6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(3-methyl-6-indazolyl)benzamide (0.17 g, 57%) was prepared from N-(1-Boc-3-methyl-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-benzamide.

¹H NMRFD-MS, m/e 426.1 (M⁺)Anal. for C₂₆H₂₆N₄O₂·TFA:


Calc: C, 62.33; H, 4.86; N, 10.39;

15 Found: C, 62.09; H, 4.70; N, 10.27.

Example 8

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(3-chloro-6-indazolyl)benzamide.

20



A) 1-Boc-3-chloro-6-nitroindazole

By methods substantially equivalent to those described in Example 1-A, 1-Boc-3-chloro-6-nitroindazole (3.49 g, 97%) was prepared from 3-chloro-6-nitro-indazole.

¹H NMRFD-MS, m/e 297.1 (M⁺)

- 55 -

Anal. for $C_{12}H_{12}ClN_3O_4$:

Calc: C, 48.41; H, 4.06; N, 14.11;

Found: C, 48.65; H, 3.99; N, 14.22.

5 B) 6-Amino-1-Boc-3-chloroindazole

By methods substantially equivalent to those described in Example 2-B, 6-amino-1-Boc-3-chloroindazole (2.35 g, 88%) was prepared from 1-Boc-3-chloro-6-nitroindazole.

 1H NMR10 FD-MS, m/e 267.1 (M^+)Anal. for $C_{12}H_{14}ClN_3O_2$:

Calc: C, 53.84; H, 5.20; N, 16.70;

Found: C, 53.74; H, 5.30; N, 16.65.

15 C) N-(1-Boc-3-chloro-6-indazolyl)-2-nitrobenzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-chloro-6-indazolyl)-2-nitrobenzamide (2.1 g, 100%) was prepared from 1-Boc-3-chloro-6-aminoindazole.

20 1H NMRFD-MS, m/e 416.0 (M^+)Anal. for $C_{19}H_{17}ClN_4O_5$:

Calc: C, 54.75; H, 4.11; N, 13.44;

Found: C, 54.94; H, 4.03; N, 13.30.

25

D) 2-Amino-N-(1-Boc-3-chloro-6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 2-B, 2-amino-N-(1-Boc-3-chloro-6-indazolyl)-benzamide (1.58 g, 83%) was prepared from N-(1-Boc-3-chloro-6-indazolyl)-2-nitrobenzamide.

30

 1H NMR

- 56 -

FD-MS, m/e 386 (M^+)

E) N-(1-Boc-3-chloro-6-indazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

5 By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-3-chloro-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (1.32 g, 81%) was prepared from 4-t-butylbenzoyl chloride and 2-amino-N-(1-Boc-3-chloro-6-indazolyl)benzamide.

10 1H NMR

FD-MS, m/e 546 (M^+)Anal. for $C_{30}H_{31}ClN_4O_4$:

Calc: C, 65.87; H, 5.71; N, 10.24;

Found: C, 65.61; H, 5.71; N, 10.18.

15

F) 2-[(4-t-butylbenzoyl)amino]-N-(3-chloro-6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(3-chloro-6-indazolyl)benzamide (0.15 g, 48%) was prepared from N-(1-Boc-3-chloro-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-benzamide.

20 1H NMR

FD-MS, m/e 446 (M^+)25 Anal. for $C_{25}H_{23}ClN_4O_2$:


Calc: C, 67.18; H, 5.19; N, 12.54;

Found: C, 67.17; H, 5.05; N, 12.31.

Example 9

30 Preparation of N²-(4-t-Butylbenzoyl)-N¹-(6-indazolyl)-carb nyl)-1,2-benzenediamine.

- 57 -



A) 2-[(4-t-Butylbenzoyl)amino]nitrobenzene

By methods substantially equivalent to those described
5 in Example 3-A, 2-[(4-t-butylbenzoyl)amino]nitrobenzene
(21.6 g, 100%) was prepared from 4-t-butylbenzoyl chloride
and 2-nitroaniline.

¹H NMR10 B) N²-(4-t-butylbenzoyl)-1,2-benzenediamine

By methods substantially equivalent to those described
in Example 1-B, N²-(4-t-butylbenzoyl)-1,2-benzenediamine
(19.87 g, 79%) was prepared from 2-[(4-t-butylbenzoyl)-
amino]nitrobenzene.

15 ¹H NMRFD-MS, m/e 298.2 (M⁺)C) N²-(4-t-Butylbenzoyl)-N¹-(6-indazolylcarbonyl)-1,2-benzenediamine

20 To a stirring solution of N²-(4-t-butylbenzoyl)-1,2-benzenediamine (830 mg, 3.1 mmol) and 6-indazolecarboxylic acid (European Pat. Appln. Pub. No. 242 167 A2, p 43) (500 mg, 3.1 mmol) in DMF (5 mL) was added EDC (1.19 g, 6.2 mmol). After 12 h, the solvent was removed in vacuo and
25 the residue was dissolved in ethyl acetate and washed twice with water and twice with brine. The organic phase was dried with MgSO₄, filtered and concentrated in vacuo, then chromatographed over silica gel, eluting with a solvent

- 58 -

gradient of dichloromethane through 5% methanol/dichloromethane. The product containing fractions were combined and concentrated in vacuo to give 330 mg (26%) of an off-white solid.

5 ^1H NMR

FD-MS, m/e 412 (M^+)

Anal. for $\text{C}_{24}\text{H}_{24}\text{N}_4\text{O}_2$:


Calc: C, 72.80; H, 5.87; N, 13.58;

Found: C, 72.15; H, 5.80; N, 13.19.

10

Example 10

Preparation of N^2 -(4-t-Butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine.



15

By methods substantially equivalent to those described in Example 9-C, N^2 -(4-t-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine (0.10 g, 20%) was prepared from N^2 -(4-t-butylbenzoyl)-1,2-benzenediamine and indole-6-carboxylic acid.

20

^1H NMR

FD-MS, m/e 411.1 (M^+)

Anal. for $\text{C}_{26}\text{H}_{25}\text{N}_3\text{O}_2 \cdot 0.3\text{H}_2\text{O}$:

Calc: C, 74.91; H, 6.19; N, 10.07;


25

Found: C, 74.94; H, 6.44; N, 9.77.

- 59 -

Example 11

Preparation of N²-(4-t-butylbenzoyl)-N¹-(6-indazolyl-carbonyl)-4-methoxycarbonyl-1,2-benzenediamine.



A) N²-(4-t-Butylbenzoyl)-4-methoxycarbonyl-1,2-benzenediamine

To a stirring solution of 4-methoxycarbonyl-1,2-benzenediamine (8.5 g, 51 mmol) and pyridine (4.1 mL, 51 mmol) in acetonitrile (225 mL) at 0 °C was added via an addition funnel a solution of 4-t-butylbenzoyl chloride (10 g, 51 mmol) in acetonitrile (25 mL). After 3 h, the mixture was concentrated to a volume of about 20 mL in vacuo and then diluted with ethyl acetate (300 mL) and water (100 mL). The phases were separated and the organic phase was washed twice with 1 M citric acid, once with brine, twice with satd aq NaHCO₃ and once again with brine. The organic phase was then dried with MgSO₄, filtered and partially concentrated in vacuo. After standing for 48 h, the resulting precipitate was filtered, washed with ethyl acetate and dried in vacuo to give 8.2 g (48%) of off white solid. By a similar procedure, a second crop of 2.6 g (16%) was isolated from the mother liquor.

25 ¹H NMR

FD-MS, m/e 326.2 (M⁺)

- 60 -

Anal. for $C_{19}H_{22}N_2O_3$:

Calc: C, 69.92; H, 6.79; N, 8.58;

Found: C, 70.02; H, 6.91; N, 8.61.

- 5 B) N^2 -(4-t-Butylbenzoyl)- N^1 -(6-indazolylcarbonyl)-4-methoxycarbonyl-1,2-benzenediamine

By methods substantially equivalent to those described in Example 9-C, N^2 -(4-t-butylbenzoyl)- N^1 -(6-indazolylcarbonyl)-4-methoxycarbonyl-1,2-benzenediamine (0.1 g, 5%)
10 was prepared from 4-methoxycarbonyl- N^2 -(4-t-butylbenzoyl)-1,2-benzenediamine and 6-indazolecarboxylic acid.


 1H NMRFD-MS, m/e 438.3 (M^+)Anal. for $C_{26}H_{22}N_4O_3$:

15 Calc: C, 68.92; H, 5.57; N, 11.91;

Found: C, 68.94; H, 5.62; N, 11.79.

Example 12

Preparation of N^2 -(4-t-Butylbenzoyl)- N^1 -(6-indolinylylcarbonyl)-1,2-benzenediamine.
20



To a stirring solution of N^2 -(4-t-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine (0.1 g, 0.24 mmol) in
25 acetic acid (1 mL) was added $NaBH_3CN$ (0.046 g, 0.73 mmol). After 2 h, the mixture was diluted with water (10 mL), the pH was basified with conc aq $NaHCO_3$ and the aqueous phase

- 61 -

was extracted twice with ethyl acetate. The combined ethyl acetate phase was washed with water and brine, then dried with MgSO_4 , filtered and concentrated in vacuo to give 70 mg (70%) of white solid.

5 ^1H NMR

FD-MS, m/e 413.52 (M^+)

Anal. for $\text{C}_{26}\text{H}_{27}\text{N}_3\text{O}_2 \cdot 1.3\text{H}_2\text{O}$:


Calc: C, 71.47; H, 6.83; N, 9.61;

Found: C, 71.53; H, 7.00; N, 9.02.

10

Example 13

Preparation of N^1 -(6-Benzimidazolylcarbonyl)- N^2 -(4-t-butylbenzoyl)-1,2-benzenediamine.



15

A) N^2 -(4-t-butylbenzoyl)- N^1 -(1-tosylbenzimidazol-6-ylcarbonyl)-1,2-benzenediamine

By methods substantially equivalent to those described in Example 9-C, N^2 -(4-t-butylbenzoyl)- N^1 -(1-tosylbenzimidazol-6-ylcarbonyl)-1,2-benzenediamine (0.432 g, 21%) was prepared from 1-tosylbenzimidazole-6-carboxylic acid and N^2 -(4-t-butylbenzoyl)-1,2-benzenediamine.

^1H NMR

25 FD-MS, m/e 566 (M^+)

Anal. for $\text{C}_{32}\text{H}_{30}\text{N}_4\text{O}_4\text{S}$:

Calc: C, 67.83; H, 5.34; N, 9.89;

- 62 -

Found: C, 67.56; H, 5.50; N, 9.77.

B) N¹-(6-Benzimidazolylcarbonyl)-N²-(4-t-butylbenzoyl)-1,2-benzenediamine

- 5 To a stirring solution of N²-(4-t-butylbenzoyl)-N¹-(1-tosylbenzimidazol-6-ylcarbonyl)-1,2-benzenediamine (360 mg, 0.63 mmol) in THF (10 mL) was added HOBT (1.36 g, 10 mmol). After stirring for 24 h, the solvent was removed in vacuo. The residue was dissolved in dichloromethane and washed with
- 10 satd aq NaHCO₃. The organic phase was allowed to stand overnight, and the resulting precipitate was filtered and dried to give 140 mg (54%) of white solid.

¹H NMRFD-MS, m/e 412.1 (M⁺)


- 15 Anal. for C₂₅H₂₄N₄O₂:

Calc: C, 72.80; H, 5.87; N, 13.58;

Found: C, 73.01; H, 6.15; N, 13.57.

Example 14

- 20 Preparation of N¹-(6-Benzotriazolylcarbonyl)-N²-[(4-t-butylbenzoyl)amino]-1,2-benzenediamine.



- 25 By methods substantially equivalent to those described in Example 9-C, N¹-(6-benzotriazolylcarbonyl)-N²-[(4-t-butylbenzoyl)amino]-1,2-benzenediamine (400 mg, 31%) was

- 63 -

prepared from benzotriazole-6-carboxylic acid and N²-[(4-t-butylbenzoyl)amino]-1,2-benzenediamine.

¹H NMR

FD-MS, m/e 413 (M⁺)


5 Anal. for C₂₄H₂₃N₅O₂:

Calc: C, 67.71; H, 5.61; N, 16.94;

Found: C, 67.47; H, 5.64; N, 16.73.

Example 15

10 Preparation of N-(6-Benzimidazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide.



15 A) 5-Nitro-1-tosylbenzimidazole

To a stirring solution of 5-nitrobenzimidazole (7.5 g, 46 mmol) in THF (300 mL) and water (150 mL) was added K₂CO₃ (15.9 g, 115 mmol), followed by p-toluenesulfonyl chloride (11.4 g, 46 mmol). After stirring for 16 h, solvents were removed in vacuo and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic phase was washed with brine, then dried with MgSO₄, filtered and concentrated in vacuo. The crude solid was dissolved in chloroform and chromatographed over a silica gel column with a gradient of chloroform through 10% methanol/chloroform. The product containing fractions were combined and concentrated in vacuo to give 11.4 g (79%) of light yellow solid.

- 64 -

¹H NMRFD-MS, m/e 317 (M⁺)Anal. for C₁₄H₁₁N₃O₄S:

Calc: C, 52.99; H, 3.49; N, 13.24;

5 Found: C, 52.92; H, 3.31; N, 13.16.

B) 2-Nitro-N-(1-tosylbenzimidazol-6-yl)benzamide

By methods substantially equivalent to those described in Example 1-B followed by those of Example 1-C, 2-nitro-N-(1-tosylbenzimidazol-6-yl)benzamide (6.8 g, 99%) was prepared from 5-nitro-1-tosylbenzimidazole.

¹H NMRFD-MS, m/e 436.1 (M⁺)Anal. for C₂₁H₁₆N₄O₅S:

15 Calc: C, 57.79; H, 3.69; N, 12.84;

Found: C, 57.52; H, 3.70; N, 13.11.

C) N-(6-Benzimidazolyl)-2-[(4-t-butylbenzoyl)amino]-benzamide

20 By methods substantially equivalent to those described in Examples 1-B and 1-C, 3.7 g (6.5 mmol) of crude 2-[(4-t-butylbenzoyl)amino]-N-(1-tosylbenzimidazol-6-yl)benzamide was prepared from 2-nitro-N-(1-tosylbenzimidazol-6-yl)-benzamide and 4-t-butylbenzoyl chloride. This material was

25 dissolved in p-dioxane (50 mL) and a solution of LiOH·H₂O (0.48 g, 11 mmol) in water (25 mL) was added with vigorous stirring. After 16 h, the solvents were removed in vacuo and the residue was partitioned between chloroform and satd aq NaHCO₃. The phases were separated and the organic phase

30 was washed with water, followed by brine, then dried over MgSO₄, filtered and concentrated in vacuo. The residue was triturated with ether, filtered and the solid was dissolved

- 65 -

in a minimal amount of chloroform and chromatographed over a silica gel column with 10% methanol/chloroform. The product containing fractions were combined and concentrated in vacuo to give 0.97 g (36% overall) of off-white solid.

5 ^1H NMRFD-MS, m/e 412.1 (M^+)Anal. for $\text{C}_{25}\text{H}_{24}\text{N}_4\text{O}_2$:


Calc: C, 72.80; H, 5.86; N, 13.58;

Found: C, 73.08; H, 5.79; N, 13.67.

10

Example 16

Preparation of 3-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-2-thiophenecaboxamide.



15

A) Methyl 3-[(4-t-Butylbenzoyl)amino]-2-thiophenecarboxylate

A flame dried flask was charged with methyl 3-amino-2-thiophenecarboxylate (5.0g, 35.0 mmol), pyridine (2.82 mL, 35.0 mmol), and dry methylene chloride (160 mL). The solution was cooled to 0 °C and 4-tert-butylbenzoyl chloride (6.21 mL, 31.8 mmol) was added. After 1 h, the solvent was removed in vacuo and the remaining material was dissolved in ethyl acetate. The organic phase was washed four times with water and once with brine. The organic phase was then dried over magnesium sulfate, filtered, and the solvent removed in vacuo. The crude product was purified by column chromatography over silica gel using an eluent of 2% ethyl

25

- 66 -

acetate in hexane and 5% ethyl acetate in hexane to afford the product (9.67g, 96% yield).

^1H NMR(CDCl_3) δ 1.36(s, 9H), 3.93(s, 3H), 7.54(d, J=8.4 Hz, 2H), 7.54(d, J=5.4 Hz, 1H), 7.95(d, J=8.4 Hz, 2H), 8.30(d, J=5.4 Hz, 1H), 11.16(s, 1H);

FD-MS, m/e 317 (M^+)

Anal. for $\text{C}_{17}\text{H}_{19}\text{NO}_3$:

Calc: C, 64.33; H, 6.03; N, 4.42;

Found: C, 64.39; H, 5.98; N, 4.46.

10

B) 3-[(4-t-Butylbenzoyl)amino]-2-thiophenecarboxylic Acid

To a stirring solution of methyl 3-[(4-t-butylbenzoyl)amino]-2-thiophenecarboxylate (9.67g, 30 mmol) in dioxane (75 mL) was added 2 M sodium hydroxide (75 mL). After 16 h, the mixture was acidified to pH 2 with 5 M hydrochloric acid, then diluted with ethyl acetate. The phases were separated and the aqueous layer was extracted a total of 3 times with ethyl acetate. The combined ethyl acetate fractions were dried over magnesium sulfate, filtered, and the solvent was removed in vacuo to afford the product (8.09 g, 89% yield).

^1H NMR(CDCl_3) δ 1.36(s, 9H), 7.54(d, J=8.4 Hz, 2H), 7.61(d, J=5.1 Hz, 1H), 7.92(d, J=8.4 Hz, 2H), 8.34(d, J=5.1 Hz, 1H), 11.04(s, 1H);

FD-MS, m/e 303 (M^+)

Anal. for $\text{C}_{16}\text{H}_{17}\text{NO}_3\text{S}$:

Calc: C, 63.34; H, 5.93; N, 4.62;

Found: C, 63.56; H, 5.93; N, 4.32.

- 67 -

C) 2-(4-t-Butylphenyl)-4-oxo-4H-thieno[3,2-d][1,3]oxazine

To a suspension of 3-[(4-t-butylbenzoyl)amino]-2-thiophenecarboxylic acid (8.09g, 27 mmol) in dry dichloromethane (135 mL) was added oxalyl chloride (11.8 mL, 135 mmol). The mixture was carefully heated with a heat gun in order to dissolve the starting material and initiate the reaction. The heat was then removed and after stirring for 2 h, the solvents were removed in vacuo. The residue was dissolved in dry dichloromethane (135 mL), and pyridine (2.2 mL, 27 mmol) was added. After 1 h, solvent was removed in vacuo. The residue was partitioned between ethyl acetate and water, and the organic phase was washed four times with water and once with brine. The organic phase was then dried over magnesium sulfate, filtered, and the solvent removed in vacuo. The crude product was purified by column chromatography over silica gel using an eluent of 10% ethyl acetate in hexane to afford the product (7.44 g, 96% yield). ^1H NMR(CDCl_3) δ 1.37(s, 9H), 7.35(d, J=5.1 Hz, 1H), 7.52(d, J=8.4 Hz, 2H), 7.91(d, J=5.1 Hz, 1H), 8.22(d, J=8.4 Hz, 2H); FD-MS, m/e 285 (M^+)

Anal. for $\text{C}_{16}\text{H}_{15}\text{NO}_2\text{S}$:

Calc: C, 67.34; H, 5.30; N, 4.91;

Found: C, 67.51; H, 5.56; N, 4.76.

D) 3-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-2-thiophenecaboxamide

To a stirring solution of 1-Boc-6-aminoindazole (100 mg, 0.43 mmol) in tetrahydrofuran (2 mL) at 0 °C was added a solution of potassium bis(trimethylsilyl)amide (180 mg, 0.90 mmol) in tetrahydrofuran (2 mL). After 15 min, this solution was transferred via syringe to a

- 68 -

stirring solution of 2-(4-t-butylphenyl)-4-oxo-4H-thieno[3,2-d][1,3]oxazine (122 mg, 0.43 mmol) in tetrahydrofuran (2 mL). After 45 min, saturated ammonium chloride was added, the mixture was diluted with ethyl acetate, and the phases were separated. The aqueous phase was extracted 3 times with ethyl acetate. The combined ethyl acetate extracts were then washed once with brine, dried over magnesium sulfate, filtered, and the solvent removed in vacuo. The crude product was purified by column chromatography over silica gel using an eluent of 40% ethyl acetate in hexane and 50% ethyl acetate in hexane to afford the product (34 mg, 15%).


¹H NMRFD-MS, m/e 418 (M⁺)Anal. for C₂₃H₂₂N₄O₂S:

Calc: C, 66.01; H, 5.30; N, 13.39;

Found C, 66.24; H, 5.30; N, 13.41.

Example 17

Preparation of N-(6-Indazolyl)-2-(5-t-butyl-1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)benzamide.



To a stirring solution of 2-amino-N-(1-Boc-6-indazolyl)benzamide (1 g, 2.8 mmol) in THF (30 mL) was

- 69 -

added 4-t-butylphthalic anhydride (1.2 g, 5.9 mmol) and the solution was heated to reflux. After 72 h, the vessel was cooled and the volume was reduced to about 10 mL in vacuo. The mixture was diluted with diethyl ether (20 mL) and after
5 sonication, a white solid was collected. This solid was processed by methods substantially equivalent to those described in Example 2-F to give 200 mg of N-(6-indazolyl)-2-(5-t-butyl-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-benzamide.

10 ¹H NMRFD-MS, m/e 438.2 (M⁺)Anal. for C₂₆H₂₂N₄O₃·0.5H₂O:


Calc: C, 69.79; H, 5.18; N, 12.51;

Found: C, 69.69; H, 5.48; N, 11.56.

15

Example 18

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-3-methylbenzamide.



20

A) N-(1-Boc-6-indazolyl)-3-methyl-2-nitrobenzamide

To a stirring solution of 3-methyl-2-nitrobenzoic acid (1.8 g, 10.1 mmol) and 1-Boc-6-amino-indazole (2.37 g, 10.1 mmol) in DMF (20 mL) was added EDC (3.17 g, 15.2 mmol).

- 70 -

After stirring for 16 h, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and 1 M citric acid. The layers were separated and the organic phase was washed again with 1 M citric acid, once with
5 water, twice with satd aq NaHCO₃, and once with brine. The organic phase was then dried over MgSO₄, filtered and concentrated in vacuo. The residue was dissolved in a minimal volume of chloroform and chromatographed over silica
10 gel, eluting with a gradient of 40% ethyl acetate/hexanes through 70% ethyl acetate/hexanes. The product containing fractions were combined and concentrated in vacuo to give 2.34 g (58%) of off-white solid.

B) 2-Amino-N-(1-Boc-6-indazolyl)-3-methylbenzamide

15 By methods substantially equivalent to those described in Example 1-B, 2-amino-N-(1-Boc-6-indazolyl)-3-methylbenzamide (1.1 g, 73%) was prepared from N-(1-Boc-6-indazolyl)-3-methyl-2-nitrobenzamide.

¹H NMR

20 FD-MS, m/e 366.4 (M⁺)

C) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methylbenzamide

By methods substantially equivalent to those described
25 in Example 1-C, N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methylbenzamide (0.46 g, 80%) was prepared from 2-amino-N-(1-Boc-6-indazolyl)-3-methylbenzamide and 4-t-butylbenzoyl chloride.

¹H NMR

30 FD-MS, m/e 526 (M⁺)

Anal. for C₃₁H₃₄N₄O₄:

- 71 -

Calc: C, 70.70; H, 6.51; N, 10.64;
Found C, 70.55; H, 6.41; N, 10.54.

D) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-3-methyl-
5 benzamide

By methods substantially equivalent to those described
in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-
3-methylbenzamide (0.19 g, 79%) was prepared from N-(1-Boc-
6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methylbenzamide.

10 ¹H NMR

FD-MS, m/e 426.1 (M⁺)


Anal. for C₂₆H₂₆N₄O₂:

Calc: C, 73.22; H, 6.14; N, 13.14;
Found C, 72.98; H, 6.26; N, 12.89.

15

Example 19

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-
3-methoxybenzamide.



20

A) N-(1-Boc-6-indazolyl)-3-methoxy-2-nitrobenzamide

By methods substantially equivalent to those described
in example 18-A, 1-[N-(1-Boc-6-indazolyl)]-2-nitro-3-

- 72 -

methoxybenzamide (2.3 g, 56%) was prepared from 3-methoxy-2-nitrobenzoic acid and 1-Boc-6-aminoindazole.

¹H NMR

FD-MS, m/e 412.2 (M⁺)

5

B) 2-Amino-N-(1-Boc-6-indazolyl)-3-methoxybenzamide

By methods substantially equivalent to those described in Example 2-B, 2-amino-N-(1-Boc-6-indazolyl)-3-methoxybenzamide (0.71 g, 93%) was prepared from 1-[N-(1-Boc-6-indazolyl)]-2-nitro-3-methoxybenzamide.

C) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methoxybenzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methoxybenzamide (0.45 g, 64%) was prepared from 2-amino-N-(1-Boc-6-indazolyl)-3-methoxybenzamide and 4-t-butylbenzoyl chloride.

¹H NMR

20 FD-MS, m/e 542.1 (M⁺)

Anal. for C₃₁H₃₄N₄O₅:

Calc: C, 68.62; H, 6.32; N, 10.32;

Found C, 68.77; H, 6.38; N, 10.13.

25 D) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-3-methoxybenzamide

By methods substantially equivalent to those described in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-3-methoxybenzamide (0.19 g, 69%) was prepared from N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-3-methoxybenzamide.

30 ¹H NMR

- 73 -

FD-MS, m/e 442.2 (M^+)Anal. for $C_{26}H_{26}N_4O_3 \cdot 0.5H_2O$:


Calc: C, 69.17; H, 6.03; N, 12.40;

Found: C, 69.46; H, 6.09; N, 11.86.

5

Example 20

Preparation of 2-[(4-Ethoxybenzoyl)amino]-N-(6-indazolyl)-benzamide.



10

A) N-(1-Boc-6-indazolyl)-2-[(4-ethoxybenzoyl)amino]-benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indazolyl)-2-[(4-ethoxybenzoyl)amino]benzamide (100 mg, 27%) was prepared from 1-Boc-6-aminoindazole and 4-ethoxybenzoyl chloride.

 1H NMRFD-MS, m/e 500.1 (M^+)20 Anal. for $C_{28}H_{28}N_4O_5$:

Calc: C, 67.19; H, 5.64; N, 11.19;

Found: C, 66.73; H, 5.59; N, 10.72.

B) 2-[(4-Ethoxybenzoyl)amino]-N-(6-indazolyl)benzamide

25 By methods substantially equivalent to those described in Example 1-F, 2-[(4-ethoxybenzoyl)amino]-N-(6-indazolyl)-benzamide (34 mg, 57%) was prepared from N-(1-Boc-6-indazolyl)-2-[(4-ethoxybenzoyl)amino]benzamide.

- 74 -

¹H NMRFD-MS, m/e 400.2 (M⁺)Anal. for C₂₃H₂₀N₄O₃·0.7H₂O:


Calc: C, 66.89; H, 5.22; N, 13.56;

5 Found: C, 67.07; H, 5.04; N, 13.22.

Example 21

Preparation of 2-[(2-Butoxy-4-methoxybenzoyl)amino]-N-(6-indazolyl)benzamide.

10



A) N-(1-Boc-6-indazolyl)-2-[(2-butoxy-4-methoxybenzoyl)-amino]benzamide

By methods substantially equivalent to those described
15 in Example 9-C, N-(1-Boc-6-indazolyl)-2-[(2-butoxy-4-methoxybenzoyl)amino]benzamide (183 mg, 30%) was prepared from 1-Boc-6-aminoindazole and 2-butoxy-4-methoxybenzoic acid.

¹H NMR20 FD-MS, m/e 558.1 (M⁺)

B) 2-[(2-Butoxy-4-methoxybenzoyl)amino]-N-(6-indazolyl)-benzamide

By methods substantially equivalent to those described
25 in Example 1-F, 2-[(2-butoxy-4-methoxybenzoyl)amino]-N-(6-indazolyl)benzamide was prepared.


¹H NMR

- 75 -

Example 22

Preparation of 2-[(4-t-Butylbenzoyl)oxy]-N-(6-indazolyl)-benzamide.

5



A) N-(1-Boc-6-indazolyl)-2-hydroxybenzamide

To a stirring solution of salicylic acid (1.06 g, 7.7 mmol) and DMF (1 drop) in dichloromethane (100 mL) at 0 °C was added oxalyl chloride (1.13 mL, mmol). After 1 h, the ice bath was removed and stirring was continued for 3.5 h. Solvent was removed under vacuum with minimum heat, and after evacuating further to remove residual oxalyl chloride, the residue was redissolved in dichloromethane (80 mL) and cooled to 0 °C. To this solution was then added a solution of 1-Boc-6-aminoindazole (1.86 g, 8 mmol) in dichloromethane (10 mL). After stirring for 10 min, triethylamine (1.24 mL, 8 mmol) was added. After 1 h, the solution was transferred to a separatory funnel and washed with cold water (200 mL). The organic layer was then washed with cold satd aq NaHCO₃ (200 mL), dried over MgSO₄, filtered and concentrated under vacuum. The product was chromatographed over silica gel (0 to 60% EtOAc in hexane) and recrystallized from dichloromethane/hexanes to give 0.482 g (17%) of crystals. mp 155-6 °C

- 76 -

¹H NMR (DMSO-d₆) δ 1.6 (s, 9H), 7.0 (m, 3H), 7.44 (t, 1H), 7.55 (d, 1H), 7.84 (d, 1H), 7.94 (s, 1H), 8.26 (s, 1H), 8.81 (s, 1H), 10.64 (s, 1H), 11.60 (s, 1H);

FD-MS, m/e 353 (M⁺)

5 Anal. for C₁₉H₁₉N₃O₄:

Calc: C, 64.58; H, 5.42; N, 11.89;

Found: C, 64.00; H, 5.46; N, 11.55.

B) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)oxy]-
10 benzamide

By methods substantially equivalent to those described in Example 1-C, N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)oxy]benzamide (239 mg, 26%) was prepared from 4-t-butylbenzoyl chloride and N-(1-Boc-6-indazolyl)-2-hydroxy-
15 benzamide.

mp 85-89 °C

¹H NMR (300 MHz) δ 1.36 (s, 9H), 1.75 (s, 1H), 7.21 (d, 1H), 7.29 (d, 1H), 7.45 (t, 1H), 7.53 (d, 2H), 7.58 (t, 1H), 8.03 (d, 1H), 8.08 (s, 1H), 8.17 (d, 2H), 8.51 (s, 1H), 8.70 (s,
20 1H);

FD-MS, m/e 513 (M⁺)

Anal. for C₃₀H₃₁N₃O₅:

Calc: C, 70.16; H, 6.08; N, 8.18;

Found: C, 71.00, H, 6.33; N, 7.55.

25

C) 2-[(4-t-Butylbenzoyl)oxy]-N-(6-indazolyl)benzamide

By methods substantially equivalent to those described in Example 1-F, 2-[(4-t-butylbenzoyl)oxy]-N-(6-indazolyl)-benzamide (21 mg, 28%) was prepared from N-(1-Boc-6-
30 indazolyl)-2-[(4-t-butylbenzoyl)oxy]benzamide.

mp-70-73 °C

- 77 -

¹H NMR (DMSO-d₆) δ 1.28 (s, 9H), 7.20 (d, 1H), 7.43 (d, 1H), 7.47 (t, 1H), 7.55 (d, 2H), 7.62 (d, 1H), 7.63 (t, 1H), 7.78 (d, 1H), 7.95 (s, 1H), 8.04 (d, 1H), 8.13 (d, 1H), 10.52 (s, 1H);

5 FD-MS, m/e 413 (M⁺)

Anal. for C₂₅H₂₃N₃O₃·TFA:


Calc: C, 61.48; H, 4.59; N, 7.97;

Found: C, 61.61; H, 4.75; N, 7.70.

10

Example 23

Preparation of N¹-(6-Indolylcarbonyl)-N²-[1-(4-pyridyl)-piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine.



15

A) 2-Nitro-N-[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]aniline

A solution of 2-nitrophenyl isocyanate (4.25 g, 25.9 mmol) and 1-(4-pyridyl)-4-piperidinemethanol (4.13 g, 21.5 mmol) in dichloromethane (100 mL) was stirred at room temperature overnight (about 18h). The mixture was concentrated and the residue purified by flash chromatography (SiO₂; CHCl₃ to 5% MeOH/1% Et₃N in CHCl₃) to yield 7.55 g (96%) of the title compound.

25 ¹H-NMR

FD-MS, m/e 357 (M+1)

- 78 -

Analysis for $C_{18}H_{20}N_4O_4$:

Calc: C, 60.67; H, 5.66; N, 15.72;

Found: C, 60.43; H, 5.55; N, 15.69.

- 5 B) N^1 -[[1-(4-Pyridyl)piperidin-4-yl]methoxycarbonyl]-1,2-benzenediamine

A solution of 2-nitro-N-[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]aniline (7.55 g, 21.2 mmol) and 5% Pd/C (4.00 g) in ethanol was placed under an atmosphere of
10 hydrogen (1 atm). After consumption of the starting material was indicated by tlc (16-20 h), the mixture was filtered through diamotaceous earth using hot ethyl acetate to wash the filter cake. Concentration of the filtrate yielded 6.58 g (96%) of the title compound.

- 15 1H -NMR

FD-MS, m/e 326 (M+)

Analysis for $C_{18}H_{22}N_4O_2$:

Calc: C, 66.24; H, 6.79; N, 17.17;

Found: C, 66.36; H, 6.81; N, 17.43.

20

- C) N^1 -(6-Indolylcarbonyl)- N^2 -[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]-1,2-benzenediamine

A solution of 1-benzyloxycarbonyl-6-indolecarboxylic acid (452 mg, 1.53 mmol), N^1 -[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]-1,2-benzenediamine (500 mg, 1.53 mmol),
25 and EDC (294 mg, 1.53 mmol) in DMF (2.5 mL) was allowed to stir overnight (about 18 h). The mixture was poured into ethyl acetate and H_2O , the aqueous layer was washed with EtOAc (3x), and the combined organic extracts were washed
30 with 1 N NaOH (2x), H_2O , brine, and dried (K_2CO_3).
Concentration and purification of the residue by flash

- 79 -

chromatography (SiO₂) followed by recrystallization (MeOH/ether) yielded 60 mg (8%) of the title compound.

¹H-NMR

FD-MS, m/e 470 (M⁺)


5 Analysis for C₂₇H₂₇N₅O₃:

Calc: C, 69.07; H, 5.80; N, 14.92;

Found: C, 66.58; H, 6.01; N, 14.14.

Example 24

10 Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-5-[(methylsulfonyl)amino]benzamide.



15 A) 6-Nitro-2-(4-t-butylphenyl)-4H-3,1-benzoxazin-4-one

To a mixture of 5-nitroanthranilic acid (24.59 g, 135 mmol) and pyridine (14.19 mL, 175.5 mmol, 1.3 eq) in DMF (140 mL) at 0 °C, under N₂, was added 4-t-butylbenzoyl chloride (31.64 mL, 162 mmol, 1.2 eq) over 15 min. After warming to room temperature, the reaction mixture was heated to 80 °C for 4 h. The reaction mixture was cooled and poured into 700 mL ice-water and stirred to break up the solid material. Filtration, with water followed with 1:2 Et₂O:hexane washes, and vacuum drying (150 °C/13 Pa/2 h) afforded a light brown solid as a mixture of acid and benzoxazinone (37.1 g, 80%). The solid was suspended in DMF

25

- 80 -

(0.4 mL, 5.4 mmol, 0.05 eq) and methylene chloride (200 mL), under N₂, and oxalyl chloride (10.4 mL, 119.2 mmol, 1.1 eq) was added dropwise. Vigorous gas evolution was observed. The solid went into solution over 2 h. The mixture was concentrated to a volume of about 125 mL (cold) in vacuo and filtered to give a light tan solid (about 10 g). A second crop was about 85% pure (about 10 g). The mother liquor was evaporated to dryness and vacuum dried (80 °C/13 Pa/3 h) to afford a light brown solid product, 95% pure (about 12 g).

5 Total yield 93.6%.

¹NMR: 1.32 (s, 9H), 7.65 (d, 2H, J=8.7 Hz), 7.89 (d, 1H, J=8.7 Hz), 8.16 (d, 2H, J=8.7 Hz), 8.35 (dd, 1H, J=8.7, 2.7 Hz), 8.75 (d, 1H, J=2.7 Hz).

15 B) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-5-nitrobenzamide

To a stirring solution of 6-nitro-2-[4-t-butylphenyl]-4H-3,1-benzoxazin-4-one (1.5 g, 4.62 mmol) in toluene (25 mL) was added 6-aminoindazole (560 mg, 4.2 mmol) and the solution was heated to reflux. After about 24 h, the solution was cooled, filtered and the solid was washed with diethyl ether. The product was then chromatographed over silica gel, eluting with 25% ethyl acetate/hexanes. The product containing fractions were combined and concentrated in vacuo to give 810 mg (42%) of pale yellow solid.

25 ¹H-NMR

FD-MS, m/e 457.2 (M⁺)

30 C) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-5-nitrobenzamide

To a stirring suspension of NaH (61 mg, 1.53 mmol) in THF (10 mL) was added 2-[(4-t-butylbenzoyl)amino]-N-(6-

- 81 -

indazolyl)-5-nitrobenzamide (700 mg, 1.53 mmol) followed by a solution of di-t-butyl dicarbonate (330 mg, 1.53 mmol) in THF (20 mL). After 24 h, the mixture was diluted with ethyl acetate and washed with 1 M citric acid, water, satd aq

5 NaHCO₃ and brine. The organic phase was then dried with MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed over silica gel eluting with 25% ethyl acetate/hexanes to give 690 mg (81%) of an off-white solid.

¹H-NMR

10 FAB-MS, m/e 558.3 (MH⁺)

Analysis for C₃₀H₃₁N₅O₆:

Calc: C, 64.62; H, 5.60; N, 12.56;

Found: C, 64.54; H, 5.67; N, 12.46.

15 D) 5-Amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

By methods substantially equivalent to those described in Example 1-B, 5-amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (175 mg, 45%) was prepared from

20 N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-5-nitrobenzamide.

¹H-NMR

FD-MS, m/e 527.2 (M⁺)

25 E) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-5-[(methylsulfonyl)amino]benzamide

To a stirring solution of 5-amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (144 mg, 0.27 mmol) and pyridine (0.066 mL, 0.82 mmol) in dichloro-

30 methane (5 mL) and THF (5 mL) was added methanesulfonyl chloride (0.023 mL, 0.30 mL). After stirring for 24 h, the solvent was removed in vacuo and the residue was dissolved

- 82 -

in ethyl acetate and washed with 1 M citric acid, water, satd aq NaHCO₃, and brine. The organic phase was then dried with MgSO₄, filtered and concentrated in vacuo and the resulting solid was recrystallized from dichloromethane/-

5 hexanes to give 137 mg (83%) of tan solid.

¹H-NMR

FD-MS, m/e 605 (M⁺)

Analysis for C₃₁H₃₅N₅O₆S:

Calc: C, 61.47; H, 5.82; N, 11.56;

10 Found: C, 61.70; H, 6.01; N, 11.47.

F) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-5-[(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
15 in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-5-[(methylsulfonyl)amino]benzamide (79 mg, 78%) was prepared from N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-5-[(methylsulfonyl)amino]benzamide.

¹H-NMR

20 FD-MS, m/e 505.1 (M⁺)

Analysis for C₂₆H₂₇N₅O₄S·TFA:

Calc: C, 54.90; H, 4.62; N, 11.52; F, 8.43;


Found: C, 55.35; H, 4.59; N, 11.05; F, 8.64.

25

Example 25

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-4-[(methylsulfonyl)amino]benzamide.

- 83 -



A) 7-Nitro-2-(4-t-butylphenyl)-4H-3,1-benzoxazin-4-one

By methods substantially equivalent to those described in Example 24-A, 7-nitro-2-(4-t-butylphenyl)-4H-3,1-benzoxazin-4-one (55 g, 98%) was prepared from 4-nitro-anthranillic acid and 4-t-butylbenzoyl chloride.

¹H-NMRFD-MS, m/e (M⁺)

10 B) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-4-nitrobenzamide

By methods substantially equivalent to those described in Example 24-B, 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-4-nitrobenzamide (824 mg, 45%) was prepared from 6-aminoindazole and 7-nitro-2-(4-t-butylphenyl)-4H-3,1-benzoxazin-4-one.

¹H-NMRFD-MS, m/e (M⁺)Analysis for C₂₅H₂₃N₅O₄:

20 Calc: C, 65.64; H, 5.07; N, 15.31;
 Found: C, 65.67; H, 5.12; N, 15.03.

C) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitrobenzamide

25 By methods substantially equivalent to those described in Example 24-C, N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitrobenzamide (910 mg, 78%) was prepared

- 84 -

from 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-4-nitro-benzamide.

¹H-NMR

FD-MS, m/e (M⁺)

5 Analysis for C₃₀H₃₁N₅O₆:

Calc: C, 64.62; H, 5.60; N, 12.56;

Found: C, 64.55; H, 5.42; N, 12.44.

10 D) 4-Amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

By methods substantially equivalent to those described in Example 2-B, 4-amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (170 mg, 20%) was prepared from N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitro-benzamide.

¹H-NMR

FD-MS, m/e (M⁺)

Analysis for C₃₀H₃₃N₅O₄:

Calc: C, 68.29; H, 6.30; N, 13.27;

20 Found: C, 68.18; H, 6.37; N, 13.25.

E) N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-[(methylsulfonyl)amino]benzamide

25 By methods substantially equivalent to those described in Example 24-E, N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-[(methylsulfonyl)amino]benzamide (130 mg, 26%) was prepared from 4-amino-N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]benzamide.

¹H-NMR

30 FD-MS, m/e 605.3 (M⁺)

Analysis for C₃₁H₃₅N₅O₆S:

- 85 -

Calc: C, 61.47; H, 5.82; N, 11.56;

Found: C, 61.22; H, 5.81; N, 11.30.

F) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indazolyl)-4-[(methyl-
5 sulfonyl)amino]benzamide

By methods substantially equivalent to those described
in Example 1-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)-
4-[(methysulfonyl)amino]benzamide (79 mg, 71%) was prepared
from N-(1-Boc-6-indazolyl)-2-[(4-t-butylbenzoyl)amino]-4-
10 [(methysulfonyl)amino]benzamide.

¹H-NMRFD-MS, m/e 505.0 (M⁺)Analysis for C₂₆H₂₇N₅O₄S·0.3TFA·0.2 H₂O:


Calc: C, 59.01; H, 4.84; N, 12.47; F, 2.26;

15 Found: C, 58.80; H, 5.14; N, 12.88; F, 3.15.

Example 26

Preparation of 5-Amino-2-[(4-t-butylbenzoyl)amino]-N-
(6-indazolyl)benzamide.

20



As a biproduct in the synthesis of Example 24-D,
5-amino-2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)benzamide
25 (130 mg, 41%) was isolated.

¹H-NMR

- 86 -

FD-MS, m/e 427.2 (M^+)Analysis for $C_{25}H_{25}N_5O_2$:


Calc: C, 70.23; H, 5.89; N, 16.38;

Found: C, 70.45; H, 6.09; N, 16.25.

5

Example 27

Preparation of 4-Amino-2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)benzamide.



10

As a biproduct in the synthesis of Example 25-D, 4-amino-2-[(4-t-butylbenzoyl)amino]-N-(6-indazolyl)benzamide (350 mg, 51%) was isolated.

15 1H -NMRFD-MS, m/e (M^+)Analysis for $C_{25}H_{25}N_5O_2$:

Calc: C, 70.24; H, 5.89; N, 16.38;


Found: C, 70.37; H, 5.99; N, 16.30.

20

Example 28

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-5-[(methylsulfonyl)amino]benzamide.

- 87 -



A) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-5-nitrobenzamide

5 By methods substantially equivalent to those described in Example 24-B, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-5-nitrobenzamide (74%) was prepared from 6-aminoindole and 6-nitro-2-[4-t-butylphenyl]-4H-3,1-benzoxazin-4-one.

¹H-NMR

10 FD-MS, m/e 456 (M⁺)

Analysis for C₂₆H₂₄N₄O₄:

Calc: C, 68.41; H, 5.30; N, 12.27;

Found: C, 68.67; H, 5.40; N, 12.28.

15 B) N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-5-nitrobenzamide

By methods substantially equivalent to those described in Example 24-C, N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-5-nitrobenzamide (72%) was prepared from 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-5-nitrobenzamide.

20 ¹H-NMR

FD-MS, m/e 555.6 (M⁺)

Analysis for C₃₁H₃₂N₄O₆:

Calc: C, 66.89; H, 5.79; N, 10.06;

25 Found: C, 67.06; H, 5.91; N, 9.96.

- 88 -

C) 5-Amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide

By methods substantially equivalent to those described in Example 2-B, 5-amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (100%) was prepared from N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-5-nitrobenzamide.

¹H-NMR

FD-MS, m/e 526.0 (M⁺)

Analysis for C₃₁H₃₄N₄O₄·0.5EtOAc·0.5H₂O:

10 Calc: C, 68.37; H, 6.78; N, 9.66;
 Found: C, 68.01; H, 6.66; N, 9.69.

D) N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-5-[(methylsulfonyl)amino]benzamide

15 By methods substantially equivalent to those described in Example 24-E, N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-amino]-5-[(methylsulfonyl)amino]benzamide (40%) was prepared from 5-amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-amino]benzamide.

20 ¹H-NMR

FD-MS, m/e 604 (M⁺)

E) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-5-[(methylsulfonyl)amino]benzamide

25 By methods substantially equivalent to those described in Example 2-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-5-[(methylsulfonyl)amino]benzamide (80%) was prepared from N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-5-[(methylsulfonyl)amino]benzamide.

30 ¹H-NMR

FD-MS, m/e 504 (M⁺)

- 89 -

Analysis for C₂₇H₂₈N₄O₄S:


Calc: C, 64.27; H, 5.59; N, 11.10;

Found: C, 64.29; H, 5.58; N, 10.94.

5

Example 29

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide.



10

A) 2-[(4-t-Butylbenzoyl)amino]-N-(1-Boc-6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
in Example 24-E, using triethylamine in place of pyridine,

15 2-[(4-t-butylbenzoyl)amino]-N-(1-Boc-6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide (16%) was prepared
from 5-amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-
amino]benzamide.

¹H-NMR20 FD-MS, m/e 682 (M⁺)Analysis for C₃₃H₃₈N₄O₈S₂·0.10H₂O:

Calc: C, 57.89; H, 5.62; N, 8.18;

Found: C, 57.84; H, 5.82; N, 8.02.

- 90 -

B) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
in Example 2-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide (100%) was prepared
from 2-[(4-t-butylbenzoyl)amino]-N-(1-Boc-6-indolyl)-
5-[bis(methylsulfonyl)amino]benzamide.

¹H-NMR

FD-MS, m/e 582.1 (M⁺)


10 Analysis for C₂₈H₃₀N₄O₆S₂:

Calc: C, 57.72; H, 5.19; N, 9.62;

Found: C, 57.49; H, 5.30; N, 9.56.

Example 30

15 Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-4-
[(methylsulfonyl)amino]benzamide.



20 A) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-4-nitro-
benzamide

By methods substantially equivalent to those described
in Example 24-B, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-
4-nitrobenzamide (81%) was prepared from 7-nitro-2-(4-t-
25 butylphenyl)-4H-3,1-benzoxazin-4-one.

¹H-NMR

FD-MS, m/e 456 (M⁺)

- 91 -

B) N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitrobenzamide

By methods substantially equivalent to those described in Example 24-C, N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitrobenzamide (49%) was prepared from 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-4-nitrobenzamide.

¹H-NMR

FD-MS, m/e 555.9 (M⁺)

10 Analysis for C₃₁H₃₂N₄O₆·0.25H₂O:

Calc: C, 66.36; H, 5.84; N, 9.98;

Found: C, 66.04; H, 5.77; N, 9.63.

15 C) 4-Amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]benzamide

By methods substantially equivalent to those described in Example 2-B, 4-amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]benzamide (93%) was prepared from N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-nitrobenzamide.

20 ¹H-NMR

FD-MS, m/e 526.0 (M⁺)

Analysis for C₃₁H₃₄N₄O₄·0.5H₂O:

Calc: C, 69.51; H, 6.59; N, 10.46;

Found: C, 69.37; H, 6.71; N, 10.17.

25

D) N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-[(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described in Example 24-E, N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-[(methylsulfonyl)amino]benzamide (66%) was prepared from 4-amino-N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]benzamide.

- 92 -

¹H-NMRFD-MS, m/e 604.2 (M⁺)Analysis for C₃₂H₃₆N₄O₆S:

Calc: C, 62.94; H, 6.21; N, 8.64;

5 Found: C, 62.99; H, 5.93; N, 8.79.

E) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-4-[(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
10 in Example 2-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-4-[(methylsulfonyl)amino]benzamide (93%) was prepared from N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)amino]-4-[(methylsulfonyl)amino]benzamide.

¹H-NMR15 FD-MS, m/e 504.0 (M⁺)Analysis for C₂₇H₂₈N₄O₄S:


Calc: C, 64.27; H, 5.59; N, 11.10;

Found: C, 64.37; H, 5.48; N, 10.91.

20

Example 31

Preparation of 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-
4-[bis(methylsulfonyl)amino]benzamide.



25

- 93 -

A) 2-[(4-t-Butylbenzoyl)amino]-N-(1-Boc-6-indolyl)-
4-[bis(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
in Example 29-A, 2-[(4-t-butylbenzoyl)amino]-N-(1-Boc-6-
5 indolyl)-4-[bis(methylsulfonyl)amino]benzamide (33%) was
prepared from N-(1-Boc-6-indolyl)-2-[(4-t-butylbenzoyl)-
amino]-4-aminobenzamide.

¹H-NMR

FD-MS, m/e 682.6 (M⁺)

10

B) 2-[(4-t-Butylbenzoyl)amino]-N-(6-indolyl)-
4-[bis(methylsulfonyl)amino]benzamide

By methods substantially equivalent to those described
in Example 2-F, 2-[(4-t-butylbenzoyl)amino]-N-(6-indolyl)-
15 4-[bis(methylsulfonyl)amino]benzamide (85%) was prepared
from 2-[(4-t-butylbenzoyl)amino]-N-(1-Boc-6-indolyl)-
4-[bis(methylsulfonyl)amino]benzamide.

¹H-NMR

FD-MS, m/e 582.1 (M⁺)

20 Analysis for C₂₈H₃₀N₄O₆S₂:


Calc: C, 57.72; H, 5.19; N, 9.61;

Found: C, 57.62; H, 5.22; N, 9.46.

Example 32

25 Preparation of 4-Hydroxy-N¹-(6-indolylcarbonyl)-N²-[1-(4-
pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine and
hydrochloride hydrate.

- 94 -

A) 4-(*tert*-butyldimethylsilyloxy)-2-nitroaniline

To a mixture of 4-amino-3-nitrophenol (10.07 g,
 5 65.3 mmol) and DMF (20 mL) was added imidazole (11.15 g,
 163.8 mmol) followed by *t*-butyldimethylsilyl chloride
 (11.82 g, 78.4 mmol) in several portions. After 5 h, the
 reaction was diluted with EtOAc (150 mL) and washed with
 water (5 x 20 mL). The organic layer was MgSO₄, dried,
 10 filtered, and concentrated. The residue was chromatographed
 (10% EtOAc/hexanes to 20% EtOAc/hexanes) to give the title
 compound as a solid (17.06 g, 97%); mp 80-83 °C; IR (CHCl₃):
 3399, 2932, 1519, 1242, 866 cm⁻¹; NMR (300 MHz, CDCl₃): δ
 0.19 (s, 6H), 0.97 (s, 9H), 6.70 (d, 1H, J = 9.0), 6.95 (d,
 15 1H, J = 3.0), 7.56 (d, 1H, J = 2.7); MS(FD): 268.2.

Analysis for C₁₂H₂₀N₂O₃Si:

Calc: C 53.70, H 7.51, N 10.44;

Found: C 53.47, H 7.50, N 10.31.

20 B) 5-(*tert*-butyldimethylsilyloxy)-2-phthalimido-1-nitro-
benzene

A mixture of 2-nitro-4-(*tert*-butyldimethylsilyloxy)-
 aniline (10.3 g, 38.5 mmol) and phthalic anhydride (6.50 g,

- 95 -

41.5 mmol) in toluene (30 mL) was refluxed for 18 h. A Dean-Stark apparatus was fitted to the flask, diisopropylethylamine (0.1 mL) was added and water was removed azeotropically over the next 24 h. About 20 mL of solvent was removed by distillation and the resultant solution allowed to cool to room temperature. The residue was diluted with methylene chloride and passed through a plug of silica gel eluting with methylene chloride. The desired fractions were combined and concentrated in vacuo. Recrystallization from methylene chloride-hexane provided 12.2 g (80%) of the title compound in two crops.

Analysis for $C_{20}H_{22}N_2O_5Si$:

Calc: C, 60.28; H, 5.56; N, 7.03;

Found: C, 60.35; H, 5.67; N, 6.98.

15

C) 5-(tert-butyldimethylsilyloxy)-2-phthalimidoaniline

A suspension of 5-(tert-butyldimethylsilyloxy)-2-phthalimido-1-nitrobenzene (5.00 g, 12.5 mmol) and 10% palladium-on-carbon (2.5 g) in ethyl acetate (60 mL) was stirred under 1 atm of hydrogen for 16 h. The mixture was filtered through a pad of diatomaceous earth and concentrated in vacuo to yield 4.1 g (89%) of the title compound.

25 D) 5-(tert-butyldimethylsilyloxy)-2-phthalimido-N-[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]aniline

A solution of 5-(tert-butyldimethylsilyloxy)-2-phthalimidoaniline (1.02 g, 2.77 mmol) in toluene (15 mL) was treated with a solution of 20% phosgene in toluene (2 mL) at reflux for 20 min. The volatile materials were removed in vacuo to give a tan solid, which was dissolved in dry methylene chloride (20 mL) and treated with 1-(4-

- 96 -

pyridyl)piperidine-4-methanol (0.53 g, 2.77 mmol). The resulting suspension was stirred for 90 min then diluted with hexane. The mixture was allowed to stand overnight and the resulting precipitate collected by vacuum filtration and
5 dried to yield 1.46g (90%) of the title compound as a tan powder.

MS-FD, m/e 587 (M).

Analysis for C₃₂H₃₈N₄O₅Si:

Calc: C, 65.50; H, 6.53; N, 9.55;

10 Found: C, 65.23; H, 6.47; N, 9.38.

E) 4-(tert-butyldimethylsilyloxy)-N²-[1-(4-pyridyl)-piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine

A solution of 5-(tert-butyldimethylsilyloxy)-2-
15 phthalimido-N-[[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl]aniline (1.34 g, 2.28 mmol) in 1 M hydrazine in methanol (6 mL) was stirred at ambient temperature for 40 h during which time a white precipitate formed. The mixture was further diluted with methylene chloride and cooled with
20 an ice bath then filtered. The filtrate was washed once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield 890 mg (86%) of the title compound as a tan powder.

25 MS-FD, m/e 456 (M).

F) 4-(tert-butyldimethylsilyloxy)-N¹-(6-indolylcarbonyl)-N²-[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine

30 A mixture of indole-6-carboxylic acid (71 mg, 0.44 mmol), bromotris(pyrrolidino)phosphonium hexafluorophosphate (204 mg, 0.44 mmol) and

- 97 -

diisopropylethylamine (0.153 mL, 0.88 mmol) in dry methylene chloride (5 mL) was stirred 10 min. 4-(tert-Butyldimethylsilyloxy)-N²-[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine (100 mg, 0.22 mmol) and N,N-dimethyl-
5 formamide (2 mL) were added and the resulting mixture stirred 64 h at ambient temperature. Saturated aqueous sodium hydrogen carbonate solution (4 mL) was added, and the resultant mixture stirred for 30 min. The mixture was
10 partitioned between ethyl acetate and water, the organic solution separated, dried (anhydrous magnesium sulfate), filtered, and concentrated in vacuo. The residue was chromatographed (silica gel, methylene chloride, 9:1 methylene chloride/methanol, 9:1:0.1 methylene
15 chloride/methanol/ammonium hydroxide) to yield 55 mg (44%) of the title compound.

G-1) 4-Hydroxy-N¹-(6-indolylcarbonyl)-N²-[1-(4-pyridyl)-piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine

A solution of 4-(tert-butyldimethylsilyloxy)-N¹-(6-indolylcarbonyl)-N²-[1-(4-pyridyl)piperidin-4-yl]-
20 methoxycarbonyl-1,2-benzenediamine (55 mg, 0.096 mmol) in tetrahydrofuran (2 mL) was treated with 5 N aqueous hydrochloric acid (0.5 mL) and allowed to stand at ambient temperature overnight. Volatile solvents were removed in
25 vacuo and the residue diluted with dilute sodium hydrogen carbonate solution, hexane, and methylene chloride. The mixture was sonicated 5 min, then filtered. The resultant material was vacuum dried 6 h to yield 37 mg (79%) of the
30 title compound as a tan solid.
MS-FD, m/e 486 (M), 309, 155, 119 (base).

- 98 -

An alternative preparation of the hydrochloride hydrate is as follows.

5 G-2) 4-Hydroxy-N¹-(6-indolylcarbonyl)-N²-[1-(4-pyridyl)-piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine hydrochloride hydrate

A solution of 4-(tert-butyldimethylsilyloxy)-N¹-(6-indolylcarbonyl)-N²-[1-(4-pyridyl)piperidin-4-yl]-methoxycarbonyl-1,2-benzenediamine (682 mg, 1.20 mmol) in 10 mL tetrahydrofuran was treated with 2.5 mL 5 N HCl and allowed to stand at ambient temperature over night. Volatile solvents were removed in vacuo and the residue neutralized with sodium hydrogen carbonate solution. The mixture was triturated with hexane over 30 min then the solid collected by filtration. The solid was purified by reverse phase HPLC (5 cm x 25 cm Vydac C18, 10 mL/min, λ=214 nm, 2-40% B. Solvent A: 0.01% HCl. Solvent B: 100% AcCN.) Lyophilization of the appropriate fractions yielded 272 mg (46.8%) of the hydrated HCl salt as a powder.

20 MS, Ion spray, m/e: 486 (p+1).

Analysis for C₂₇H₂₇N₅O₄·HCl·H₂O:

Calc.: C, 60.06; H, 5.60; N, 12.97;


Found: C, 60.26; H, 5.23; N, 13.23.

25

Example 33

Preparation of 4-Hydroxy-N²-(4-t-butylbenzoyl)-N¹-(6-indolylcarbonyl)-1,2-benzenediamine.

- 99 -



A) 4-*t*-Butyldimethylsilyloxy- N^2 -(4-*t*-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine

5 Using the procedure described in Example 9, Part C, 4-*t*-butyldimethylsilyloxy- N^2 -(4-*t*-butylbenzoyl)-1,2-benzenediamine (1.15 g, 2.9 mmol) and indole-6-carboxylic acid (0.46 g, 2.9 mmol) yielded 780 mg (50%) of the title compound.

10 ^1H -NMR

FD-MS, m/e 541.2 (M^+)

Analysis for $\text{C}_{32}\text{H}_{39}\text{N}_3\text{O}_3\text{Si}$:

Calc: C, 70.94; H, 7.26; N, 7.76;

Found: C, 70.93; H, 7.13; N, 7.75.

15

B) 4-Hydroxy- N^2 -(4-*t*-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine

To a stirring solution of 4-*t*-butyldimethylsilyloxy- N^2 -(4-*t*-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2-benzenediamine (680 mg, 1.26 mmol) in THF (10 mL) was added a 1.0 M solution of tetrabutylammonium fluoride in THF (1.3 mL, 1.3 mmol). After 15 min, the solution was poured into ethyl acetate (300 mL) and washed once with water, twice with 1 M citric acid, once again with water, twice with satd aq sodium bicarbonate, and once with brine. After drying with MgSO_4 , the organic phase was filtered, silica gel (3 g) was added, and the mixture was concentrated in vacuo. The resulting powder was loaded onto a silica gel column which was preequilibrated with 25% ethyl acetate/dichloromethane and was eluted with a gradient of 25% ethyl

20

25

30

- 100 -

acetate/dichloromethane through 50% ethyl acetate/dichloromethane. The product containing fractions were combined and concentrated in vacuo to give a thick oil which was dissolved in diethyl ether, sonicated, and

5 concentrated in vacuo to give the title compound as a white solid (480 mg, 88%).

¹H-NMR

FD-MS, m/e 427.3 (M+)


Analysis for C₂₆H₂₅N₃O₃:

10 Calc: C, 73.05; H, 5.89; N, 9.83;
 Found: C, 73.02; H, 5.78; N, 9.60.

Example 34

Preparation of 4-Hydroxy-N²-(4-t-butylbenzoyl)-

15 N¹-(3-chloroindol-6-ylcarbonyl)-1,2-benzenediamine.



A) 3-Chloroindole-6-carboxylic acid

20 To a solution of indole-6-carboxylic acid (2.45 g, 15.2 mmol) in dichloromethane (100 mL) and DMF (10 mL) was added N-chlorosuccinimide (2 g, 15.2 mmol). After 3 h, the solvent was removed in vacuo and the residue was suspended in dichloromethane, sonicated and filtered to give 2.38 g
25 (80%) of the title compound.

¹H-NMR

FD-MS, m/e 195.604 (M+)

Analysis for C₉H₆ClNO₂:

Calc: C, 55.26; H, 3.09; N, 7.16;

- 101 -

Found: C, 55.18; H, 3.10; N, 7.05.

B) 4-t-Butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-N¹-(3-chloroindol-6-ylcarbonyl)-1,2-benzenediamine

5 Using the procedure described in Example 9, Part C, 4-t-butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-1,2-benzenediamine (750 mg, 1.9 mmol) and 3-chloroindole-6-carboxylic acid (372 mg, 1.9 mmol) yielded 790 mg (72%) of the title compound.

10 ¹H-NMR

FD-MS, m/e 575.1 (M⁺)

Analysis for C₃₂H₃₈ClN₃O₃Si:

Calc: C, 66.70; H, 6.65; N, 7.29;

Found: C, 66.60; H, 6.63; N, 7.22.

15

C) 4-Hydroxy-N²-(4-t-butylbenzoyl)-N¹-(3-chloroindol-6-ylcarbonyl)-1,2-benzenediamine

Using the procedure described in Example 33, Part B, 4-t-butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-N¹-(3-chloroindol-6-ylcarbonyl)-1,2-benzenediamine (760 mg, 1.3 mmol) yielded 520 mg (87%) of the title compound.

¹H-NMR

FD-MS, m/e 461.1 (M⁺)

Analysis for C₂₆H₂₄ClN₃O₃:

25 Calc: C, 67.60; H, 5.24; N, 9.10;


Found: C, 67.42; H, 5.39; N, 9.04.

Example 35

Preparation of 4-Hydroxy-N²-(4-t-butylbenzoyl)-

30 N¹-(3-bromoindol-6-ylcarbonyl)-1,2-benzenediamine.

- 102 -



A) 3-Bromoindole-6-carboxylic acid

Using the procedure described in Example 34, Part A,
 5 indole-6-carboxylic acid (2.6 g, 16.1 mmol) and
 N-bromosuccinimide (2.9 g, 16.1 mmol) yielded 2.88 g (75%)
 of the title compound.

¹H-NMRFD-MS, m/e 239.0 (M⁺)10 Analysis for C₉H₆BrNO₂:

Calc: C, 45.03; H, 2.52; N, 5.83;

Found: C, 45.19; H, 2.46; N, 5.87.

B) 4-t-Butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-N¹-(3-
 15 bromoindol-6-ylcarbonyl)-1,2-benzenediamine

Using the procedure described in Example 9, Part C,
 4-t-butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-1,2-
 benzenediamine (750 mg, 1.9 mmol) and 3-bromoindole-6-
 carboxylic acid (456 mg, 1.9 mmol) yielded 930 mg (79%) of
 20 the title compound.

¹H-NMRFD-MS, m/e 621.1 (M⁺)Analysis for C₃₂H₃₈BrN₃O₃Si:

Calc: C, 61.93; H, 6.17; N, 6.77;

25 Found: C, 62.09; H, 6.15; N, 6.83.

C) 4-Hydroxy-N²-(4-t-butylbenzoyl)-N¹-(3-bromoindol-
 6-ylcarbonyl)-1,2-benzenediamine

Using the procedure described in Example 33, Part B,
 30 4-t-butyldimethylsilyloxy-N²-(4-t-butylbenzoyl)-N¹-

- 103 -

(3-bromoindol-6-ylcarbonyl)-1,2-benzenediamine (850 mg, 1.37 mmol) yielded 450 mg (65%) of the title compound.

¹H-NMR

FD-MS, m/e 504.9 (M⁺)


5 Analysis for C₂₆H₂₄BrN₃O₃:

Calc: C, 61.67; H, 4.78; N, 8.30;

Found: C, 61.92; H, 4.92; N, 8.13.

Example 36

10 Preparation of N¹-(3-Chloroindol-6-ylcarbonyl)-N²-[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine.



15

Using the procedure described in Example 23, Part C, and purifying with preparative RPHPLC method A, N²-[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine (326 mg, 1.0 mmol) and 3-chloroindole-6-carboxylic acid (195 mg, 1.0 mmol) yielded the title compound.


20

FIA-MS, m/e 504.0 (MH⁺)

Example 37

25 Preparation of N¹-(3-Bromoindol-6-ylcarbonyl)-N²-[1-(4-pyridyl)piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine.

- 104 -




Using the procedure described in Example 23, Part C, and purifying with preparative RPHPLC method A,
 5 N²-[1-(4-Pyridyl)-piperidin-4-yl]methoxycarbonyl-1,2-benzenediamine (326 mg, 1.0 mmol) and 3-bromoindole-6-carboxylic acid (240 mg, 1.0 mmol) yielded the title compound.

FIA-MS, m/e 550.0 (MH⁺)

10

Example 38

Preparation of N-(6-Indazolyl)-2-[1-(4-pyridyl)-piperidin-4-yl]carbonylaminobenzamide hydrochloride.



15

A) 2-[1-(4-Pyridyl)piperidin-4-ylcarbonyl]amino-N-(1-Boc-indazol-6-yl)benzamide

To a stirring suspension of 1-(4-pyridyl)piperidine-carboxylic acid (350 mg, 1.70 mmol) in dichloromethane
 20 (50 mL) at reflux was added thionyl chloride (0.190 mL, 2.55 mmol). After 4 h, the solvent was removed in vacuo and the residue was redissolved in dichloromethane (20 mL) and added to a stirring solution of 2-amino-N-(1-Boc-6-
 25 indazolyl)benzamide (300 mg, 0.85 mmol) in pyridine (5 mL) and dichloromethane (20 mL). After 30 min, the solvent was

- 105 -

removed in vacuo; and the residue was partitioned between ethyl acetate (300 mL) and 1 N NaOH (150 mL). The layers were separated and the organic phase was washed with brine, dried with MgSO_4 , filtered and concentrated in vacuo. The solid was suspended in diethyl ether, sonicated and filtered to give 455 mg (99%) of the title compound.

$^1\text{H-NMR}$

FD-MS, m/e 541(M+)

Analysis for $\text{C}_{30}\text{H}_{32}\text{N}_6\text{O}_4$:

10 Calc: C, 66.65; H, 5.97; N, 15.55;
 Found: C, 65.58; H, 6.15; N, 15.04.

B) 2-[1-(4-Pyridyl)piperidin-4-ylcarbonyl]amino-N-(6-indazolyl)benzamide hydrochloride

15 Using the procedure described in Example 1, Part F, purifying with preparative RPHPLC method B, 2-[1-(4-pyridyl)piperidin-4-ylcarbonyl]amino-N-(1-Boc-indazol-6-yl)benzamide (455 mg, 0.84 mmol) yielded 110 mg (28%) of the title compound.

20 $^1\text{H-NMR}$

FIA-MS, m/e 441.0 (M+)

Analysis for $\text{C}_{25}\text{H}_{24}\text{N}_6\text{O}_2 \cdot 1.0\text{HCl} \cdot 1.1\text{H}_2\text{O}$:


 Calc: C, 60.45; H, 5.52; N, 16.91; Cl, 7.14;
 Found: C, 60.23; H, 5.13; N, 16.76; Cl, 7.20.

25

Example 39

Preparation of N^4 -Acetyl- N^2 -(4-t-butylbenzoyl)- N^1 -(6-indolylcarbonyl)-1,2,4-benzenetriamine.

- 106 -

A) 2-amino-4-*N*-acetylamino-nitrobenzene

To a stirring solution of 2,4-diaminonitrobenzene (5 g, 33 mmol) and pyridine (5.25 mL, 66 mmol) in THF (30 mL) at 0 °C, was added a solution of acetyl chloride (2.2 mL, 31 mmol) in THF (20 mL) via an addition funnel. The rate of the addition was controlled such that the internal temperature did not rise above 5 °C (about 30 min). The cold bath was then removed and after an additional 30 min, the solvent was removed in *vacuo*. The residue was dissolved in chloroform, stirred overnight, and the resulting precipitate was filtered and dried to give 4.35 g (72%) of the title compound.

15 ¹H-NMRFD-MS, m/e 195 (M⁺)Analysis for C₈H₉N₃O₃:

Calc: C, 49.23; H, 4.65; N, 21.53;

Found: C, 49.21; H, 4.71; N, 21.61.

20

B) 2-(4-*t*-Butylbenzoyl)amino-4-*N*-acetylamino-nitrobenzene

Using the procedure described in Example 1, Part C, 2-amino-4-*N*-acetylamino-nitrobenzene (4 g, 21 mmol) and 4-*t*-butylbenzoyl chloride (4.4 mL, 23 mmol) yielded 3.6 g (49%) of the title compound.

25 ¹H-NMRFD-MS, m/e 355 (M⁺)

- 107 -

C) 2-(4-*t*-Butylbenzoyl)amino-4-*N*-acetylaminoaniline

Using the procedure described in Example 1, Part B,
2-(4-*t*-butylbenzoyl)amino-4-(acetylamino)nitrobenzene
yielded 1.38 g (50%) of the title compound.

5 ¹H-NMR

FD-MS, m/e 325.3 (M+)

Analysis for C₁₉H₂₃N₃O₂:

Calc: C, 70.13; H, 7.12; N, 12.91;

Found: C, 70.06; H, 6.89; N, 12.64.

10

D) N⁴-Acetyl-N²-(4-*t*-butylbenzoyl)-N¹-(6-indolylcarbonyl)-
1,2,4-benzenetriamine

To a stirring solution of 2-(4-*t*-butylbenzoyl)amino-4-
(acetylamino)aniline (40 mg, 0.12 mmol), 6-indolecarboxylic
15 acid (40 mg, 0.24 mmol) and bromotris(pyrrolidino)-
phosphonium hexafluorophosphate (112 mg, 0.12 mmol) in
dichloromethane (10 mL) and DMF (1 mL) was added
N,N-diisopropylethylamine (42 mg, 0.36 mmol). After 3 days,
the solvent was removed in vacuo and the residue was
20 dissolved in ethyl acetate and washed once with 1 N HCl,
once with satd aq sodium bicarbonate, dried with MgSO₄,
filtered and concentrated in vacuo. The residue was then
chromatographed over silica gel, eluting with 10%
methanol/dichloromethane and the product containing
25 fractions were combined and concentrated to give 40 mg (71%)
of the title compound.

¹H-NMR

FD-MS, m/e 469.2 (M+)

Analysis for C₂₈H₂₈N₄O₃:


30 Calc: C, 71.78; H, 6.02; N, 11.96;

Found: C, 69.22; H, 6.26; N, 11.26.

- 108 -

Example 40

Preparation of N¹-(6-Indolylcarbonyl)-N²-[1-(4-pyridyl)-piperidin-4-yl]methylaminocarbonyl-1,2-benzenediamine.



5

A) 1-(4-Pyridyl)piperidine-4-methylamine

A solution of 1-(4-pyridyl)piperidine-4-methanol (5.87 g, 30.6 mmol), phthalimide (4.59 g, 31.2 mmol), and triphenylphosphine (8.10 g, 30.9 mmol) in 125 mL of THF at -5 °C was treated with a solution of diethyl azodicarboxylate (5.38 g, 30.9 mmol) in THF (40 mL). After 16 h, the mixture was poured into EtOAc and 1N HCl. The aqueous layer was washed with EtOAc (2x), pH adjusted to 12 by addition of 5N NaOH, and washed with EtOAc (3x). The combined organic extracts were dried (K₂CO₃) and concentrated yielding 8.45 g (86%) of the substituted phthalimide. The crude material (5.47 g, 17.0 mmol) was then treated with hydrazine hydrate (3.5 mL, 60.0 mmol) in EtOH (50 mL). The mixture was heated at 75 °C for 5 h, cooled, diluted with CH₂Cl₂ (100 mL), and cooled to 0 °C. The solid was removed by filtration and the filtrate was concentrated yielding 3.32 g of the title compound which was used without further purification.

¹H-NMR

25

B) 2-[1-(4-Pyridyl)piperidin-4-ylmethylaminocarbonyl]-amino-nitrobenzene

A solution of 1-(4-pyridyl)piperidine-4-methylamine (1.34 g, 7.01 mmol) and 2-nitrophenyl isocyanate (1.21 g, 7.40 mmol) in methylene chloride was stirred at room

30

- 109 -

temperature. Concentration in vacuo and purification by flash chromatography (silica gel, 5% methanol/1% triethylamine/94% chloroform) yielded 1.59 g (64%) of the title compound.

5 ¹H-NMR, IR

MS-FD m/e 355 (p)

Analysis for C₁₈H₂₁N₅O₃:

Calc: C, 60.83; H, 5.96; N, 19.71;

Found: C, 60.66; H, 5.90; N, 19.50.

10

C) N¹-[1-(4-Pyridyl)piperidin-4-ylmethylaminocarbonyl]-1,2-benzenediamine

A solution of 2-[1-(4-pyridyl)piperidin-4-ylmethylaminocarbonyl]amino-nitrobenzene (1.02 g, 2.87 mmol) in ethanol was hydrogenated at atmospheric pressure over 5% palladium-on-carbon. After completion (16-20 h), the mixture was filtered through diatomaceous earth, using hot ethyl acetate to wash the filter cake. Concentration of the filtrate in vacuo yielded 930 mg (99%) of the title compound.

20

¹H-NMR, IR

MS-FD m/e 326 (p+1)

Analysis for C₁₈H₂₃N₅O:

Calc: C, 66.44; H, 7.12; N, 21.52;

25 Found: C, 65.39; H, 7.02; N, 20.76.

D) N¹-(4-Chlorobenzoyl)-N²-[1-(4-pyridyl)piperidin-4-ylmethylaminocarbonyl]-1,2-benzenediamine

Using a similar procedure to that of Example 39, Part D, the above amine (100 mg) was coupled with 6-indole-carboxylic acid (98 mg) using bromotris(pyrrolidino)-phosphonium hexafluorophosphate (289 mg) and N,N-diisopropylethylamine (120 mg) in dichloromethane (5 mL). Following the initial chromatography, the product

- 110 -


was further purified by RPHPLC [similar to Method B, but 90/10 (A/B) through 50/50 (A/B)] to provide the title compound (50 mg, 34%).

FIA-MS, m/e 469.2 (M+1)

5

Example 41

Preparation of N-(6-Indolyl)-4-(methylsulfonylamino)-2-[(1-(4-pyridyl)piperidin-4-ylmethoxycarbonyl)amino]-benzamide.



10

A) N-(6-indolyl)-2-amino-4-nitrobenzamide

Using the procedure described in Example 44, Part A, 4-nitroisatoic anhydride yielded 9.61 g (54%) of the title compound as a solid.

15

NMR

B) N-(1-tert-butoxycarbonyl-6-indolyl)-2-amino-4-nitrobenzamide

Using the procedure described in Example 1, Part A, N-(6-indolyl)-2-amino-4-nitrobenzamide yielded 3.47 g (27%) of the title compound as a solid.


20

NMR

C) N-(1-boc-6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-nitrobenzamide

25

- 111 -



To a mixture of 1-(4-pyridyl)piperidine-4-ylmethanol (193 mg, 1.0 mmol) and methylene chloride (15 ml) was added methanesulfonic acid (65 μ L, 1.0 mmol). After stirring for 15 seconds, quinoline (0.15 mL, 1.27 mmol) was added, immediately followed by 1.93 M phosgene in toluene (0.65 μ L, 1.25 mmol). After 5 min, the reaction was placed in a 35 $^{\circ}$ C oil bath for 45 min. The reaction was cooled to room temperature and N-(1-boc-6-indolyl)-2-amino-4-nitrobenzamide (398 mg, 1.0 mmol) and quinoline (0.15 mL, 1.27 mmol) were added. After stirring overnight, the reaction was diluted with CHCl_3 (75 mL) and washed with 1 N NaOH (2x10 mL) and H_2O (10 mL). The organic layer was concentrated and the crude residue was chromatographed to give 101 mg (16%) of the title compound as a solid.

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6): δ 10.78(s, 1H); 10.24(br s, 1H); 8.79(s, 1H); 8.75(s, 1H); 8.08(m, 2H); 8.02(s, 2H); 7.63(d, $J=3.6$ Hz, 1H); 7.58(d, $J=8.7$ Hz, 1H); 7.47(d, $J=9.3$ Hz, 1H); 6.74(d, $J=9.0$ Hz, 2H); 6.67(d, $J=3.6$ Hz, 1H); 4.00(d, $J=6.3$ Hz, 2H); 3.88(d, $J=14.4$ Hz, 2H); 2.76(t, $J=12.0$ Hz, 2H); 1.93(m, 1H); 1.70(d, $J=9.9$ Hz, 2H); 1.21(m, 2H);


MS-FD m/e: 615.2 (p+1).

Analysis for $\text{C}_{32}\text{H}_{34}\text{N}_6\text{O}_7$:

Calc: C, 62.53; H, 5.58; N, 13.67;
*Found: C, 62.68; H, 4.89; N, 15.71.

- 112 -

D) N-(1-Boc-6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-aminobenzamide



5 Using the procedure described in Example 2, Part B, N-(1-boc-6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-nitrobenzamide (2.28 mmol) yielded 1.05 g (79%) of the title compound as a solid.

IR(KBr): 1727, 1597, 1264; ¹H-NMR (300 MHz, DMSO-d₆): δ


10 8.65(s, 1H); 8.09(d, J=5.7 Hz, 2H); 7.68(d, J=9.0 Hz, 1H); 7.58(s, 1H); 7.46(m, 2H); 6.78(m, 2H); 6.64(s, 1H); 6.24(d, J=9.0 Hz, 1H); 5.96(s, 3H); 3.94(m, 4H); 2.80(m, 2H); 1.73(m, 3H); 1.18(m, 2H); MS-FD m/e: 585.0 (p+1).

Analysis for C₃₂H₃₆N₆O₅:

15 Calc: C, 65.74; H, 6.21; N, 14.37;
*Found: C, 65.04; H, 5.76; N, 15.94.

E) N-(1-boc-6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-(methylsulfonylamino)benzamide

20



- 113 -

Using the procedure described in Example 24, Part E, N-(1-boc-6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-aminobenzamide was reacted with

- 5 methanesulfonyl chloride (0.58 mmol) to yield 143 mg (41%) of the title compound as a white solid.

¹H-NMR (300 MHz, DMSO-d₆): δ 10.62(s, 1H); 10.39(s, 1H); 8.67(s, 1H); 8.07(m, 3H); 7.84(d, J=8.7 Hz, 1H); 7.60(d, J=3.6 Hz, 1H); 7.54(d, J=8.1 Hz, 1H); 7.43(d, J=8.4 Hz, 1H); 10 6.94(d, J=8.7 Hz, 1H); 6.80(d, J=6.3 Hz, 2H); 6.64(d, J=3.6 Hz, 1H); 3.95(m, 4H); 3.06(s, 1H); 2.82(t, J=12.5 Hz, 2H); 1.91(m, 1H); 1.72(d, J=11.7 Hz, 2H); 1.60(s, 9H); 1.19(m, 2H); MS-FD m/e: 663.1 (p+1).

Analysis for C₃₃H₃₈N₆O₇S:

- 15 Calc: C, 59.81; H, 5.78; N, 12.68;
 *Found: C, 60.75; H, 6.43; N, 12.45.

F) N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-ylmethoxycarbonylamino]-4-(methylsulfonylamino)benzamide

- 20 A sample of N-(1-boc-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylmethoxycarbonylamino]-4-(methylsulfonylamino)-benzamide (120 mg, 0.18 mmol) was heated at 180°, until TLC indicated that the reaction had gone to completion, to yield 95 mg (94%) of the title compound as a tan solid.

- 25 IR(KBr): 1711, 1646, 1419; ¹H-NMR (300 MHz, DMSO-d₆): δ 11.40(s, 1H); 11.19(s, 1H); 8.08(d, J=5.7 Hz, 2H); 7.83(d, J=8.7 Hz, 1H); 7.53(d, J=8.4 Hz, 1H); 7.39(s, 1H); 7.25(s, 1H); 7.09(s, 1H); 6.95(d, J=8.4 Hz, 1H); 6.81(m, 3H); 6.45(s, 1H); 3.94(m, 4H); 3.10(s, 3H); 2.82(t, J=12.3 Hz, 2H); 1.70(m, 3H); 1.09(m, 2H); MS-FD m/e: 563.0 (p+1).


Analysis for C₂₈H₃₀N₆O₅S·0.5 H₂O:

- Calc: C, 58.84; H, 5.47; N, 14.70;
 Found: C, 58.92; H, 5.33; N, 14.45.

- 114 -


Example 42

Preparation of N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]-4-(acetylamino)benzamide.



5

A) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-nitrobenzamide



10

Using the procedure described in Example 38, Part A, N-(1-tert-butoxycarbonyl-6-indolyl)-2-amino-4-nitrobenzamide (1.09 mmol) was reacted to yield 408 mg (64%) of the title compound as a yellow solid.


- 15 IR(KBr): 1742, 1650, 1537, 1344; $^1\text{H-NMR}$ (300 MHz, DMSO-d_6):
 δ 10.76(s, 1H); 10.65(s, 1H); 8.93(s, 1H); 8.68(s, 1H);
 8.14(d, J=6.6 Hz, 2H); 8.06-7.98(m, 2H); 7.61(d, J=3.9 Hz, 1H); 7.56(d, J=8.4 Hz, 1H); 7.47(d, J=9.0 Hz, 1H); 7.05(d, J=6.9 Hz, 2H); 6.65(d, J=3.6 Hz, 1H); 4.11(d, J=13.5 Hz,
 20 2H); 3.20-3.10(m, 2H); 2.79(m, 1H); 1.98-1.90(m, 2H);
 1.61(s, 11H); MS-FD m/e: 584.9 (p+1).
 Analysis for $\text{C}_{31}\text{H}_{32}\text{N}_6\text{O}_6\text{S} \cdot 3 \text{H}_2\text{O}$:

- 115 -

Calc: C, 58.30; H, 6.00; N, 13.16;

Found: C, 58.12; H, 5.63; N, 12.94.

B) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-
5 piperidin-4 ylcarbonylamino]-4-aminobenzamide



Using the procedure described in Example 2, Part B,
10 N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-
piperidin-4 ylcarbonylamino]-4-nitrobenzamide (0.65 mmol)
was reacted to yield 236 mg (65%) of the title compound as a
solid.

¹H-NMR(300 MHz, DMSO-d₆): δ 11.72(s, 1H); 10.04(s, 1H);
15 8.58(s, 1H); 8.09(d, J=5.7 Hz, 2H); 7.76(s, 1H); 7.66(d,
J=8.7 Hz, 1H); 7.58(d, J=3.6 Hz, 1H); 7.51(d, J=8.4 Hz, 1H);
7.43(d, J=8.4 Hz, 1H); 6.78(d, J=6.0 Hz, 2H); 6.63(d, J=3.6
Hz, 1H); 6.28(d, J=8.7 Hz, 1H); 5.91(s, 2H); 3.93(d, J=12.3
Hz, 2H); 2.88(m, 2H); 2.48(m, 1H); 1.90-1.85(m, 4H); 1.61(s,
20 1H); MS-FD m/e: 554.9 (p+1).


Analysis for C₃₁H₃₄N₆O₄:

Calc: C, 67.13; H, 6.18; N, 15.15;

*Found: C, 65.96; H, 5.74; N, 17.01.

- 116 -

C) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-(acetylamino)benzamide



5

Using the procedure described in Example 24, Part E, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-aminobenzamide (0.18 mmol) was reacted with acetyl chloride to yield 83 mg (77%) of the title compound as a white solid.

¹H-NMR (300 MHz, DMSO-d₆): δ 11.09(s, 1H); 10.39(s, 1H); 10.23(s, 1H); 8.63(s, 1H); 8.53(d, J=4.5 Hz, 1H); 8.45(s, 1H); 8.08(d, J=5.4 Hz, 2H); 7.81(d, J=8.7 Hz, 1H); 7.60-7.32(m, 3H); 6.77(d, J=6.0 Hz, 2H); 6.64(d, J=3.3 Hz, 1H); 3.92(d, J=13.2 Hz, 2H); 2.88(m, 2H); 2.48(m, 1H); 1.95(s, 3H); 1.91-1.82(m, 2H); 1.60(s, 4H); FIA-MS m/e: 597.4 (p+1).

D) N-(6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylcarbonylamino]-4-(acetylamino)benzamide

Using the procedure described in Example 41, Part F, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-(acetylamino)benzamide was reacted to yield 60 mg (93%) of the title compound as a tan solid.

¹H-NMR (300 MHz, DMSO-d₆): δ 11.22(s, 1H); 11.06(s, 1H); 10.21(s, 2H); 8.48(s, 1H); 8.09(d, J=5.4 Hz, 2H); 7.88(s, 1H); 7.81(d, J=8.7 Hz, 1H); 7.60(d, J=8.7 Hz, 1H); 7.45(d,

- 117 -

J=8.4 Hz, 1H); 7.28(s, 1H); 7.17(d, J=8.4 Hz, 1H); 6.78(d, J=6.0 Hz, 2H); 6.35(s, 1H); 3.92(d, J=13.8 Hz, 2H); 2.88(t, J=11.4 Hz, 2H); 2.48(m, 1H); 2.03(s, 3H); 1.88(d, J=11.1 Hz, 2H); 1.58(d, J=14.7 Hz, 2H); FIA-MS m/e: 497.2 (p+1).


5 Analysis for $C_{28}H_{28}N_6O_3 \cdot 1.5 H_2O$:

Calc: C, 64.24; H, 5.97; N, 16.05;


Found: C, 63.92; H, 5.40; N, 15.73.

Example 43

10 Preparation of N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]-4-(methylsulfonylamino)benzamide.



15 A) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-(methylsulfonylamino)-benzamide



20

Using the procedure described in Example 24, Part E,
N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-
piperidin-4-ylcarbonylamino]-4-aminobenzamide (0.17 mmol)

- 118 -

was reacted to yield 35 mg (65%) of the title compound as a yellow solid.

¹H-NMR (300 MHz, DMSO-d₆): δ 11.33(s, 1H); 10.17(s, 1H); 8.62(s, 1H); 8.53(d, J=3.9 Hz, 1H); 8.08(d, J=5.4 Hz, 2H); 8.02(s, 1H); 7.70(d, J=8.7 Hz Hz, 1H); 7.58(d, J=3.9 Hz Hz, 1H); 7.52(d, J=8.4 Hz, 1H); 7.42(d, J=8.7 Hz, 1H); 7.34(m, 1H); 3.92(d, J=13.8 Hz, 2H); 2.81(m, 2H); 1.88(d, J=11.7 Hz, 4H); 1.61(s, 9H); FIA-MS m/e: 633.2 (p+1).

10 B) N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]-4-(methanesulfonylamino)benzamide

Using the procedure described in Example 41, Part F, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-4-(methanesulfonylamino)-benzamide (0.096 mmol) was reacted to yield 35 mg (68%) of the title compound as a yellow solid.

MS-IS m/e: 533.0 (p+1)


Analysis for C₂₇H₂₈N₆O₄S·1 H₂O:

Calc: C, 58.91; H, 5.49; N, 15.26;

20 *Found: C, 58.90; H, 5.35; N, 13.71.


Example 44

Preparation of N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]benzamide.



- 119 -

A) N-(6-indolyl)-2-aminobenzamide



A mixture of isatoic anhydride (5.06 g, 31 mmol),
 5 6-aminoindole (4.103 g, 31 mmol), toluene (300 mL) and DMF
 (30 mL) was heated to reflux for 18 hours. The reaction was
 cooled, filtered, and chromatographed to yield 4.103 g (53%)
 of the title compound as a tan solid.

IR(KBr): 1635, 1521, 1334; ¹H-NMR (300 MHz, DMSO-d₆): δ
 10 10.98(s, 1H); 9.87(s, 1H); 7.94(s, 1H); 7.59(d, J=7.8 Hz,
 1H); 7.41(d, J=8.4 Hz, 1H); 7.24-7.12(m, 3H); 6.71(d, J=8.4
 Hz, 1H); 6.55(t, J=7.4 Hz, 1H); 6.33(s, 1H); 6.25(s, 2H);
 MS-ES m/e: 252.2 (p+1).


Analysis for C₁₅H₁₃N₃O:

15 Calc: C, 71.70; H, 5.22; N, 16.72;
 Found: C, 71.63; H, 5.18; N, 16.68.

B) N-(1-tert-butoxycarbonyl-6-indolyl)-2-aminobenzamide

Using the procedure described in Example 1, Part A,
 20 N-(6-indolyl)-2-aminobenzamide (2 mmol) was reacted to yield
 281 mg (40%) of the title compound as a white solid.

C) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]benzamide



- 120 -

Using the procedure described in Example 38, Part A, N-(1-tert-butoxycarbonyl-6-indolyl)-2-aminobenzamide (0.74 mmol) was reacted to yield 343 mg (86%) of the title compound as a white solid.

IR(CHCl₃): 1729, 1597, 1511, 1431, 1347; ¹H-NMR (300 MHz, DMSO-d₆): δ 10.65(s, 1H); 10.49(s, 1H); 8.68(s, 1H); 8.16(d, J=8.1 Hz, 2H); 8.07(s, 2H); 7.79(d, J=7.5 Hz, 1H); 7.60-7.44(m, 3H); 7.20(t, J=7.4 Hz, 1H); 6.78(s, 2H); 6.64(s, 1H); 3.92(d, J=13.2 Hz, 2H); 2.89(t, J=11.6 Hz, 2H); 2.60(m, 1H); 1.87(d, J=13.5 Hz, 2H); 1.61(s, 11H); MS-IS m/e: 540.4 (p+1).

Analysis for C₃₁H₃₃N₅O₄:

Calc: C, 69.00; H, 6.16; N, 12.98;
Found: C, 69.15; H, 6.34; N, 12.72.

D) N-(6-indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]benzamide

Using the procedure described in Example 41, Part F, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]benzamide (0.56 mmol) was reacted to yield 232 mg (94%) of the title compound as a tan solid.

IR(CHCl₃): 1601, 1510, 1448; ¹H-NMR (300 MHz, DMSO-d₆): δ 11.06(s, 1H); 10.79(s, 1H); 10.33(s, 1H); 8.23(d, J=8.4 Hz, 1H); 8.08(d, J=4.8 Hz, 2H); 7.94(s, 1H); 7.80(d, J=7.8 Hz, 1H); 7.45(d, J=8.4, 2H); 7.28(s, 1H); 7.21-7.17(m, 2H); 6.77(d, J=5.7 Hz, 2H); 6.36(s, 1H); 3.91(d, J=13.2 Hz, 2H); 2.87(t, J=11.6 Hz, 2H); 2.60(m, 1H); 1.86(m, 2H); 1.55(m, 2H); MS-IS m/e: 440.2 (p+1).


Analysis for C₂₆H₂₅N₅O₂:

Calc: C, 71.05; H, 5.73; N, 15.93;
Found: C, 70.96; H, 5.89; N, 15.67.

- 121 -


Example 45

Preparation of N-(6-Indolyl)-2-[1-(4-pyridyl)piperidin-4-yl-carbonylamino]-5-(methylsulfonylamino)benzamide.



5

A) N-(6-indolyl)-2-amino-5-nitrobenzamide



10

Using the procedure described in Example 4, Part A, 5-nitroisatoic anhydride (34 mmol) was reacted to yield 11.89 g (64%) of the title compound as a yellow solid.

¹H-NMR (300 MHz, DMSO-d₆): δ 11.04(s, 1H); 10.33(s, 1H); 8.57(s, 1H); 8.04(d, J=9.0 Hz, 1H); 7.91(s, 1H); 7.60(s, 2H); 7.44(d, J=8.4 Hz, 1H); 7.27(s, 1H); 7.19(d, J=8.4 Hz, 1H); 6.82(d, J=9.0 Hz, 1H); 6.35(s, 1H);

MS-FD m/e: 296.0 (p).


20 B) N-(1-tert-butoxy-6-indolyl)-2-amino-5-nitrobenzamide

Using the procedure described in Example 1, Part A, N-(6-indolyl)-2-amino-5-nitrobenzamide (6.77 mmol) was reacted to yield 1.287 g (48%) of the title compound as a yellow solid.

25

- 122 -

C) N-(1-tert-butoxycarbonyl-6-indolyl)-2-piperidin-4-ylcarbonylamino]-5-nitrobenzamide



5

Using the procedure described in Examp. N-(1-tert-butoxycarbonyl-6-indolyl)-2-aminobenzamide (2.42 mmol) was reacted to yield 1.125 g (8% yield) of compound as a yellow solid.


10 IR(CHCl₃): 1508, 1345, 1156; ¹H-NMR (300 MHz, CDCl₃): 11.09(s, 1H); 10.85(s, 1H); 8.66(s, 1H); 8.12(d, J=5.4 Hz, 2H); 7.62(d, J=3.6 Hz, 1H); 6.95(d, J=6.0 Hz, 2H); 6.66(d, J=3.6 Hz, 2H); 3.05(t, J=11.6 Hz, 2H); 2.75(t, J=10.8 Hz, 2H); 1.61(s, 9H); MS-FD m/e: 583.

Analysis for C₃₁H₃₂N₆O₆·1 H₂O:

Calc: C, 61.78; H, 5.69; N, 13.94

*Found: C, 62.15; H, 5.83; N, 13.04

20 D) N-(1-tert-butoxycarbonyl-6-indolyl)-2-piperidin-4-ylcarbonylamino]-5-aminobenzamide



- 123 -

Using the procedure described in Example 2, Part B, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonyl]amino]-5-nitrobenzamide (1.86 mmol) was reacted to yield 1.11 g (100%) of the title compound as a yellow solid.


IR(CHCl₃): 1729, 1596, 1517, 1431, 1346; ¹H-NMR (300 MHz, DMSO-d₆): δ 10.28(s, 1H); 9.78(s, 1H); 8.69(s, 1H); 8.05(d, J=5.7 Hz, 2H); 7.59-7.42, (m, 4H); 6.85(s, 2H); 6.7(d, J=6.0 Hz, 1H); 6.66-6.62(m, 2H); 5.17(s, 2H); 3.89(d, J=13.5 Hz, 2H); 2.82(t, J=13.5 Hz, 2H); 2.46(m, 1H); 1.79(d, J=13.8 Hz, 2H); 1.60(s, 9H); 1.56(m, 2H); ; MS-FD m/e: 454.2 (p-BOC).

Analysis for C₃₁H₃₄N₆O₄·3.5 H₂O:

Calc: C, 60.28; H, 6.69; N, 13.60;

*Found: C, 59.96; H, 5.94; N, 12.71.

E) N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-5-methylsulfonylaminobenzamide



Using the procedure described in Example 24, Part E, N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-5-aminobenzamide (0.98 mmol) was reacted to yield 442 mg (71%) of the title compound as a white solid.

IR(KBr): 1733, 1646, 1546, 1345, 1151; ¹H-NMR (300 MHz, DMSO-d₆): δ 10.50(s, 1H); 10.16(s, 1H); 9.81(s, 1H); 8.63(s, 1H); 8.14(d, J=6.9 Hz, 2H); 7.84(d, J=8.7 Hz, 1H); 7.59-7.42(m, 4H); 7.31(d, J=8.4 Hz, 1H); 7.11(d, J=6.9 Hz, 2H); 6.64(s, 1H); 4.14(d, J=13.5 Hz, 2H); 3.22(m, 2H);

- 124 -

3.01(s, 3H); 2.74(m, 1H); 1.92(d, J=6.0 Hz, 2H); 1.60(s, 11H); MS-IS m/e: 633.2 (p+1).

Analysis for C₃₂H₃₆N₆O₆S·6.5 H₂O:

Calc: C, 51.26; H, 6.59; N, 11.21;

5 *Found: C, 51.19; H, 4.96; N, 11.10.

F) N-(6-indolyl)-2-[1-(4-pyridyl)piperidin-4-ylcarbonylamino]-5-(methylsulfonylamino)benzamide

Using the procedure described in Example 41, Part F,
10 N-(1-tert-butoxycarbonyl-6-indolyl)-2-[1-(4-pyridyl)-piperidin-4-ylcarbonylamino]-5-methylsulfonylaminobenzamide (0.63 mmol) was reacted to yield 312 mg (93%) of the title compound as a tan solid.

IR(KBr): 1645, 1542, 1151, 981; ¹H-NMR (300 MHz, DMSO-d₆):
15 δ 11.07(s, 1H); 10.34(s, 1H); 10.23(s, 1H); 9.80(s, 1H); 8.14(d, J=7.2 Hz, 2H); 7.93(s, 1H); 7.91(d, J=10.8 Hz, 2H); 7.49(s, 1H); 7.43(d, J=8.4 Hz, 1H); 7.32-7.26(m, 3H); 7.16(d, J=9.0 Hz, 1H); 7.11(d, J=7.2 Hz, 2H); 6.35(s, 1H); 4.15(d, J=13.5 Hz, 2H); 3.20(m, 2H); 3.01(s, 3H); 2.97(m,
20 1H); 1.91(d, J=13.5 Hz, 2H); 1.60(m, 2H); MS-IS m/e: 533.2 (p+1).

Analysis for C₂₇H₂₈N₆O₄S·6.5 H₂O:


Calc: C, 49.91; H, 6.36; N, 12.93;

25 *Found: C, 50.03; H, 4.84; N, 12.61.

Example 46

Preparation of N²-(1-Benzylpiperidin-4-ylcarbonyl)-4-hydroxy-N¹-(6-indolylcarbonyl)-1,2-benzenediamine.

- 125 -



A) N-(1-benzylpiperidin-4-ylcarbonyl)-5-t-butyl-dimethylsilyloxy-2-(phthalimido)aniline

- 5 A solution of N-benzylpiperidine-4-carboxylic acid (298 mg, 1.36 mmol) in 1 mL thionyl chloride was refluxed for 30 min. The mixture was concentrated in vacuo and the residue dissolved in 4 mL methylene chloride and 1 mL pyridine. The aniline (500 mg, 1.36 mmol) from Example 32, 10 Part C was added all at once. The mixture was stirred 1 h then partitioned between methylene chloride and saturated sodium hydrogen carbonate. The organic portion was dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified on silica gel, eluting 500 mL 15 methylene chloride then 300 mL 9:1 methylene chloride/methanol. Appropriate fractions were combined and concentrated in vacuo and the residue crystallized from methylene chloride/hexane to yield 350 mg (46%) of the title compound.
- 20 FD-MS m/e: 569(p), 368.

B) N²-(1-benzylpiperidin-4-ylcarbonyl)-4-hydroxy-N¹-(6-indolylcarbonyl)-1,2-benzenediamine

- 25 The above aniline (310 mg, 0.54 mmol) was dissolved in 2 mL hot 1M hydrazine in methanol and warmed for 1 h during which time a white precipitate formed. The mixture was

- 126 -

allowed to cool, then slurried with methylene chloride and filtered. The concentration of the filtrate in vacuo yielded 235 mg (99%) of the crude aniline as an orange solid.


- 5 The crude aniline (229 mg, 0.52 mmol), indole-6-carboxylic acid (168 mg, 1.04 mmol), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (485 mg, 1.04 mmol) and diisopropylethylamine (362 μ L, 2.08 mmol) were combined 3 mL methylene chloride, 2 mL tetrahydrofuran and 2 mL
- 10 dimethylformamide. The resultant mixture was allowed to shake at 275 rpm on a platform shaker for 3 days then stand an additional 3 days. The mixture was filtered then purified on Aldrich C₁₈ silica eluting with a step gradient of 20-30-40% acetonitrile/water. Appropriate fractions were
- 15 combined and concentrated in vacuo to yield 102 mg (34%) of the intermediate bisamide.

- The bisamide (102 mg, 0.18 mmol) was dissolved in 3 mL 2:1 tetrahydrofuran/5N HCl and allowed to stand overnight. Volatile solvent was removed in vacuo and the residue
- 20 neutralized with saturated sodium hydrogen carbonate causing a precipitate to form. The mixture was sonicated in the presence of ether/hexane for 5-10 min and filtered. The collected solid was dried under vacuum for 60 h to yield 59 mg (72%) of the title compound.
- 25 MS, FD+, m/e: 468(p).

- 127 -

What is claimed is:

1. A method of inhibiting factor Xa comprising using an effective amount of a factor Xa inhibiting compound of formula I



wherein

- 10 A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted benzene in which A^3 is CR^3 , A^4 is CR^4 , A^5 is CR^5 , and A^6 is CR^6 ; wherein
- 15 R^3 is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω -carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;
- 20 one of R^4 and R^5 is hydrogen, methyl, halo, trifluoromethyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO- , R^fO_2C- , $R^fO_2C-CH_2-$, $R^fO_2C-CH_2-O-$, 3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-amino;
- 25 the other of R^4 and R^5 is hydrogen, halo or methyl; and R^6 is hydrogen, fluoro, hydroxy, [(1-2C)alkyl]-carbonyloxy (which may bear an ω -carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;
- 30 in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is hydrogen, acetyl, trifluoroacetyl, phenylalanyl, 2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or R^hSO_h- (wherein h is 1 or 2); and R^h is (1-4C)alkyl,

- 128 -

trifluoromethyl, phenyl, 3,5-dimethylisoxazol-4-yl or dimethylamino; or

two adjacent residues selected from R^3 , R^4 , R^5 and R^6 together form a benz ring; and the other two are each
 5 hydrogen; or

A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted heteroaromatic ring in which

(a) one of A^3 , A^4 , A^5 and A^6 is N, and each of the others
 10 is CR^3 , CR^4 , CR^5 or CR^6 , respectively;

(b) two adjacent residues of A^3 , A^4 , A^5 and A^6 together form S, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively;

(c) two non-adjacent residues of A^3 , A^4 , A^5 and A^6 are each
 15 N, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively; or


(d) A^3 and A^4 together form a fused benz ring, and A^5 and A^6 together form -NH-;

wherein

20 each of R^3 , R^4 , R^5 and R^6 is hydrogen, or one or two of R^3 , R^4 , R^5 and R^6 is independently chloro, bromo or methyl and the others are hydrogen;

L^1 is -NH-CO- or -CO-NH- such that $-L^1-Q^1$ is -NH-CO- Q^1 or -CO-NH- Q^1 ;

25 Q^1 is




wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-,
 -C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen,
 30 fluoro, chloro, bromo or methyl;

R^2 is $-L^{2A}-Q^{2A}$, $-L^{2B}-Q^{2B}$, $-L^{2C}-Q^{2C}$ or $-L^{2D}-Q^{2D}$ wherein

- 129 -


L^{2A} is a direct bond; and
Q^{2A} is



- 5 in which D is carbonyl or -CHR^k- in which R^k is hydrogen, hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy, [(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or two (1-2C)alkyl substituents on the nitrogen; and one of R^m and Rⁿ is hydrogen and the other is amino, bromo,
10 (1-4C)alkyl or (1-4C)alkoxy, or R^m and Rⁿ together form a benz ring;

L^{2B} is -NH-CO-, -O-CO-, -CH₂-O- or -O-CH₂- such that
-L^{2B}-Q^{2B} is -NH-CO-Q^{2B}, -O-CO-Q^{2B}, -CH₂-O-Q^{2B} or -O-CH₂-Q^{2B};
and

- 15 Q^{2B} is



- in which R^o is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy, benzyloxy or (1-4C)alkylthio; and R^p is 1-hydroxyethyl,
20 1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl, 4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or -J-R^q in which J is a single bond, methylene, carbonyl, oxo, -S(O)_q- (wherein q is 0, 1 or 2), or -NR^r- (wherein R^r is hydrogen or methyl); and R^q is (1-6C)alkyl, phenyl,
25 3-pyridyl or 4-pyridyl;

L^{2C} is -NR^v-CO-X-, -NR^v-CS-Y-, -CH₂-CO-NR^w-CH₂-,
-O-CO-, -O-CH₂-, -S-CH₂- or -CH₂-NR^x-CH₂- such that -L^{2C}-Q^{2C}
is -NR^v-CO-X-Q^{2C}, -NR^v-CS-Y-Q^{2C}, -CH₂-CO-NR^w-CH₂-Q^{2C},
-O-CO-Q^{2C}, -O-CH₂-Q^{2C}, -S-CH₂-Q^{2C} or -CH₂-NR^x-CH₂-Q^{2C} in

- 130 -

which X is $-(CH_2)_x-$ (wherein x is 0, 1 or 2), $-NR^W-$,
 $-NR^W-CH_2-$, $-O-$, $-O-CH_2-$ or $-S-CH_2-$; Y is $-NR^W-CH_2-$ or
 $-O-CH_2-$; each of R^V and R^W is independently hydrogen, benzyl
or (1-6C)alkyl which is not branched at the α -position; and
5 R^X is hydrogen, benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl;
and

Q^{2C} is 1-(4-pyridyl)piperidin-4-yl, 1-(4-pyridyl)-
piperidin-3-yl or 1-(4-pyridyl)pyrrolidin-3-yl in which the
pyridyl may bear a substituent at its 2-position selected
10 from cyano, aminomethyl, carboxy, hydroxymethyl and
(1-2C)alkyl;

L^{2D} is $-NH-CO-$ such that $-L^{2D}-Q^{2D}$ is $-NH-CO-Q^{2D}$; and
 Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-
9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a
15 chloro, methyl or methoxy substituent), benzofuran-2-yl
(which may bear a chloro, methyl or methoxy substituent),
4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl or
3,4-didehydropiperidin-4-yl (either one bearing a
substituent at the 1-position selected from methylsulfonyl,
20 phenylsulfonyl, (1-5C)alkyl, (4-7C)cycloalkyl, tetrahydro-
pyran-4-yl, 4-thiacyclohexyl and $-CH_2-R^Z$ in which R^Z is
isopropyl, cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl,
or pyridyl in which the phenyl may bear one or two
substituents independently selected from halo, cyano,

25 hydroxy, methoxy, acetoxy, benzyloxy, amino, acetylamino,
nitro and 3,4-methylenedioxy, and the thienyl or furyl may
bear a methyl or nitro substituent);

or a prodrug of the compound of formula I;

30 or a pharmaceutically acceptable salt of the compound
of formula I or prodrug thereof.

2. The method of claim 1 in which the factor Xa
inhibiting compound is one wherein

- 131 -

A³, A⁴, A⁵ and A⁶, together with the two carbons to which they are attached, complete a substituted benzene in which A³ is CR³, A⁴ is CR⁴, A⁵ is CR⁵, and A⁶ is CR⁶; wherein

5 R³ is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω-carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy methoxy or methyl substituents), methyl or methoxy;

one of R⁴ and R⁵ is hydrogen, methyl, halo, trifluoro-
10 methyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO-, R^fO₂C-, R^fO₂C-CH₂-, R^fO₂C-CH₂-O-, 3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-amino;

the other of R⁴ and R⁵ is hydrogen, halo or methyl; and
15 R⁶ is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω-carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy methoxy or methyl substituents), methyl or methoxy;

in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is
20 hydrogen, acetyl, trifluoroacetyl, phenylalanyl, 2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or R^hSO₂-; and R^h is (1-4C)alkyl, trifluoromethyl, phenyl, 3,5-dimethylisoxazol-4-yl or dimethylamino; or

two adjacent residues selected from R³, R⁴, R⁵ and R⁶
25 together form a benz ring; and the other two are each hydrogen; or

A³, A⁴, A⁵ and A⁶, together with the two carbons to which they are attached, complete a substituted heteroaromatic ring in which

30 (a) one of A³, A⁴, A⁵ and A⁶ is N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;

(b) two adjacent residues of A³, A⁴, A⁵ and A⁶ together form S, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;

- 132 -


(c) two non-adjacent residues of A³, A⁴, A⁵ and A⁶ are each N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively; or

(d) A³ and A⁴ together form a fused benz ring, and A⁵ and A⁶ together form -NH-;
 5 wherein

each of R³, R⁴, R⁵ and R⁶ is hydrogen, or one or two of R³, R⁴, R⁵ and R⁶ is independently chloro, bromo or methyl and the others are hydrogen;

10 L¹ is -NH-CO- or -CO-NH- such that -L¹-Q¹ is -NH-CO-Q¹ or -CO-NH-Q¹;

Q¹ is




15 wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-, -C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen, fluoro, chloro, bromo or methyl;

R² is -L^{2A}-Q^{2A}, -L^{2B}-Q^{2B}, -L^{2C}-Q^{2C} or -L^{2D}-Q^{2D} wherein

L^{2A} is a direct bond; and

20 Q^{2A} is



in which D is carbonyl or -CHR^k- in which R^k is hydrogen, hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy,
 25 [(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or two (1-2C)alkyl substituents on the nitrogen; and one of R^m and Rⁿ is hydrogen and the other is amino, bromo,


- 133 -

(1-4C)alkyl or (1-4C)alkoxy, or R^m and R^n together form a benz ring;

L^{2B} is -NH-CO-, -O-CO-, -CH₂-O- or -O-CH₂- such that
- L^{2B} - Q^{2B} is -NH-CO- Q^{2B} , -O-CO- Q^{2B} , -CH₂-O- Q^{2B} or -O-CH₂- Q^{2B} ;

5 and

Q^{2B} is



in which R^O is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy,
10 benzyloxy or (1-4C)alkylthio; and R^P is 1-hydroxyethyl,
1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl,
4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or -J- R^Q
in which J is a single bond, methylene, carbonyl, oxo,
-S(O)_q- (wherein q is 0, 1 or 2), or -NR^x- (wherein R^x is
15 hydrogen or methyl); and R^Q is (1-6C)alkyl, phenyl,
3-pyridyl or 4-pyridyl;

L^{2C} is -NR^v-CO-X-, -NR^v-CS-Y-, -CH₂-CO-NR^w-CH₂-,
-O-CO-, -O-CH₂-, -S-CH₂- or -CH₂-NR^x-CH₂- such that - L^{2C} - Q^{2C}
is -NR^v-CO-X- Q^{2C} , -NR^v-CS-Y- Q^{2C} , -CH₂-CO-NR^w-CH₂- Q^{2C} ,
20 -O-CO- Q^{2C} , -O-CH₂- Q^{2C} , -S-CH₂- Q^{2C} or -CH₂-NR^x-CH₂- Q^{2C} in
which X is -(CH₂)_x- (wherein x is 0, 1 or 2), -NR^w-CH₂-,
-O-CH₂- or -S-CH₂-; Y is -NR^w-CH₂- or -O-CH₂-; each of R^v
and R^w is independently hydrogen, benzyl or (1-6C)alkyl
which is not branched at the α-position; and R^x is hydrogen,
25 benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl; and

Q^{2C} is 1-(4-pyridyl)piperidin-4-yl in which the pyridyl
may bear a substituent at its 2-position selected from
cyano, aminomethyl, carboxy, hydroxymethyl and (1-2C)alkyl;

L^{2D} is -NH-CO- such that - L^{2D} - Q^{2D} is -NH-CO- Q^{2D} ; and

30 Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-
9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a
chloro, methyl or methoxy substituent), benzofuran-2-yl

- 134 -

(which may bear a chloro, methyl or methoxy substituent),
4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl bearing a
substituent at the 1-position selected from methylsulfonyl,
phenylsulfonyl and $-\text{CH}_2-\text{R}^Z$ in which R^Z is isopropyl,
5 cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl, or pyridyl
in which the phenyl may bear one or two substituents
independently selected from halo, cyano, hydroxy, methoxy,
acetoxo, benzyloxy, amino, acetylamino, nitro and
3,4-methylenedioxy, and the thienyl or furyl may bear a
10 methyl or nitro substituent;
or a prodrug of the compound of formula I;
or a pharmaceutically acceptable salt of the compound
of formula I or prodrug thereof.

15 3. The method of Claim 1 or 2 wherein for an alkyl
group or the alkyl portion of an alkyl containing group,
(1-2C)alkyl is methyl or ethyl; (1-4C)alkyl is methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl;
(1-6C)alkyl is methyl, ethyl, propyl, butyl, pentyl or
20 hexyl; and halo is bromo or chloro.

4. The method of Claim 3 wherein for an alkyl group
or the alkyl portion of an alkyl containing group,
(1-2C)alkyl is methyl; (1-4C)alkyl is methyl, isopropyl,
25 butyl or t-butyl; (1-6C)alkyl is methyl, butyl or hexyl; and
halo is chloro.

5. The method of any of the above Claims 1-4 wherein
the compound of formula I is one in which each of A^3 , A^5 and
30 A^6 is CH.

6. The method of any of the above Claims 1-5 wherein
 Q^1 is 6-indolyl or 6-indazolyl.

- 135 -


7. The method of any of the above Claims 1-6 wherein R^2 is (4-t-butylbenzoyl)amino, (4-methoxybenzoyl)amino, or [1-(4-pyridyl)piperidin-4-yl]methoxycarbonylamino.

5 8. The method of any of the above Claims 1-7 wherein L^1-Q^1 is $-NH-CO-Q^1$.

9. The method of any of the above Claims 1-7 wherein L^1-Q^1 is $-CO-NH-Q^1$.

10

10. A novel compound of formula I



15 wherein

A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted benzene in which A^3 is CR^3 , A^4 is CR^4 , A^5 is CR^5 , and A^6 is CR^6 ; wherein

20 R^3 is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω -carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;

one of R^4 and R^5 is hydrogen, methyl, halo, trifluoromethyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO- , R^fO_2C- , $R^fO_2C-CH_2-$, $R^fO_2C-CH_2-O-$, 3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-amino;

25 the other of R^4 and R^5 is hydrogen, halo or methyl; and
30 R^6 is hydrogen, fluoro, hydroxy, [(1-2C)alkyl]-carbonyloxy (which may bear an ω -carboxy substituent),

- 136 -

benzoyloxy (which may bear one or more halo, hydroxy, methoxy or methyl substituents), methyl or methoxy;

in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is hydrogen, acetyl, trifluoroacetyl, phenylalanyl,

- 5 2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or R^hSO_h- (wherein h is 1 or 2); and R^h is (1-4C)alkyl, trifluoromethyl, phenyl, 3,5-dimethylisoxazol-4-yl or dimethylamino; or

- two adjacent residues selected from R^3 , R^4 , R^5 and R^6
10 together form a benz ring; and the other two are each hydrogen; or

A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted heteroaromatic ring in which


- 15 (a) one of A^3 , A^4 , A^5 and A^6 is N, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively;
(b) two adjacent residues of A^3 , A^4 , A^5 and A^6 together form S, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively;
20 (c) two non-adjacent residues of A^3 , A^4 , A^5 and A^6 are each N, and each of the others is CR^3 , CR^4 , CR^5 or CR^6 , respectively; or
(d) A^3 and A^4 together form a fused benz ring, and A^5 and A^6 together form -NH-;

- 25 wherein

each of R^3 , R^4 , R^5 and R^6 is hydrogen, or one or two of R^3 , R^4 , R^5 and R^6 is independently chloro, bromo or methyl and the others are hydrogen;


- L^1 is -NH-CO- or -CO-NH- such that $-L^1-Q^1$ is -NH-CO- Q^1
30 or -CO-NH- Q^1 ;

- 137 -

Q¹ is

wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-,
 5 -C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen,
 fluoro, chloro, bromo or methyl;


R² is -L^{2A}-Q^{2A}, -L^{2B}-Q^{2B}, -L^{2C}-Q^{2C} or -L^{2D}-Q^{2D} wherein
 L^{2A} is a direct bond; and

Q^{2A} is

10

in which D is carbonyl or -CHR^k- in which R^k is hydrogen,
 hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy,
 [(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or
 15 two (1-2C)alkyl substituents on the nitrogen; and one of R^m
 and Rⁿ is hydrogen and the other is amino, bromo,
 (1-4C)alkyl or (1-4C)alkoxy, or R^m and Rⁿ together form a
 benz ring;

L^{2B} is -NH-CO-, -O-CO-, -CH₂-O- or -O-CH₂- such that
 20 -L^{2B}-Q^{2B} is -NH-CO-Q^{2B}, -O-CO-Q^{2B}, -CH₂-O-Q^{2B} or -O-CH₂-Q^{2B};
 and

Q^{2B} is

25 in which R^o is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy,
 benzyloxy or (1-4C)alkylthio; and R^p is 1-hydroxyethyl,

- 138 -

1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl,
4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or -J-R^Q
in which J is a single bond, methylene, carbonyl, oxo,
-S(O)_q- (wherein q is 0, 1 or 2), or -NR^F- (wherein R^F is
5 hydrogen or methyl); and R^Q is (1-6C)alkyl, phenyl,
3-pyridyl or 4-pyridyl;

L^{2C} is -NR^V-CO-X-, -NR^V-CS-Y-, -CH₂-CO-NR^W-CH₂-,
-O-CO-, -O-CH₂-, -S-CH₂- or -CH₂-NR^X-CH₂- such that -L^{2C}-Q^{2C}
is -NR^V-CO-X-Q^{2C}, -NR^V-CS-Y-Q^{2C}, -CH₂-CO-NR^W-CH₂-Q^{2C},
10 -O-CO-Q^{2C}, -O-CH₂-Q^{2C}, -S-CH₂-Q^{2C} or -CH₂-NR^X-CH₂-Q^{2C} in
which X is -(CH₂)_x- (wherein x is 0, 1 or 2), -NR^W-,
-NR^W-CH₂-, -O-, -O-CH₂- or -S-CH₂-; Y is -NR^W-CH₂- or
-O-CH₂-; each of R^V and R^W is independently hydrogen, benzyl
or (1-6C)alkyl which is not branched at the α-position; and
15 R^X is hydrogen, benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl;
and

Q^{2C} is 1-(4-pyridyl)piperidin-4-yl, 1-(4-pyridyl)-
piperidin-3-yl or 1-(4-pyridyl)pyrrolidin-3-yl in which the
pyridyl may bear a substituent at its 2-position selected
20 from cyano, aminomethyl, carboxy, hydroxymethyl and
(1-2C)alkyl;

L^{2D} is -NH-CO- such that -L^{2D}-Q^{2D} is -NH-CO-Q^{2D}; and
Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-
9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a
25 chloro, methyl or methoxy substituent), benzofuran-2-yl
(which may bear a chloro, methyl or methoxy substituent),
4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl or
3,4-didehydropiperidin-4-yl (either one bearing a
substituent at the 1-position selected from methylsulfonyl,
30 phenylsulfonyl, (1-5C)alkyl, (4-7C)cycloalkyl, tetrahydro-
pyran-4-yl, 4-thiacyclohexyl and -CH₂-R^Z in which R^Z is
isopropyl, cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl,
or pyridyl in which the phenyl may bear one or two
substituents independently selected from halo, cyano,

- 139 -

hydroxy, methoxy, acetoxy, benzyloxy, amino, acetylamino, nitro and 3,4-methylenedioxy, and the thienyl or furyl may bear a methyl or nitro substituent);

or a prodrug of the compound of formula I;

5 or a pharmaceutically acceptable salt of the compound of formula I or prodrug thereof.

11. The compound of claim 10 wherein

10 A^3 , A^4 , A^5 and A^6 , together with the two carbons to which they are attached, complete a substituted benzene in which A^3 is CR^3 , A^4 is CR^4 , A^5 is CR^5 , and A^6 is CR^6 ; wherein

15 R^3 is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω -carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy methoxy or methyl substituents), methyl or methoxy;

one of R^4 and R^5 is hydrogen, methyl, halo, trifluoromethyl, nitro, amino(imino)methyl, amino(hydroxyimino)-methyl, R^fO- , R^fO_2C- , $R^fO_2C-CH_2-$, $R^fO_2C-CH_2-O-$,
20 3-methoxycarbonyl-1-oxopropyl, R^gNH- or bis(methylsulfonyl)-amino;

the other of R^4 and R^5 is hydrogen, halo or methyl; and
25 R^6 is hydrogen, hydroxy, [(1-2C)alkyl]carbonyloxy (which may bear an ω -carboxy substituent), benzoyloxy (which may bear one or more halo, hydroxy methoxy or methyl substituents), methyl or methoxy;

in which R^f is hydrogen, (1-4C)alkyl or benzyl; R^g is hydrogen, acetyl, trifluoroacetyl, phenylalanyl,
2-(t-butoxycarbonylamino)-4-methylsulfinyl-1-oxobutyl or
30 R^hSO_2- ; and R^h is (1-4C)alkyl, trifluoromethyl, phenyl, 3,5-dimethylisoxazol-4-yl or dimethylamino; or

two adjacent residues selected from R^3 , R^4 , R^5 and R^6 together form a benz ring; and the other two are each hydrogen; or

- 140 -

A³, A⁴, A⁵ and A⁶, together with the two carbons to which they are attached, complete a substituted heteroaromatic ring in which


- (a) one of A³, A⁴, A⁵ and A⁶ is N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;
- (b) two adjacent residues of A³, A⁴, A⁵ and A⁶ together form S, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively;
- (c) two non-adjacent residues of A³, A⁴, A⁵ and A⁶ are each N, and each of the others is CR³, CR⁴, CR⁵ or CR⁶, respectively; or
- (d) A³ and A⁴ together form a fused benz ring, and A⁵ and A⁶ together form -NH-;

wherein

- each of R³, R⁴, R⁵ and R⁶ is hydrogen, or one or two of R³, R⁴, R⁵ and R⁶ is independently chloro, bromo or methyl and the others are hydrogen;


L¹ is -NH-CO- or -CO-NH- such that -L¹-Q¹ is -NH-CO-Q¹ or -CO-NH-Q¹;

- Q¹ is




- wherein -E-G-NH- is -CH₂-CH₂-NH-, -C(R^a)=CH-NH-, -C(R^a)=N-NH-, -N=CH-NH- or -N=N-NH- in which R^a is hydrogen, fluoro, chloro, bromo or methyl;
- R² is -L^{2A}-Q^{2A}, -L^{2B}-Q^{2B}, -L^{2C}-Q^{2C} or -L^{2D}-Q^{2D} wherein L^{2A} is a direct bond; and

- 141 -

Q^{2A} is

in which D is carbonyl or -CHR^k- in which R^k is hydrogen,
 5 hydroxy, (1-6C)alkoxy or -CH₂-R^j in which R^j is carboxy,
 [(1-4C)alkoxy]carbonyl or carbamoyl which may bear one or
 two (1-2C)alkyl substituents on the nitrogen; and one of R^m
 and Rⁿ is hydrogen and the other is amino, bromo,
 (1-4C)alkyl or (1-4C)alkoxy, or R^m and Rⁿ together form a
 10 benz ring;

L^{2B} is -NH-CO-, -O-CO-, -CH₂-O- or -O-CH₂- such that
 -L^{2B}-Q^{2B} is -NH-CO-Q^{2B}, -O-CO-Q^{2B}, -CH₂-O-Q^{2B} or -O-CH₂-Q^{2B};
 and

Q^{2B} is

15

in which R^o is hydrogen, halo, (1-6C)alkyl, (1-4C)alkoxy,
 benzyloxy or (1-4C)alkylthio; and R^p is 1-hydroxyethyl,
 1-hydroxy-1-methylethyl, 1-methoxy-1-methylethyl,
 20 4-piperidinyl, 4-pyridinyl, dimethylaminosulfonyl or -J-R^q
 in which J is a single bond, methylene, carbonyl, oxo,
 -S(O)_q- (wherein q is 0, 1 or 2), or -NR^r- (wherein R^r is
 hydrogen or methyl); and R^q is (1-6C)alkyl, phenyl,
 3-pyridyl or 4-pyridyl;

25 L^{2C} is -NR^v-CO-X-, -NR^v-CS-Y-, -CH₂-CO-NR^w-CH₂-,
 -O-CO-, -O-CH₂-, -S-CH₂- or -CH₂-NR^x-CH₂- such that -L^{2C}-Q^{2C}
 is -NR^v-CO-X-Q^{2C}, -NR^v-CS-Y-Q^{2C}, -CH₂-CO-NR^w-CH₂-Q^{2C},
 -O-CO-Q^{2C}, -O-CH₂-Q^{2C}, -S-CH₂-Q^{2C} or -CH₂-NR^x-CH₂-Q^{2C} in
 which X is -(CH₂)_x- (wherein x is 0, 1 or 2), -NR^w-CH₂-,

- 142 -

-O-CH₂- or -S-CH₂-; Y is -NR^W-CH₂- or -O-CH₂-; each of R^V and R^W is independently hydrogen, benzyl or (1-6C)alkyl which is not branched at the α -position; and R^X is hydrogen, benzyloxycarbonyl or [(1-4C)alkoxy]carbonyl; and

5 Q^{2C} is 1-(4-pyridyl)piperidin-4-yl in which the pyridyl may bear a substituent at its 2-position selected from cyano, aminomethyl, carboxy, hydroxymethyl and (1-2C)alkyl;

 L^{2D} is -NH-CO- such that -L^{2D}-Q^{2D} is -NH-CO-Q^{2D}; and

 Q^{2D} is selected from 4-(4-pyridinyl)benzyloxy, 9-oxo-
10 9H-fluoren-3-yl, benzo[b]thiophen-2-yl (which may bear a chloro, methyl or methoxy substituent), benzofuran-2-yl (which may bear a chloro, methyl or methoxy substituent), 4-(4-morpholinyl)-4-oxobutyl, and 4-piperidinyl bearing a substituent at the 1-position selected from methylsulfonyl, phenylsulfonyl and -CH₂-R^Z in which R^Z is isopropyl,
15 cyclopropyl, phenyl, furyl, thienyl, 2-thiazolyl, or pyridyl in which the phenyl may bear one or two substituents independently selected from halo, cyano, hydroxy, methoxy, acetoxyl, benzyloxy, amino, acetylamino, nitro and
20 3,4-methylenedioxy, and the thienyl or furyl may bear a methyl or nitro substituent;

 or a prodrug of the compound of formula I;

 or a pharmaceutically acceptable salt of the compound of formula I or prodrug thereof.

25

12. The compound of Claim 10 or 11 wherein for an alkyl group or the alkyl portion of an alkyl containing group, (1-2C)alkyl is methyl or ethyl; (1-4C)alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl; (1-6C)alkyl is methyl, ethyl, propyl, butyl, pentyl
30 or hexyl; and halo is bromo or chloro.

13. The compound of Claim 12 wherein for an alkyl group or the alkyl portion of an alkyl containing group,

- 143 -

(1-2C)alkyl is methyl; (1-4C)alkyl is methyl, isopropyl, butyl or t-butyl; (1-6C)alkyl is methyl, butyl or hexyl; and halo is chloro.

5 14. The compound of any of the above Claims 10-13 wherein the compound of formula I is one in which each of A³, A⁵ and A⁶ is CH.

10 15. The compound of any of the above Claims 10-14 wherein Q¹ is 6-indolyl or 6-indazolyl.

15 16. The compound of any of the above Claims 10-15 wherein R² is (4-t-butylbenzoyl)amino, (4-methoxybenzoyl)-amino, or [1-(4-pyridyl)piperidin-4-yl]methoxycarbonylamino.

 17. The compound of any of the above Claims 10-16 wherein -L¹-Q¹ is -NH-CO-Q¹.

20 18. The compound of any of the above Claims 10-16 wherein -L¹-Q¹ is -CO-NH-Q¹.

25 19. A pharmaceutical composition comprising a compound of formula I, or prodrug or pharmaceutically acceptable salt thereof, as claimed in Claims 10 in association with a pharmaceutically acceptable carrier, excipient or diluent.


 20. A process for preparing a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in claim 10 which is selected from

30 (A) for a compound of formula I in which the linkage of R² to the ring terminates in -NH-CO-, -NR^V-CO- or -NR^V-CS-, acylating an amine of formula II,

Nc1cc(L1-Q1)ccc1


II

(B) for a compound of formula I in which $-L^1-Q^1$ is $-NH-CO-Q^1$, acylating an amine of formula III



III


(C) for a compound of formula I in which $-L^1-Q^1$ is
15 $-CO-NH-Q^1$ and R^2 is of the form $-NH-CO-Q^2$, acylating an
amine of formula H_2N-Q^1 using a [1,3]oxazine of formula IV,




IV

(D) for a compound of formula I in which R² is -L^{2A}-Q^{2A} and D is carbonyl, diacylating a compound of formula II using an anhydride of formula V;

- 145 -



(E) for a compound of formula I in which R² is -O-CO-Q^{2B}, acylating an alcohol of formula VI



5

using an acid of formula HO-CO-Q^{2B}, or an activated derivative thereof;

(F) for a compound of formula I in which -E-G-NH- is -CH₂-CH₂-NH-, reducing the double bond of a corresponding compound of formula I in which -E-G-NH- is -CH=CH-NH-;

(G) for a compound of formula I in which R⁴ or R⁵ is amino, reducing the nitro group of a corresponding compound of formula I in which R⁴ or R⁵ is nitro;

(H) for a compound of formula I in which R⁴ or R⁵ is methylsulfonylamino, substituting the amino group of a corresponding compound of formula I in which R⁴ or R⁵ is amino using an activated derivative of methanesulfonic acid; and

(I) for a compound of formula I in which R⁴ or R⁵ is bis(methylsulfonyl)amino, substituting the methylsulfonylamino group of a corresponding compound of formula I in which R⁴ or R⁵ is methylsulfonylamino; and

whereafter, for any of the above procedures, when a functional group is protected using a protecting group, removing the protecting group;

whereafter, for any of the above procedures, when a pharmaceutically acceptable salt of a compound of formula I

- 146 -

is required, it is obtained by reacting the basic form of a basic compound of formula I with an acid affording a physiologically acceptable counterion or the acidic form of an acidic compound of formula I with a base affording a
5 physiologically acceptable counterion or by any other conventional procedure; and

wherein, unless otherwise specified, L^1 , Q^1 , R^2 , R^m , R^n , A^3 , A^4 , A^5 and A^6 have any of the values defined in claim 10.

10

21. The use of a factor Xa inhibiting compound of formula I substantially as hereinbefore described with reference to any of the Examples.

15

22. A novel compound of formula I substantially as hereinbefore described with reference to any of the Examples.

20 23. A process for preparing a novel compound of formula I substantially as hereinbefore described with reference to any of the Examples.

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US98/13416

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/253, 318, 359, 394, 406, 419; 546/194, 268.4, 273.4, 275.7, 277.4; 548/261, 304.4, 362.5, 469, 494

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,978,787 A (HAGA et al.) 18 December 1990, column 1.	1-4, 10-12, 19, 20
A	US 4,256,901 A (P.Y.E. GANGNEUX) 17 March 1981, column 1.	1-4, 10-12, 19, 20
A	US 5,569,768 A (BOYD et al.) 29 October 1996, columns 2-6.	1-4, 10-12, 19, 20
A	US 5,576,343 A (NAGAHARA et al.) 19 November 1996, columns 1-2.	1-4, 10-12, 19, 20
A	WALLIS R.B. Inhibitors of coagulation factor Xa: from macromolecular beginnings to small molecules. Current Opinion in Therapeutic Patents. August 1993, Vol. 3, No. 8, pages 1173-1179.	1-4, 10-12, 19, 20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 SEPTEMBER 1998

Date of mailing of the international search report

20 OCT 1998

 Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN HUANG

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13416

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-9, 14-18, 21-23
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13416

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 31/40, 31/41, 31/415, 31/445, 31/495, 31/505; CO7D 209/04, 209/12, 209/18, 231/56, 235/04, 235/06, 235/08, 249/16, 401/12, 403/12, 409/12.

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/253, 318, 359, 394, 406, 419; 546/194, 268.4, 273.4, 275.7, 277.4; 548/261, 304.4, 362.5, 469, 494

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-23 in part, drawn to a compound of formula I wherein A3, A4, A5, A6 complete a substituted benzene.

Group II, claim(s) 1-23 in part, drawn to a compound of formula I wherein one of A3, A4, A5, A6 is N.

Group III, claim(s) 1-23 in part, drawn to a compound of formula I wherein two adjacent residues of A3, A4, A5, A6 together form S.

Group IV, claims 1-23 in part, drawn to a compound of formula I wherein two non-adjacent residues of A3, A4, A5, A6 are each N.

Group V, claims 1-23 in part, drawn to a compound of formula I wherein A3 and A4 together form a fused benz ring and A5 and A6 together form -NH-.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: group I is drawn to a substituted benzene, group II is drawn to a pyridine compound, group III is drawn to a thiophene compound, group IV is drawn to a pyrimidine or a pyrazine compound while group V is drawn to an indole compound. A benzene, a pyridine, a thiophene, a pyrimidine or a pyrazine and an indole would not have been of sufficient similarity to allow for a Markush grouping to exhibit utility, absent some teaching of equivalence in the prior art.